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Abstract 
Metal-organic frameworks (MOFs) are a class of crystalline materials defined by high surface area 
and porosity. MOFs are constructed from organic linkers and metal nodes, resulting in a structure 
that extends in two or three dimensions. Owing to their porosity and surface areas, MOFs have 
been used extensively for gas storage, catalysis and biological applications such as drug delivery. 
Biomolecules are molecules of biological origin, including proteins, enzymes and DNA which, due 
to their unique properties, are of interest in numerous fields including as therapeutics or 
biocatalysts. However, their use can be limited by their low stability in  non-biological conditions. 
Thus, a means of protecting biomolecules from challenge conditions (high or low pH, organic 
solvents or elevated temperatures) could expand the opportunities for their application. One 
such method of protection is biomimetic mineralisation wherein a MOF coating is grown around 
the biomolecule. This protective strategy is also applicable to larger biological assemblies such as 
cells. 
The primary aim of this thesis was to investigate a number of MOFs, for example those possessing 
biocompatible building blocks, and determine whether these materials were able to encapsulate 
proteins via biomimetic mineralisation and offer protection against harsh conditions. By 
extension, this allowed investigation of the MOF features necessary to facilitate biomimetic 
mineralisation. Initially zinc-based MOFs with amino-acid linkers, L-glutamic acid and L-carnosine 
(β-Alanine-L-Histidine), were investigated. However, zinc glutamate (BioMOF-1) was unable to 
encapsulate proteins, while zinc carnosine (BioMOF-2) was unable to stabilise encapsulated 
proteins against test challenge conditions. 
The focus was then shifted to zinc-based MOFs with N-donor containing ligands; 3,3’,5,5’-
tetramethyl-4,4’-bipyrazole (H2Me4bpz) and 4,5‐di(1H‐tetrazol‐5‐yl)‐2H‐1,2,3‐triazole (H3TDT). 
Both MOFs are formed from azole donors, like zeolitic imidazole frameworks (ZIFs) which are 
most widely employed for biomolecule encapsulation and protection. While enzyme was 
potentially encapsulated within Zn(Me4bpz), the majority of activity observed was due to enzyme 
leaching resulting from MOF decomposition. For Zn(TDT), the sodalite topology was unable to be 
synthesised in aqueous conditions, instead a highly unstable material with unknown structure 
was formed. Due to the low stability, no further analysis was performed. 
While none of the studied MOFs successfully encapsulated and protected enzymes, key 
conclusions were still made from this work. The zinc glutamate and zinc carnosine studies 
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highlighted that increased MOF biocompatibility does not necessarily lead to successful 
biomimetic mineralisation. Further, the results for Zn(Me4bpz) and Zn(TDT) showed that the sole 
presence of azole donors does not guarantee successful biomimetic mineralisation. Instead, this 
is likely more dependent on the mechanism of MOF formation rather than the donor type. To 
further increase the understanding of biomimetic mineralisation and the required MOF 
chemistry, future work is needed. This future work may include a greater diversity of MOFs with 
biologically derived linkers and linkers containing solely azole donors. Further, the ligands used 
in this thesis could be altered to understand the effect of varying donor sets on the ability of the 
MOF to undergo biomimetic mineralisation. 
. 
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CHAPTER 1: Introduction 
1.1 Biomolecules 
Biomolecules are molecules of biological origin, including proteins and DNA. Of particular interest 
to this project are enzymatic proteins which act as catalysts in biological systems. Proteins are 
comprised of amino-acids joined by amide bonds to form a linear chain, known as the primary 
structure. Hydrogen bonding between these amino-acid residues leads to the formation of 
helices or sheets, which make up the secondary structure. Further secondary interactions lead to 
the formation of the 3-D (tertiary) structure and multiple amino-acid chains may interact to form 
a larger (quaternary) structure (Figure 1). Each of these levels of protein structure influence the 
resultant physical and chemical properties, which lead to unique functionalities. Thus, the 
structure of a protein is vital for its function. 
 
Figure 1: The four levels of the structure of a protein. 
Proteins have shown importance in medicine as therapeutics, and in food technologies due to 
their structural properties.6-9 Due to their catalytic activity under benign conditions and excellent 
chemo-, regio- and enantioselectivity, enzymes are widely investigated as catalysts for fine 
chemical synthesis. For example, cytochrome P450s could be used to catalyse the hydroxylation 
of various hydrophobic compounds,10 alcohol dehydrogenases could catalyse oxidoreduction 
reactions,11 and aldolases can be used for aldol addition reactions.11 As a consequence of their 
biological origins and lack of by-products, they are viewed as a greener and more biocompatible 
alternative to synthetic catalysts.  
A major limitation of enzymes in chemical synthesis is their limited stability in non-native 
environments. Typically, functional structures are only retained at low or room temperatures, in 
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aqueous solutions, and biological pH. However, the exact conditions required for stability vary 
between enzymes, as do the optimal conditions in which they operate (Figure 2). 
 
Figure 2: a) pH and b) temperature stability ranges for lipase (Geotrichum marinum) (light blue),12 
urease (Enterobacter sp.) (yellow),13 trypsin (Balistes capriscus) (grey),14 pepsin (albatrossia 
pectoralis) (orange)15 and catalase (Oceanobacillus oncorhynchi subsp. incaldanensis) (dark 
blue).16 The green bar represents the pH or temperature at which the protein is most stable. 
If these native conditions are not maintained, denaturation of the enzyme can occur by  
disruption of the secondary interactions, leading to a break down in the secondary, tertiary or 
quaternary protein structure. As the structure of an enzyme is vital for its function, this 
denaturation leads to a loss of enzymatic ability. Given that a majority of industrial chemical 
syntheses utilise elevated temperature, organic solvents or other denaturing conditions, this 
introduces significant limitations and makes the use of enzymes challenging.  
1.2 Biomolecule protection 
In order to expand the conditions in which enzymes are stable, some form of protection needs 
to be implemented. This could potentially allow them to be used, for example, at elevated 
temperatures or in organic solvents, thereby making them applicable for industrial chemical 
processes. Due to the high demand to achieve this, it has been a widely investigated area with a 
number of strategies being reported in the literature which include cross-linking,17 binding to a 
surface,18 and encapsulation in a gel or mesoporous silica (Figure 3).19  
While in all three cases, these methods were able to effectively protect or stabilise proteins, they 
each come with notable limitations. Cross-linking proteins relies on the presence and suitable 
concentrations of specific amino-acid residues within the protein structure. Further, the location 
of the cross links needs to be considered as they may block the active site. Thus, the cross-linking 
process needs to be tailored specifically to the target protein, but still may not be viable for some 
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biomolecules. For the surface-binding strategy, similar limitations are faced as the surface to 
needs to be tailored to the size, chemistry and structure of the target protein. Conversely, the 
gel encapsulation method is a general approach that does not require significant tailoring for 
each target biomolecule. However, the gels can have high density which may restrict the diffusion 
of substrate through to the encapsulated enzymes or lack the stability for use in fine chemical 
synthesis. Similarly, mesoporous silica can be used to encapsulate and protect enzymes.20, 21 
However, it has been reported that encapsulated biomolecules can leach from the silica relatively 
quickly, making it unsuitable for many applications.22 Instead it would be highly desirable to have 
a generally applicable, highly porous coating that could allow facile substrate diffusion without 
enzyme leaching. 
 
Figure 3: Schematic of enzyme protection via cross-linking, binding to a surface and encapsulation 
in a gel (or mesoporous silica). 
1.3 MOFs for biomolecule protection 
Metal-organic frameworks (MOFs) are a class of crystalline materials defined by high porosity 
and surface areas.23 They are composed of metal nodes connected via organic linkers to form a 
framework structure (Figure 4).24, 25 One key feature of MOFs that lend them to an extremely 
diverse array of applications is the ability to customise the structure and chemistry. The metal 
node, organic linkers and synthetic conditions can all be altered to impact their physical and 
chemical properties. 
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Figure 4: Schematic representation showing the components and structure of a metal-organic 
framework (MOF). 
For example, varying the linker length while keeping the metal node constant can lead to the 
formation of isoreticular MOF families which are comprised of materials with identical topology 
but varying pore sizes.26 A well-known example of this is the University of Oslo (UiO) family of 
MOFs, comprising of UiO-66, UiO-67 and UiO-68 which contain linkers with increasing numbers 
of phenyl groups such that the pore size varies but the topology remains identical (Figure 5). 
 
Figure 5: Representations of the structures of UiO-66, UiO-67 and UiO-68 highlighting the 
increasing pore size as a result of ligand extension from 1,4-benzene dicarboxylate to 4,4’-
biphenyl dicarboxylate and 4,4”-terphenyl dicarboxylate respectively. Zr = red, O = blue, C = grey, 
H = white.27 
The geometry and connectivity of the ligand can vary the structure of MOFs. For example, 
comparison of linear ligands such as the benzene dicarboxylate used in MOF-525 and tritopic 
ligands such as 1,3,5-benzenetribenzoate used in MOF-17728 shows that this leads to the 
formation of MOFs with significantly different topologies, pore sizes and surface areas (Figure 6). 
Furthermore, the pore chemistry can be altered by addition of functional groups, which, for 
example, can be used to change pore hydrophobicity or serve as binding sites.29, 30 
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Figure 6: a) The benzene dicarboxylate ligand from MOF-5,25 and b) the 1,3,5-benzenetribenzoate 
linker used in MOF-177.28 
The binding sites present in the ligand can also be varied from carboxylate or azolate moieties 
which may impact the strength of the metal-ligand bond and the stability of the MOF. Typically, 
the metal-ligand bond is the source of MOF decomposition by either ligand protonation for 
chemical degradation or by bond breaking in thermal degradation. Thus, the MOF stability is 
typically improved by increasing the strength of this metal-ligand bond, which can be done using 
high-valent metal salts.31 
The metal nodes can also be used to alter the MOF structure, while keeping the ligand constant.  
For example, Zr(IV) and Ti(IV) have been used to synthesise two MOFs with distinct structures 
that incorporate the benzene dicarboxylate linker (UiO-66 and MIL-125) (Figure 7).32 Variation of 
metal nodes can also be used to alter the biocompatibility of the resultant MOFs. 
 
Figure 7: a) the benzene dicarboxylate linker, b) the crystal structure of MIL-125 (Ti = blue, O = 
red, C =white),33 and c) the crystal structure of UiO-66 (Zr = red, O = blue, C = grey, H = white).27  
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As a consequence of these structural variations, MOFs are highly mutable materials whereby 
their properties can be varied to suit specific applications; this has been extensively documented 
in the literature. For example, the use of transition metals, either as the node or incorporated via 
post-synthetic metalation, in combination with the high surface areas make MOFs advantageous 
as heterogenous catalysts.34-37 Moreover, the ability to alter the pore and aperture sizes within 
MOFs leads to applications in size-selective separation (gas and liquid phases).38-40 The high 
porosity of MOFs and their ability to retain small molecules leads to potential use in gas 
storage.39, 41, 42 Other applications for MOFs include luminescence,43 lasing,44 drug delivery,45 
non-linear optics46 and biological protection.6  
Very recently, MOFs have been used to encapsulate proteins and provide protection against 
harsh conditions.47 Due to the porous nature of MOFs, which allows transport of small molecule 
substrates and escape of products, the enzymatic activity is retained. Early approaches explored 
the use of MOFs for biomolecule protection by infiltrating the protein into a pre-made 
mesoporous MOF structure, immobilizing microperozidase-11, horseradish peroxidase (HRP) and 
cytochrome c.48, 49 In all cases, this method yielded high enzyme loading, and the encapsulated 
enzyme was more durable, and more recyclable compared to the free enzyme or enzyme loaded 
into a mesoporous silica support. Strong interactions between the framework and the enzymes 
ensured no leaching occurred. However, if the enzymes or framework are varied these 
interactions may not be strong enough to prevent leaching. Further, this method is limited by the 
pore aperture size of the MOF wherein only biomolecules with sizes smaller than the pores can 
be used. Finally, synthesis of mesoporous MOFs presents challenges regarding stability, in 
addition to the high chance of interpenetrated MOF growth as the linker size increases, which 
leads to a subsequent reduction in porosity. 
As a result of these challenges, this method of biomolecule encapsulation is different to the 
process used herein. 
1.4 Biomimetic mineralisation of MOFs for biomolecule encapsulation/protection 
Biomimetic mineralisation is a process wherein a MOF coating is formed around a biomolecule, 
offering protection from external conditions (Figure 8). This occurs in much the same way as 
biomineralisation in Nature, where the growth of shells of calcium carbonate around sea urchins 
or crustaceans (Figure 8).47 In this process, the biomolecule promotes the formation of the MOF 
such that it forms around the biomolecule, completely enshrouding it within a growing MOF 
particle (these may aggregate  to form a more complex biocomposite). 
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Figure 8: A schematic comparing biomimetic mineralisation to encapsulate biomolecules within 
a crystalline MOF to biomineralisation in Nature.47 
A more general approach to enzyme encapsulation within MOFs is via a co-precipitation 
mechanism. The key difference between this and biomimetic mineralisation is that the enzyme 
does not accelerate MOF growth during co-precipitation.50 There have been numerous studies 
showing that co-precipitation leads to protection of encapsulated enzyme against harsh 
conditions.50-52 Yet there have also been findings indicating that the protective capacity of an 
identical MOF biocomposite formed via the co-precipitation mechanism is lower than that 
obtained from biomimetic mineralisation.6  
The original, and most commonly studied, MOF reported to successfully encapsulate and protect 
enzymes by both co-precipitation and biomimetic mineralisation is ZIF-8 (Figure 9).47, 52 ZIF-8 can 
be formed at room temperature in aqueous conditions, making the synthesis compatible with 
proteins. Moreover, ZIF-8 has been documented to have low cytotoxicity, making it suitable for 
biological applications.6  
The initial studies of biomimetic mineralisation by ZIF-8 were reported by Liang.47 In this study, a 
number of proteins and enzymes were encapsulated within ZIF-8 crystals, as confirmed by 
Fourier-transform infrared (FTIR) spectroscopy and confocal laser scanning microscopy (CLSM). 
Following this, the enzymatic activity of the ZIF-8 biocomposite of horseradish peroxidase 
(HRP@ZIF-8) was then analysed using a pyrogallol assay. The results of these assays showed that 
the activity loss of HRP@ZIF-8 following exposure to proteolytic agents (trypsin), boiling water 
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and boiling DMF was significantly less than that of free HRP, HRP protected by calcium carbonate 
and HRP protected by mesoporous silica. This study also showed that pH modification could be 
used to remove the ZIF-8 coating and release the encapsulated biomolecule with retained 
activity. Following this initial report of ZIF-8 encapsulation of biomolecules, an extremely large 
number of additional ZIF-8 studies have been presented. These further confirmed the ability of 
ZIF-8 to successfully encapsulate and protect a wide range of biomolecules.53-58  
 
Figure 9: a) The ligand used to form ZIF-8, b) crystal structure of ZIF-8, showing the 3.4 Å pore 
aperture (green) (C = grey, N = purple, H = white, Zn = red)59 and c) the topology of sodalite ZIF-8, 
the orange balls represent the largest sphere able to fit inside the pores without touching the van 
der Waals radii.60 
Maddigan and co-workers investigated the effect of protein surface chemistry on successful 
encapsulation of the proteins within a ZIF-8 framework for a variety of proteins including BSA 
and haemoglobin (Hb).61 Their results indicated that encapsulation within ZIF-8 was favoured by 
proteins with a isoelectric point (pI) less than approximately 7 such that they possessed 
negatively charged surfaces in the reaction conditions. This was proposed to allow for zinc 
aggregation at the charged protein surface, which then seeded the growth of ZIF-8 around the 
protein. The growth of ZIF-8 occurs via a stepwise deprotonation mechanism outlined in Scheme 
1, which is thought to be one of the key reasons for its ability to successfully undergo biomimetic 
mineralisation. 
Despite the well-documented success of ZIF-8, a primary limitation of ZIF-8 is the relatively small 
aperture size (3.4 Å) (Figure 9), which restricts the size of molecule able to diffuse through the 
MOF to the enzymatic site.59 While some flexibility within the ZIF-8 structure has been 
reported,62 this is minimal and so only molecules of a similar size to the aperture size will readily 
diffuse throughout the framework; molecules notably larger than the pore aperture will be 
retained on the surface of the ZIF.59 This has been well characterised by Eum and co-workers, 
finding that there were competing effects between the size of the molecule and the 
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hydrophobicity of the MOF which impacted the diffusion ability of select molecules.63 
Furthermore, despite the relatively low toxicity of ZIF-8, the significant quantities of imidazole 
resulting from ZIF decomposition may pose risks. Imidazole has been shown to have serious 
effects on the platelet metabolism; it inhibits platelet aggregation which in turn hinders 
clotting.64 
 
Scheme 1: The proposed mechanism of ZIF-8 formation. 
Recent work by Liang and co-workers showed that the hydrophobicity of ZIF-8 caused 
encapsulated catalase to become inactive.65 This was proposed to be due to the greater affinity 
that proteins have for hydrophobic surfaces, which led to conformational changes and 
subsequent activity loss. In comparison, hydrophilic MOFs, such as ZIF-90 and MAF-7  (Figure 10 
and Figure 11 respectively), could successfully encapsulate and protect enzymes without 
appreciable activity loss.50, 65 The data is still ambiguous in regard to whether these two MOF 
biocomposites form via biomimetic mineralisation or co-precipitation. 
Similar to ZIF-8, ZIF-90 forms with a sodalite topology containing pores of 11.2 Å and pore 
apertures of 3.5 Å.3 Similarly, MAF-7 which, although not labelled as a ZIF, is formed from a very 
similar ligand to the ZIF materials, using a triazole instead of imidazole-based ligands, and 
possesses an identical sodalite topology (Figure 11).1, 65 While the ZIF-90 and MAF-7 coatings did 
not cause encapsulated enzymes to lose activity, their use is still hindered by relatively small pore 
apertures of 3.5 Å and 3.2 Å respectively.1, 3 As such, it would be of interest to investigate 
alternative MOFs that do not face these limitations. 
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Figure 10: a) The ZIF-90 ligand, b) the structure of a single ZIF-90 cage with ZnN4 tetrahedra 
shown in pink (C = blank, N = green, O = red), the yellow ball represents the largest sphere able to 
fit in the cage without touching the van der Waals sphere, and c) the extended ZIF-90 network 
showing the sodalite topology.3 
 
Figure 11: a) The MAF-7 ligand and b) crystal structure of MAF-7 cage, green ball shows the 
largest sphere able to fit in the pore without touching the van der Waals spheres.1 
Despite the growing quantity of studies on biomimetic mineralisation with MOFs, it is still a 
relatively new field. As such, there remains a lack of understanding regarding the specific features 
of the MOFs that are key to ensuring successful biomimetic mineralisation. Thus, investigation 
into MOF chemistry and how specific features impact the ability of the MOF to undergo 
biomimetic mineralisation is important. This may allow for the production of general screening 
procedures to make it quicker and easier to select a MOF suitable for protecting a biomolecule 
in specific environments. 
1.5 Thesis Aims and Overview 
Protection and stabilisation of biomolecules is necessary to expand the conditions where they 
are stable, thus increasing the viability of their use across a range of applications. In particular, 
this thesis focuses on enzymes due to their vast array of promising applications, including in fine 
chemical synthesis, as a result of their enzymatic activity and high selectivity. The use of a 
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biomimetic mineralisation process allows the encapsulation of biomolecules within a protective, 
highly porous MOF shell, which allows excellent diffusion of substrate through to the enzymatic 
site. Further, the high stability of MOFs across a wide range of conditions such as heating, pH and 
organic solvents make them well suited to this application. However, despite significant research 
into the use of MOFs for biomimetic mineralisation, there are still a large number of factors that 
impact this process that are not well understood. One such key factor is the features of the MOFs 
that ensure successful biomimetic mineralisation. In addition, MOFs commonly used for this 
process, for example ZIF-8, have significant limitations in regard to pore size and potential 
toxicity. 
This thesis describes research undertaken to add to current knowledge of biomimetic 
mineralisation by investigating different MOFs. The ability of these materials to encapsulate and 
protect enzymes was explored to examine whether they provide valid alternatives to ZIF-8 and 
related materials. Further, the mechanism by which these MOFs encapsulate biomolecules will 
be examined, to assess whether encapsulation occurs via biomimetic mineralisation or co-
precipitation. Specifically, key focuses include the use of MOFs with biologically-derived linkers 
(Chapter 2), and MOFs with linkers possessing solely N-donor binding sites (Chapter 3), like the 
ZIF and MAF materials previously explored. Combined, these studies will provide a better 
understanding of enzyme encapsulation via biomimetic mineralisation. 
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CHAPTER 2: BioMOFs for enzyme encapsulation 
2.1 Introduction and scope of the chapter 
The term BioMOF refers to MOFs with biologically derived components.66-68 For this thesis, 
bioMOF refers to MOFs comprised of linkers of biological origin. There have been a wide variety 
of different bioMOFs reported in literature, including examples where amino-acids and peptides 
have been used as the ligands.69-72 Amino-acids are organic molecules with carboxylic acid and 
amine functional groups connected via an alpha carbon; the third group attached to the alpha 
carbon varies between amino-acid and, thus, modifies the chemistry. Peptides are formed by 
connecting amino-acids via amide bonds. There are twenty-one commonly occurring natural 
amino-acids, which allows for a vast library of peptides. Thus, amino-acid derived MOFs can have 
a wide range of chemical and physical properties. MOFs using cyclodextrin linkers (CD-MOFs) 
have also been extensively reported.73 Due to the different types of cyclodextrins available; α-, 
β- and γ-CD, different MOF structures are able to be obtained. As such, a very wide variety of 
applications have been proposed for CD-MOFs including drug delivery,74-76 removal of 
insecticides,77 sensors,78 food packaging,79 electrical conductors80 and photocatalysis.81 Other 
sugars such as lactate have also been used as MOF linkers.82 In particular, calcium lactate MOFs 
have been reported for use as agricultural fumigant encapsulants which are non-harmful due to 
the biocompatibility of both the linker and the metal used. Porphyrin-based MOFs have also been 
synthesised.83 Porphyrins are heterocyclic macrocycle organic compounds which contains four 
modified pyrrole groups connected via alpha carbons. One particular porphyrin based MOF, PCN-
221,83 was used for drug delivery due to the high potential drug loading and high 
biocompatibility. The Rosi group has also shown that nucleobases, specifically adenine, can be 
used to form clusters with zinc, which were subsequently linked by an organic linker to form an 
extended porous and crystalline structure.84 
Given this extremely diverse range of applications for bioMOFs, work presented  herein examines 
their effectiveness for encapsulating biomolecules. It was proposed that the biological origin of 
both the linkers used and the biomolecules to be encapsulated could increase compatibility 
between the framework structure and the biomolecule, while also increasing the overall 
biocompatibility of the material. This project direction will utilise an extensive body of research 
on bioMOFs. 
  13 
2.1.1 Review of bioMOFs for biomolecule encapsulation 
A brief survey of reported amino-acid derived MOF structures is presented below to highlight the 
diversity of the field and to identify desirable MOFs for protein encapsulation. Several key criteria 
were established for the bioMOFs to enable them to be considered for use in the biomimetic 
mineralisation of biomolecules. These included: 
• A 2-D or 3-D connected structure with > 3.4 Å pore openings; 
• Binary (or two component) MOFs; 
• Chemically and thermally stable materials demonstrating permanent porosity; 
• Commercially available or synthetically accessible linkers; 
• Use of a non-toxic metal ion; 
• Aqueous (or predominantly aqueous solvent mixtures) used for synthesis; 
• Room temperature synthesis conditions 
Pore apertures greater than 3.4 Å represent an advance over ZIF-8, allowing for less hindered 
diffusion of larger substrates and products. The use of binary MOFs is desirable for two key 
reasons; MOFs which are able to successfully undergo biomimetic mineralisation are typically 
binary MOFs and it significantly reduces the complexity of the synthesis and characterisation. In 
particular, the use of additional components can lead to the formation of competing phases. 
Permanent porosity is required to ensure substrate diffusion can occur at all times without 
dependence on the reaction medium. By extension, the MOF must be stable in the thermal or 
chemical conditions where the composite will be used. One of the key advantages of using 
biologically derived linkers is the potentially higher biocompatibility and so the metal used should 
not compromise those advantages. Aqueous and room temperature synthesis conditions are 
needed to ensure the MOF synthesis is compatible with biomolecule encapsulation; otherwise 
denaturation may occur before encapsulation within the MOF. While the majority of MOF 
syntheses are performed solvothermally (in solution at high temperatures) in organic solvents, 
variations can be made to facilitate formation in water at room temperature. 
The use of a non-toxic metal ion would allow for potential applications in biological systems, for 
example as therapeutics. Endogenous elements such as magnesium, iron, zinc, calcium and 
potassium are of particular interest for use in bioMOFs to be used in biological systems as higher 
quantities of MOF can be used before reaching a toxic concentration.85 In addition, each of these 
elements perform vital roles in biological systems, such that both the metal and ligand and/or 
encapsulated material can be utilised. For these reasons, bioMOFs synthesised using these 
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elements as the metal source are most common. Further, exogenous elements such as copper 
or silver could also be considered for use in bioMOFs owing to their antimicrobial and imaging 
activities.85 
Numerous MOFs have been synthesised with single amino-acid,69, 86 di- and tri-peptide linkers,72, 
87 or other ligands onto which these molecules have been appended.88 MOFs have also been 
formed with a combination of both organic and biologically derived linkers (mixed-linker MOFs), 
yet this adds synthetic complexity.84, 89 
A selection of permanently porous materials with high thermal and chemical stability were 
examined, with many not meeting key criteria mentioned above. However, a small sample of 
known MOFs met most or all of the aforementioned requirements. A summary of these MOFs is 
outlined in Table 1 followed by a more in-depth discussion. 














Reference 90 90 91 71 4 5, 70 
2-D/3-D       
>3.4 Å pore apertures       
Binary MOF       
Chemically/thermally 
stable 
      
Permanent porosity       
Easily accessible 
components 
      
Non-toxic metal ion       
Aqueous/room temp. 
synthesis 
      
 
Of these six amino-acid based MOFs, the two most complex and also least suitable MOFs were 
two copper-based MOFs using tripeptide linkers of the form Gly-L-His-X (X = Gly or Lys).90 Both 
materials were synthesised in aqueous conditions at room temperature, making the synthesis 
suitable for use with biomolecules, and both had a similar 3-D structure with 1-D channels (Figure 
12). However, the relative synthetic complexity and availability of the tripeptide linkers used in 
the MOF presented a challenge as it would limit availability for MOF synthesis. Further, both 
MOFs have relatively small pore apertures of 2.4 Å which would hinder substrate diffusion. Thus, 
these issues deem the MOFs to be unsuitable. 
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Figure 12: a) Gly-L-His-Gly ligand and Cu(Gly-L-His-Gly) MOF single crystal structures viewed 
along the b) [100] and c) [111] directions. d) Gly-L-His-Lys ligand and Cu(Gly-L-His-Lys) MOF 
viewed along the e) [100] and f) [111] directions.90 
To reduce synthetic complexity, bioMOFs containing di-peptide linkers were subsequently 
investigated. All of the suitable dipeptide MOFs found contained zinc metal nodes, likely to due 
to its biological compatibility and low toxicity. 
A zinc bioMOF with a Gly-Thr dipeptide linker was reported to form in methanol as a 2-D layered 
framework with 2.8 Å pore apertures opening into 1-D channels (Figure 13).91 This small pore 
size is unfavourable and therefore made this MOF unsuitable.  
 
Figure 13: a) Gly-Thr ligand and b) Zn(Gly-Thr)2 MOF structure viewed along the a axis.91 
The threonine group can be replaced by alanine in the peptide to form a Gly-Ala dipeptide based 
bioMOF.71 Unlike the Gly-Thr bioMOF, this material has a 3-D grid-like structure consisting of 1-
D, square-shaped pores that were 4.8 Å at their widest dimension (Figure 14).While this pore 
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aperture size meets the criteria, the methyl groups of the dipeptide linker protrude into the 
pores, which would likely hinder substrate diffusion. Further, the literature synthesis conditions 
required extensive heating. As noted above, while such synthetic conditions could be modified, 
the ”hour-glass” shaped pores were undesirable and this material was not investigated. 
 
Figure 14: a) Gly-Ala dipeptide ligand and b) Zn(Gly-Ala)2 MOF structure viewed along the c axis.71 
One additional bioMOF comprised of dipeptide linkers was considered, namely, a zinc MOF with 
L-carnosine linkers (β-Ala-L-His) (Figure 15).4 As a result of the imidazole functionality present in 
the linker, it is postulated that this may have similarities to the chemistry of ZIF-8 (although it 
was noted that both the amine and carboxylic acid groups are also involved in bonding). Zinc 
carnosine forms a 3-D framework with 1-D channels possessing ca. 5.2 Å pore apertures, which 
are larger than that of ZIF-8 (3.4 Å), making this bioMOF very promising from a substrate diffusion 
regard.  
 
Figure 15: a) Carnosine (β-Ala-L-His dipeptide) ligand and b) zinc carnosine MOF structure viewed 
along the b axis.4 
Zinc carnosine has also been reported to have numerous biological applications due to its low 
toxicity and has been approved by the therapeutic goods administration (TGA) under the name 
polaprezinc (PZ) as a commercially available drug.92 Both zinc and carnosine are postulated to 
provide many benefits regarding brain health and immunity, leading to use as health 
supplements. There have been many published reports detailing potential clinical uses of zinc 
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carnosine including zinc supplementation, treatment of ulcers93 and ulcerative colitis,94 reducing 
risk of heat stroke,95 improving gut repair processes,96 and prevention of some 
neurodegenerative diseases.97 As such, it is feasible to consider biological applications for zinc 
carnosine when used for biomolecule encapsulation. While the reported synthesis required the 
use of both organic solvents (dimethylformamide (DMF)) and extensive heating, the many 
promising aspects of this MOF discussed above outweigh this negative. Thus, developing a 
method to synthesise Zn carnosine in aqueous conditions at room temperature was deemed 
necessary. 
MOFs with single amino-acid ligands were also investigated to further reduce synthetic 
complexity. A zinc-based MOF using L-glutamic acid linkers has been reported (Figure 16).5, 70 As 
the linker is a single amino-acid, it is readily available and economically viable. The exact size of 
the pore apertures was not specified in the literature data, however, calculations from single 
crystal data suggest that the apertures would be approximately 5 by 10 Å, suggesting improved 
substrate diffusion compared to ZIF-8. The literature synthesis of zinc glutamate bioMOF was 
performed in an aqueous solution at room temperature (although with added sodium 
hydroxide), meaning that limited modifications were needed. Therefore, this bioMOF was also 
used in this project. 
 
Figure 16: a) L-Glutamic acid amino-acid ligand and b) zinc glutamate MOF structure viewed 
along the c axis, H atoms removed for clarity.5 
This chapter will outline the investigation of the two latter bioMOFs; zinc glutamate (ZnGlut) 
(bioMOF-1) and zinc carnosine (ZnCar) (bioMOF-2). Specifically, to investigate whether these 
MOFs afford protective coatings around enzymes and to determine whether these coatings form 
via biomimetic mineralisation. 
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2.2 Results and discussion 
2.2.1 Zinc Glutamate (BioMOF-1) 
2.2.1.1 Biocompatible synthesis and characterisation of bioMOF-1 
To synthesise bioMOF-1, the literature conditions were initially trialled. This procedure involved 
direct mixing of a 1:2.5:1 molar ratio of L-glutamic acid, zinc sulphate and sodium hydroxide. To 
promote the formation of the correct crystalline zinc glutamate material, the metal salt and 
linker/base were dissolved separately in water, followed by dropwise addition of the zinc solution 
to the linker solution with stirring. Powder X-ray diffraction (PXRD) indicated that the precipitate 
formed via this method was crystalline and matched with the simulated PXRD pattern for zinc 
glutamate (Figure 17). 
 
Figure 17: PXRD pattern of synthesised bioMOF-1 (red, baseline corrected) compared to the 
pattern (black) simulated from single crystal data. 
Despite the synthesis method for bioMOF-1 being biocompatible, using these conditions caused 
immediate formation of the MOF upon mixing. Ideally, delayed MOF formation in the absence of 
enzyme is beneficial when attempting biomimetic mineralisation for two key reasons. The first 
reason being that if a MOF was synthesised very rapidly, the growth may be seeded 
independently of the protein/biomolecule via co-precipitation instead of biomimetic 
mineralisation. The second reason is to make detection of biomimetic mineralisation easier by 
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making it clearer whether the presence of enzyme led to accelerated MOF growth. More precise 
and quantitative measurements could then be carried using turbidity tests or in situ small angle 
X-ray scattering (SAXS) as required. 
Attempts to delay the formation of bioMOF-1 were performed by varying the type and amount 
of base, metal salt, and the concentration of other reagents. It was postulated that weaker bases 
could slow bioMOF formation, as could the use of metal salts with weaker conjugate bases. The 
weaker bases should give less rapid ligand deprotonation and, thus, slower MOF formation. The 
general method for these tests was to dissolve the ligand and base in water (5 mL), dissolve the 
zinc salt in water (5 mL) and add the zinc solution dropwise to the ligand solution with stirring. 
The conditions tested and results are summarised in Table 15 in the appendix, with PXRD data 
shown in Figure 18 and Figure 19 for select groups of data.  
The shaded conditions in Table 15 (appendix) consistently produced the correct crystalline 
structure of bioMOF-1, as indicated by the PXRD data (Figure 18 and Figure 19) and so these 
appeared to have the greatest potential. Within these groups, the rate of precipitation could be 
easily controlled through variation of the base concentration. The use of zinc nitrate was due to 
the longer overall delay in precipitation able to be achieved. 
 
Figure 18: PXRD data for bioMOF-1 formed with varying amounts of base (NaHCO3) using zinc 
nitrate hexahydrate as the metal source, compared to the simulated pattern for bioMOF-1. 
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Figure 19: PXRD data for bioMOF-1 formed with varying amounts of base (NaHCO3) using zinc 
acetate dihydrate as the metal source, compared to the simulated pattern for bioMOF-1 
constructed from single crystal data. 
2.2.1.2 Synthesis of protein@bioMOF-1 biocomposites 
To ensure that biomolecule addition did not alter the structure of the MOF formed, MOF 
syntheses were conducted with a suite of proteins. The biomolecule encapsulation procedure 
involved the addition of enzyme into the ligand solution, followed by dropwise addition of the 
zinc solution. PXRD patterns for bioMOF-1 composites formed in the presence of various proteins 
displayed some slight peak shifts, but overall indicated no significant structural changes (Figure 
20). The original literature data for zinc glutamate also showed small shifts in the PXRD patterns 
for samples that were dried versus those treated with water.70 Thus, the small shifts observed in 
the experimental PXRD patterns were likely due to slight solvation changes. 
The rates of precipitation of bioMOF-1 formed in the presence of each protein were observed 
and compared to bioMOF-1 without protein (Table 2) to probe whether biomimetic 
mineralisation might be occurring. 
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Figure 20: PXRD for a) bioMOF-1 after addition of various enzymes during MOF synthesis 
compared to the simulated PXRD pattern from single crystal data. 
Table 2: Resultant precipitation times after addition of various proteins to bioMOF-1. a coloured 
enzyme, b pI refers to the pH at which the protein carries no charge, c range of pIs resulting from 
mixture of isozymes. 
Protein (2 mg) pIb MW (kDA) Time for Initial Precipitation 
No protein - - 5 min 
HRPa 3-9c 44 3 min 
BSA 5.3 66 20-30 min 
Aminated BSA >5.3  5 min 
Catalasea 5.4 250 5-10 min 
Myoglobina 7.6 17 11 min 
Trypsin 10.7 23.3 4 min 
Lysozyme 11, 11.3 14.4 - 
 
The results in Table 2 suggested that some slight acceleration of the MOF precipitation was 
occurring upon addition of select enzymes. For ZIF-8, it has been reported that proteins with 
lower pIs underwent facile biomimetic mineralisation.61 At the pH in which ZIF-8 is synthesised 
the proteins with lower pIs carry greater negative charge, causing them to aggregate zinc ions 
and promote the formation of the MOF around the protein. However, for bioMOF-1 there did 
not appear to be a relationship between pI and MOF growth rate. Amination (Scheme 2) of BSA 
was used to increase the pI of the protein to cause a reduced precipitation time compared to the 
unmodified enzyme, which could suggest that higher pIs may be more favourable in this system.  
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Scheme 2: A reaction scheme showing the amination of carboxylic acid sites on a protein. 
To confirm these precipitation times with higher accuracy, turbidity testing was performed for 
bioMOF-1 formed in the presence of BSA, HRP and catalase to represent proteins that either 
accelerated or delayed MOF formation (Figure 21). Turbidity testing involved collecting solution-
state UV-Vis data during the precipitation event at a wavelength that was not absorbed by the 
material forming. Thus, increases in absorbance are due to greater interference with incident 
light due to precipitation. Higher absorbances are due to greater light scattering due to a larger 
quantity of material being formed and were not necessarily indicative of larger particle size.  
 
Figure 21: Solution-state UV-Vis turbidity data for comparison of bioMOF-1 formation without 
protein (black) and with protein added initially (BSA (red), HRP (blue) and catalase (green)). Time 
refers to the time after addition of zinc to ligand solution. 
The turbidity data confirmed the previously observed precipitation times for bioMOF-1 formed 
in the presence of HRP, BSA and catalase and in the absence of enzyme. However, in the presence 
of each enzyme, the rate of MOF growth was reduced, as could be seen by the slower increase 
in absorbance once precipitation began. To further confirm this, catalase was added after 
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bioMOF-1 had begun to form (Figure 22). The addition of catalase caused the rate of MOF growth 
to reduce, further suggesting that the presence of proteins hindered or obstructed MOF growth.   
 
Figure 22: Turbidity data for bioMOF-1 with catalase added after 6 minutes. Time refers to time 
after addition of zinc to ligand solution. 
It was noted that the original precipitation time of bioMOF-1 in the absence of enzyme was 
relatively short for the conditions tested above, being only 5 minutes. This may have been too 
short to show good distinction between enzymes that accelerated precipitation, and those that 
did not. The experiments were thus repeated with a reduced amount of base, so that bioMOF-1 
formed overnight in the absence of enzyme (Table 3). This was then performed in the presence 
of a selection of proteins, including examples that both accelerated and delayed MOF formation 
in the previous attempts. 
Table 3: Resultant precipitation times after addition of various proteins to bioMOF-1 with 
varying amounts of NaHCO3 added. 
Protein (2 mg) Precipitation Time (0.0625 M NaHCO3) Precipitation Time (0.05 M NaHCO3) 
No protein 5 min Overnight 
HRP 3 min 2.5 hours 
Trypsin 4 min Overnight 
Catalase 5-10 min 2.5 hours 
Myoglobin 11 min 2.5 hours 
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From these results it can be seen that trends are not consistent between trials, with enzymes 
appearing to accelerate the formation of bioMOF-1 in one trial, not accelerating it in the other 
and vice versa. As such, this implied significant discrepancies in precipitation between runs and 
so it is possible that there are additional factors influencing MOF formation. 
To determine whether the proteins were present within the MOF composite, visual inspection 
was used as a preliminary test. Proteins that contain an iron-heme group within their structure, 
such as catalase, HRP and myoglobin, appear coloured due to the Soret bands of the heme group 
allowing it to absorb visible light. The colour of the bioMOF-1 composite formed in the presence 
of catalase, myoglobin and HRP was noted, as was the colour of pure bioMOF-1 and bioMOF-1 
composites formed with non-heme containing proteins (Table 4). 
Table 4: Resultant product colourings after addition of various proteins to bioMOF-1. a coloured 
enzyme, b pI refers to the pH at which the protein carries no charge, c range of pIs resulting from 
mixture of isozymes. 
Protein (2 mg) pIb MW (kDA) Colour of solid 
No protein - - White 
HRPa (red) 3-9c 44 Off white  
BSA (white) 5.3 66 White 
Aminated BSA >5.3  White 
Catalasea (green) 5.4 250 Green 
Myoglobina (green) 7.6 17 Green/brown 
Trypsin (white) 10.7 23.3 White 
 
When formed in the absence of protein, bioMOF-1 is a white powder, therefore, any colouration 
present in bioMOF-1 composites formed with protein was likely to be a result of the biomolecule. 
In the presence of non-heme containing, non-coloured proteins, bioMOF-1 also formed as a 
white powder, indicating the general presence of protein did not impact the colour of the 
material. BioMOF-1 formed with heme-containing proteins consistently possessed similar 
colouring to the pure enzymes, indicating that enzyme was likely present in these samples.  
To confirm these observations, solid-state UV-Vis spectroscopy was used to analyse samples of 
bioMOF-1 synthesised in the presence of the heme-containing enzymes. Each of these enzymes 
exhibits a Soret peak at ca. 400 nm due to the heme group which was used to confirm the 
presence of the enzyme within the MOF samples. Solid-state UV-Vis data confirmed that pure 
bioMOF-1 shows no absorbance in this wavelength region. 
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Figure 23: Solid-state UV-Vis data for a) HRP@bioMOF-1,  b) myoglobin@bioMOF-1 and c) 
catalase@bioMOF-1 in addition to solution-state UV-Vis data for the supernatants and water 
washes from the enzyme@bioMOF-1 syntheses. 
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The UV-Vis data for bioMOF-1 formed in the presence of HRP (Figure 23) showed no Soret peak 
at 400 nm, indicating that no HRP was present within the MOF sample, or it was below the 
detection limit. Solution-state UV-Vis analysis was performed on the filtrate of the 
HRP@bioMOF-1 synthesis which exhibited a strong Soret peak at 400 nm, as did the initial water 
washing solution. This indicated that the enzyme preferentially remained in solution, and any 
enzyme present in the solid was easily removed by washing. Conversely, for bioMOF-1 formed 
in the presence of myoglobin and catalase, the UV-Vis data contained Soret peaks at 400 nm, 
indicating that enzyme was present in both of the MOF samples (Figure 23b/c). The UV-Vis data 
for neither the filtrate nor the water washes contained Soret peaks at 400 nm. This indicated that 
minimal concentrations of catalase and myoglobin remained in solution and that washing the 
samples with water was unable to remove the enzyme from the MOF. 
Interestingly, previous observations indicated that both catalase and myoglobin delayed MOF 
growth, while HRP accelerated it. In turn, UV-Vis data showed that catalase and myoglobin were 
present in the enzyme@bioMOF-1 sample, while HRP was not. This suggested that enzymes 
which were attracted to the MOF, hindered MOF formation, which is very different to the 
mechanism by which ZIF-8 biocomposites form. This strongly indicated that the precipitation of 
bioMOF-1 occurred either independently of the enzyme, or as a co-precipitation event wherein 
the presence of protein inhibited MOF formation. Alternatively, it was possible that the protein 
complexed with one of the MOF components to prevent it from being involved in the MOF 
formation. This latter theory was supported by the understanding that the biomimetic 
mineralisation method for ZIF-8 involves the aggregation of zinc ions around the protein. While 
this is one of the key reasons for the success of ZIF-8 for biomolecule encapsulation, it may be a 
downfall for bioMOF-1 if these complexes are hindering MOF formation. 
2.2.1.3 Analysis of protein encapsulation/protection within bioMOF-1 
Despite the previous results suggesting that it was unlikely that bioMOF-1 forms composites via 
biomimetic mineralisation with the enzymes used, the ability of the MOF to protect proteins was 
still investigated. It was possible that bioMOF-1 may be undergoing co-precipitation with the 
protein, which has been reported to lead to effective biomolecule encapsulation and protection.6  
To provide a preliminary insight into the likelihood of protein encapsulation, confocal laser 
scanning microscopy (CLSM) was used. CLSM records images of fluorescent materials with high 
resolution. Fluorescently tagged enzymes were added to the synthesis of bioMOF-1 to allow for 
confocal imaging of the resultant enzyme@MOF materials. The CLSM images gave an indication 
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of the location of the fluorescent enzyme in relation to the MOF crystals.65, 98 Thus, it could be 
inferred whether the enzyme was likely to be encapsulated within the crystal or surface bound. 
However, it must be acknowledged that this technique assumes that the fluorescently tagged 
enzyme behaves like the native enzyme and that the presence of the fluorescent tag did not alter 
the enzyme-MOF interactions. Fluorescein isothiocyanate (FITC) was chosen as the fluorescent 
tag to be used as it has been frequently used for biomimetic mineralisation for other MOFs.47, 99 
For these studies, FITC-tagged catalase (FCAT) and FITC-tagged myoglobin (FMb) were used as 
UV-Vis data indicated that native catalase and myoglobin were both present in 
enzyme@bioMOF-1 composites. CLSM images were taken for FCAT@bioMOF-1 and 
FMb@bioMOF-1 (Figure 24) formed using the two different syntheses that have been previously 
explored (pure MOF precipitation after 5 minutes or overnight due to varying base 
concentration). It was postulated that the crystals formed with a reduced base concentration 
would be larger due to the slower growth.  In all cases, the precipitation times agreed with that 
for the native enzymes, indicating that the tagged enzymes were likely behaving comparatively. 
 
Figure 24: Confocal images (overlay of bright field and fluorescence) for FCAT@bioMOF-1 formed 
with a) 0.0625 M NaHCO3 and b) 0.05 M NaHCO3 and FMb@bioMOF-1 formed with c) 0.0625 M 
NaHCO3 and d) 0.05 M NaHCO3. Tagged protein shown in green. 
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The confocal images for both FCAT@bioMOF-1 and FMb@bioMOF-1 showed non-homogenous 
distribution of the enzyme across the MOF crystals. This indicated that the enzyme was most 
likely surface bound or at defects of the crystals, and so was unlikely to be encapsulated within 
the MOF. These results were not altered by the rate at which the crystals formed.  
To test this hypothesis, a method of removing surface-bound enzyme was developed. This would 
ensure that any enzyme remaining in the MOF sample after this procedure must be 
encapsulated. To identify washing conditions, FITC-tagged catalase and myoglobin were 
adsorbed to bioMOF-1 crystals by soaking crystals in an enzyme solution for 3 minutes, before 
isolation via centrifugation. This analysis was performed for FMb and FCAT. The enzyme-on-
bioMOF-1 samples were then washed with various mixtures of SDS and EDTA followed by CLSM 
analysis (Table 16). If any fluorescence remained after the washing procedure it was deemed to 
be unsuccessful. 
One notable observation was the similarity in appearance for the enzyme@bioMOF-1 (Figure 24) 
and enzyme-on-bioMOF-1 (Table 16) crystalline composites for both FCAT and FMb prior to 
washing, suggesting that the enzyme was predominantly surface-adsorbed in the former. 
In regard to the success of the washing procedures for surface-bound FMb, the only washing 
procedure that appeared to remove all protein was a 1:1 mixture of 10% SDS and 10% EDTA. 
However, it was extremely difficult to find crystals within the confocal sample which indicated 
that a significant proportion of the sample has dissolved. Thus, no washing procedure was found 
to be effective for removing surface-bound myoglobin without decomposing the MOF, and no 
further analysis was performed with myoglobin@bioMOF-1. 
Surface-bound FCAT was removed with a 1:1 mixture of 10% SDS and 1% EDTA solutions. This 
difference between the behaviour of FCAT and FMb may have been due to the different pI of the 
enzymes, which would in turn cause differences in the overall surface charge and, thus, 
interactions with the MOF. Alternatively, it may be due to the significantly smaller size of Mb 
compared to catalase, which might have allowed it to get closer to the MOF or fit into defects on 
the crystal surface thereby conferring stronger binding or protection from the washing solutions. 
It was noted that while the aqueous 1:1 mixture of 10% SDS and 1% EDTA was effective at 
removing FCAT from the surface of the crystal, there were still signs of tagged enzyme left in 
solution in the confocal images. Hence, further water washes were performed to ensure this was 
removed effectively. It was also noted that the washing solutions may have slightly different 
effects on untagged proteins compared to those with FITC groups. 
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CAT@bioMOF-1 was washed with a 1:1 mixture of 10% SDS and 1% EDTA to indicate what 
proportion of the enzyme was encapsulated within the MOF (Figure 82 in the appendix), 
However, as a result of errors present in solid-state UV-Vis spectroscopy, this data was deemed 
to be unreliable. 
Instead, CLSM was performed on a sample of FCAT@bioMOF-1 before and after washing with 
the 1:1 mixture of 10% SDS and 1% EDTA (Figure 25). 
 
Figure 25: CLSM images (fluorescence, bright field and overlay) of FCAT@bioMOF-1 a) before and 
b/c) after washing with a 1:1 mixture of 10% SDS and 1% EDTA (x3). Tagged enzyme is shown in 
green. 
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As seen in previous CLSM images of FCAT@bioMOF-1, there was a clear presence of fluorescent 
enzyme which was co-located with the crystals (Figure 25a). However, upon washing with the 
1:1 mixture of 10% SDS and 1% EDTA the fluorescent enzyme was either removed completely 
(Figure 25b) or was reduced in quantity (Figure 25c). This further suggested that a large 
proportion of enzyme present in the bioMOF-1 samples was surface bound. It also justified why 
there was still a Soret peak at 400 nm in the solid-state UV-Vis data for FCAT@bioMOF-1 after 
washing with the 1:1 10% SDS and 1% EDTA mixture (see appendix data Figure 82).  
To quantify the total enzyme removal, solution-state fluorescence data was collected for 
FCAT@bioMOF-1 before and after washing with the 1:1 mixture of 10% SDS and 1% EDTA. This 
analysis was performed by dissolving the washed and unwashed samples in 10% EDTA (any 
remaining solid was removed via centrifugation) and the supernatant was analysed by 
fluorescence spectroscopy. This fluorescence intensity was then converted to an FCAT 
concentration using a calibration curve (Figure 88 in the appendix). The fluorescence data for 
FCAT@bioMOF-1 before and after the washing procedure (Table 5) revealed that there was more 
than a 70% reduction in FCAT concentration upon removing surface-bound enzyme, further 
indicating that the enzyme was predominantly surface bound. 
Table 5: Fluorescence data and FCAT concentration calculations for FCAT@ZnGlut before and 



















344.61 404.78 1.0 0.40 4.1 24.2 (100%) 
FCAT@ZnGLUT  
(1:1 10% SDS 
1% EDTA Wash) 
40.68 29.43 1.0 0.029 16.7 7.18 (29.6%) 
 
Due to these combined observations, no further work was carried out for any enzyme@bioMOF-
1 material due to the inability to consistently encapsulate the enzyme within the MOF crystals. 
Furthermore, it was noted that any encapsulation was not likely to be occurring via the 
biomimetic mineralisation mechanism and therefore may not afford the protections needed. 
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2.2.2 Zinc Carnosine (BioMOF-2) 
2.2.2.1 Biocompatible synthesis and characterisation of bioMOF-2 
The second bioMOF of interest, zinc carnosine (bioMOF-2), was also initially synthesised via the 
literature conditions wherein a solution of L-Carnosine (0.03 M) and zinc nitrate hexahydrate 
(0.06 M) in water and DMF was heated overnight at 100°C.4 The only deviation from the literature 
synthesis was that temperature ramping was not used, primarily because large crystals were not 
needed. PXRD data for the synthesised MOF crystals matched the PXRD pattern simulated from 
single crystal data for zinc carnosine (Figure 26). It was noted that there were discrepancies in 
relative peak intensities, however, this was attributed to preferred orientation effects. 
 
Figure 26: PXRD data for experimental bioMOF-2 (red) compared to simulated pattern (black) 
constructed from single crystal data. 
As the reported synthesis for bioMOF-2 required the use of both organic solvents (DMF) and 
extensive heating, which are incompatible with protein protection, the procedure was altered to 
ensure the MOF could be synthesised in the presence of biomolecules. 
Specifically, a procedure needed to be designed using only aqueous, or predominantly aqueous, 
conditions at room temperature and near biological pH. Initial attempts to do this were based 
around the method used for the synthesis of bioMOF-1. This involved addition of base, replacing 
solvents with water and removal of heating. The attempted conditions are shown in Table 6. The 
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general procedure for these trials was to dissolve the linker and base in water (5 mL) and dissolve 
the zinc salt in water (5 mL) separately, followed by dropwise addition of the zinc solution to the 
ligand solution. 
Table 6: Synthetic conditions in purely aqueous solutions attempted for bioMOF-2. All trials were 
performed in water (10 mL). 
Carnosine 
(mmol) 
Base (mmol) Zn Salt (mmol) 




























































40 min water Amorphous 
 
However, PXRD data indicated that all materials formed were amorphous and so, unlike bioMOF-
1, bioMOF-2 could not be formed in aqueous conditions purely by the addition of base. From the 
literature synthesis of zinc carnosine, it was noted that a methanol wash was used prior to 
isolation of the material. Further, for the ZIF-8 synthesis under biomimetic mineralisation 
conditions, alcohol washes are also performed.2, 61, 100 Thus, additions of, and/or washes with 
varying volumes of either methanol or ethanol during the synthesis of bioMOF-2 were attempted 
(Table 7). These attempts were conducted with the same general method as above, with all 
solvents other than water added to the ligand solution prior to the addition of zinc. 
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Table 7: Synthetic conditions from bioMOF-2 with added alcohol. All contained 0.22 mmol L-
Carnosine and 0.44 mmol Zn(NO3)2·6H2O. 
Condition to be 
investigated 
Base (mmol) Solvents used (mL) 








H2O (10 mL) 
MeOH (5 mL) 
(2:1) immediate Amorphous 
NaHCO3 
(0.3125 mmol) 
H2O (10 mL) 
MeOH WASH 
 immediate Amorphous 
No base 
H2O (10 mL) 
MeOH WASH 
 
No precipitate formed 
overnight 
N/A 
Use of EtOH in 
synthesis; 
amount of base 
(2:1 H2O : EtOH) 
NaHCO3 
(0.3125 mmol) 
H2O (10 mL) 
EtOH (5 mL) 
(2:1) immediate ZnCar 
NaHCO3 
(0.1560 mmol) 
H2O (10 mL) 
EtOH (5 mL) 
(2:1) Immediate ZnCar 
NaHCO3 
(0.0786 mmol) 
H2O (10 mL) 
EtOH (5 mL) 
(2:1) Immediate ZnCar 
No base 
H2O (10 mL) 
EtOH (5 mL) 
(2:1) 35 min ZnCar 
Use of EtOH is 
synthesis; 
amount of base 
(9:1 H2O : EtOH) 
NaHCO3 
(0.0786 mmol) 
H2O (9 mL) 
EtOH (1 mL) 
(9:1) 10 seconds ZnCar 
No base 
H2O (9 mL) 
EtOH (1 mL) 
(9:1) overnight ZnCar 
Use of an EtOH 




H2O (10 mL) 
EtOH WASH 
 5 min Amorphous 
No base 
H2O (10 mL) 
EtOH WASH 
 





Figure 27: PXRD data for bioMOF-2 formed with 2:1 H2O : MeOH + NaHCO3 (purple), pure water 
+ NaHCO3 with an EtOH wash (blue), 2:1 H2O : EtOH  with no base (green), 9:1 H2O : EtOH with 
no base (orange) and with NaHCO3 (red) compared to the pattern of bioMOF-2 simulated from 
the single crystal data. 
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Despite the original literature synthesis of zinc carnosine using methanol to wash the solid 
obtained from the reaction, the addition of methanol to the synthesis of bioMOF-2 did not yield 
the desired crystalline product. Further, washing the amorphous product with methanol did not 
form the crystalline product. 
However, the addition of ethanol promoted the formation of crystalline bioMOF-2, with higher 
ethanol concentrations promoting more rapid MOF growth, such that no base was needed, 
unlike for bioMOF-1 formation which required base. It was also confirmed that purely washing 
the final product with ethanol was not sufficient to convert the amorphous precipitate into 
crystalline bioMOF-2, indicating that the ethanol needed to be present during the synthesis. 
PXRD data also indicated that lower concentrations of ethanol formed more crystalline material 
(Figure 27), possibly due to slower precipitation. This is supported by the comparison between 
bioMOF-2 samples formed with or without the addition of sodium bicarbonate; with base 
present the material forms much more quickly and is consequently less crystalline. 
Time lapse photos were taken of bioMOF-2 formed using 0.005 M and 0 M NaHCO3 in 2:1 mixture 
of water to ethanol to show the rate and quantity of precipitate formed over time (Figure 28). 
 
Figure 28: Time-lapse photos of bioMOF-2 formed in the presence of base (15(4)) and no base 
(15(5)) in a 2:1 water to ethanol solution a) before addition of zinc solution and b) immediately, 
c) 5 minutes, d) 30 minutes, e) 1 hour and f) 3 hours after addition of zinc to ligand solution. 
To ensure the material studied was highly crystalline, all further work with bioMOF-2 utilised the 
synthesis in a 9:1 water and ethanol mixture with no added base. This synthesis also afforded the 
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longest delay in precipitation time, making it well suited to biomimetic mineralisation for reasons 
mentioned previously. Further, the reduced concentration of ethanol increased the 
biocompatibility of the MOF synthesis. 
To characterise the morphology of bioMOF-2 crystals, scanning electron microscopy (SEM) was 
utilised (Figure 29). The SEM images showed that bioMOF-2 formed as homogenous plate-like 
crystals (≈ 1 µm), with sharp edges indicating high crystallinity. As is shown in Figure 29d, 
aggregates also formed, however, as no compositional information was obtained, no comment 
can be made on their origin.  
 
Figure 29: SEM images for bioMOF-2 crystals at a) 5,000 x, b) 10,000 and c) 50,000 x 
magnification, and d) an unknown aggregate at 5,000 x magnification. 
The thermal and chemical stability of bioMOF-2 was analysed to understand which environments 
the MOF could tolerate which, unlike for bioMOF-1, had not been reported extensively in 
literature. 
To test the stability of bioMOF-2 across a range of acidic and basic pHs (Table 17 in the appendix), 
the MOF was stirred in a solution of known pH for 1 hour, after which time the solid was isolated 
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by centrifugation and dried. PXRD analysis (Figure 83 in the appendix) revealed that bioMOF-2 
was stable over a pH range of 3 to 9, with good stability in mildly acidic conditions. 
This pH stability contrasts with other MOFs that have been used for biomolecule encapsulation, 
including ZIFs and MAF-7. To provide some context, the pH stability range for bioMOF-2 was 
compared to a range of other MOFs (Table 8). 
Table 8: Comparison of pH stability ranges for bioMOF-2 to a variety of other MOFs. 






ZIF-8101 -NH (imidazole) Zn 5-12 
ZIF-90102 -NH (imidazole) Zn >6 
MAF-765 -NH (triazole) Zn >5 
UiO-66103 -COOH Zr 1-7 
NU-1000103 -COOH Zr 1-11 
MOF-808103 -COOH Zr 1-7 
MOF-545103 -COOH Zr <0-7 
 
From this small sample of MOFs, those containing carboxylate binding sites were generally more 
stable in acidic conditions, while those containing solely N-donor sites are stable at higher pHs. 
Thus, as bioMOF-2 contains both of these binding sites, it is sensible that the stability range 
included a moderate range of both acidic and basic pHs. 
To test the thermal and chemical stability of bioMOF-2, MOF samples were placed in either water 
or DMF and exposed to elevated temperatures for one hour (Table 9). In all cases, PXRD data 
revealed no decomposition (Figure 83 in the appendix), showing that bioMOF-2 possessed very 
high thermal stability and excellent chemical stability. 
Table 9: Thermal and DMF stability tests for bioMOF-2. 
Solvent Temperature After 1 hour PXRD Conclusion 
Water 
r.t. 




Heat gun (10 s) 
DMF 
r.t. 
Heat gun (30 s) 
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2.2.2.2 Synthesis of protein@bioMOF-2 biocomposites 
To add protein to bioMOF-2 for attempted encapsulation, the enzyme was added to the ligand 
solution, followed by dropwise addition of the aqueous zinc solution. As both bioMOF-2 and ZIF-
8 contain imidazole groups, the proteins chosen for bioMOF-2 included ones that underwent 
successful biomimetic mineralisation with ZIF-8, as well as ones that did not.61 Namely, BSA, 
catalase and HRP underwent biomimetic mineralisation with ZIF-8, whereas myoglobin, trypsin 
and lysozyme did not.  
To ensure that the addition of enzyme did not alter the structure of the MOF, PXRD data for 
protein@bioMOF-2 composites were collected. PXRD analysis of bioMOF-2 formed with protein 
showed no peak shifts or changes in relative peak intensities compared to the pure bioMOF-2, 
indicating that no significant structural changes occurred upon enzyme inclusion in the reaction 
mixture (Figure 30).  
 
Figure 30: PXRD for bioMOF-2 after addition of various enzymes during MOF synthesis compared 
to pure bioMOF-2. 
To determine whether the addition of protein impacted crystal morphology, SEM images of pure 
bioMOF-2 and catalase@bioMOF-2 were compared (Figure 31). 
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Figure 31: Comparison of SEM images of catalase@bioMOF-2 (a-c) and bioMOF-2 (d) at 5,000 x, 
10,000 x, and 50,000 x magnification. 
The crystals of CAT@bioMOF-2 have very sharp and well-defined faces and edges, explaining the 
high crystallinity observed in the PXRD pattern. Further, there are some larger aggregates of 
unknown origin in the CAT@bioMOF-2 sample (Figure 31a) which look similar to the aggregates 
seen for pure bioMOF-2 (Figure 29). Interestingly the SEM images show that CAT@bioMOF-2 
forms as block-shaped crystals, compared to pure bioMOF-2 which formed as plate-like crystals, 
of similar size. The exact reasoning is difficult to confirm, it may have been due to encapsulated 
enzymes promoting the formation of a different crystal morphology or the enzyme may promote 
aggregation of the plate-shaped crystals. Nevertheless, the SEM data indicated that the presence 
of enzyme impacted the crystal growth of bioMOF-2 composites. 
To determine whether biomimetic mineralisation was occurring for bioMOF-2 biocomposite 
formation, the precipitation rates of the MOF with and without added enzyme were compared 
(Table 10). As previously mentioned, a key indicator of biomimetic mineralisation is accelerated 
MOF growth in the presence of enzyme. 
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Table 10: Resultant precipitation times after addition of various proteins to bioMOF-2. a 
coloured enzyme, b pI refers to the pH at which the protein carries no charge, c range of pIs 
resulting from mixture of isozymes. 
Protein (2 mg) pIb MW (kDA) Time for Initial Precipitation 
No protein - - Overnight 
HRPa 3-9c 44 Immediate 
BSA 5.3 66 5-10 seconds 
Catalasea 5.4 250 Immediate 
Myoglobina 7.6 17 2 hours 
Trypsin 10.7 23.3 3 days 
Lysozyme 11, 11.3 14.4 2.5 hours 
 
The precipitation times showed that significant acceleration of the MOF precipitation occurred 
upon addition of lower pI proteins, suggesting that both bioMOF-2 and ZIF-8 follow similar trends 
wherein proteins of lower pI accelerate MOF formation. MOF precipitation was also accelerated, 
to a lesser degree, by higher pI proteins (myoglobin, lyzozyme), suggesting that pI was not 
necessarily the only factor governing biocomposite formation for bioMOF-2.  
While the precipitation times recorded in Table 10 are representative of the time taken for the 
initial precipitate to begin to form, it was also noted that the precipitation occurred very slowly, 
such that samples were collected after stirring overnight. This suggested that MOF growth 
occurred gradually as opposed to an instantaneous precipitation event. 
To confirm the accuracy of these precipitation times and to determine whether MOF growth 
occurred gradually, turbidity testing was subsequently performed for the formation of bioMOF-
2 in the presence of select enzymes (Figure 32). BSA, HRP and catalase were chosen to represent 
the enzymes that rapidly increased the precipitation time, while myoglobin represented those 
that only slightly accelerated bioMOF-2 formation.  
For bioMOF-2 formed in the presence of myoglobin, previous observations suggested that 
precipitation did not begin until 2.5 hours after combining the ligand and zinc solutions. Yet, 
turbidity data showed that precipitation commenced immediately after adding zinc to the ligand 
and myoglobin solution, but at a very slow rate ceasing after approximately 75 minutes. Thus, 
there are slight variations in the precipitation times between repeats of the experiment; 
however, the turbidity data still supported the general trend in observed precipitation times 
wherein select proteins significantly accelerate MOF formation (within seconds), while others 
accelerate it to a lesser extent.  
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Figure 32: Solution-state UV-Vis turbidity data for bioMOF-2 formed in the presence of a) BSA 
(black), HRP (red) and CAT (blue) and b) Myoglobin. Time refers to the time after addition of zinc 
to ligand solution. The rate of the change of absorbance is indicative of the rate of precipitation, 
while absolute absorbance values do not necessarily indicate a greater volume of precipitation, 
or greater particle size. 
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The turbidity data showed that bioMOF-2 formed very rapidly in the presence of BSA, HRP and 
catalase upon addition of the zinc solution such that precipitation had begun before the 
collection of UV-Vis data had commenced. As a result, the turbidity data does not effectively 
depict the rapid formation. The turbidity data also showed that the maximum absorbances 
recorded for bioMOF-2 formed in the presence of each of these proteins varied significantly. To 
investigate the cause of this variation, multiple turbidity testing runs were performed for each 
protein. The turbidity data revealed that the maximum absorbance reached for separate runs 
using the same protein also varied significantly. Thus, changes in the maximum absorbance 
reached per run were likely due to natural variations in the quantity of product produced and 
was not related to the specific protein used. 
Interestingly, for bioMOF-2 formed with catalase, BSA and HRP, there was no gradual MOF 
formation after the initial precipitation event as was previously theorised. The alternate 
explanation for the formation of a large quantity of MOF when left overnight was that a second 
precipitation event occurred during this time. To investigate this further, the bioMOF-2 
precipitate formed immediately in the presence of catalase, HRP and BSA was isolated and the 
supernatant was left to stir overnight, after which time additional material formed. This 
supported the hypothesis that at least two distinct precipitation events were occurring in the 
presence of these enzymes; one immediately after combining the ligand, enzyme and metal 
solutions, and one overnight. No such two-step precipitation was observed for enzymes that did 
not induce immediate precipitation (Table 11), suggesting that proteins with lower pIs promoted 
the formation of two distinct precipitates, while those with higher pIs did not. 
Table 11: Proteins used in the synthesis of bioMOF-2 and whether they resulted in the formation 
of one or two distinct precipitates. 
Protein (2 mg) pI MW (kDA) 
Number of Precipitates 
One Two 
No protein - -   
HRP 3-9 44   
BSA 5.3 66   
Catalase 5.4 250   
Myoglobin 7.6 17   
Trypsin 10.7 23.3   
Lysozyme 11, 11.3 14.4   
 
To determine the compositions of each precipitate and to potentially determine the cause of the 
two precipitation events, both were isolated and analysed separately. Henceforth the first and 
second precipitates are referred to as bioMOF-2-1 and bioMOF-2-2, respectively. BioMOF-2-1 
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formed in the presence of heme-containing enzymes possessed strong colouration similar to that 
of the pure enzyme, while bioMOF-2-2 possessed only very slight colouration. The initial 
precipitation event likely removed a large quantity of protein from the reaction mixture, leaving 
minimal protein available for potential encapsulation within the crystalline precipitate that 
formed subsequently. To assist in the identification of the two precipitates, PXRD data was 
collected for each. PXRD data showed that only bioMOF-2-2 was the correct crystalline zinc 
carnosine material, while bioMOF-2-1 was amorphous (Figure 33). 
 
Figure 33: PXRD data for bioMOF-2-1 (black) and bioMOF-2-2 (red) formed in the presence of 
catalase compared to the simulated pattern constructed from single crystal data (blue). 
Thus, what was initially thought to be acceleration of MOF formation caused by protein present 
in solution, was instead the precipitation of an amorphous material. The MOF did not form until 
the solution was left to stir overnight, and so this formation was no more rapid than when 
enzyme was not present. Thus, it was improbable that biomimetic mineralisation was occurring 
in this system via the same mechanism observed for ZIF-8. 
To characterise the initial amorphous precipitate, 1H NMR spectroscopy was used, which 
produced a spectrum consisting solely of solvent peaks, confirming that no carnosine was 
present. As such, it was postulated that this initial precipitate was either excess enzyme 
precipitating out of solution, or a zinc salt-enzyme composite. The latter proposal is supported 
by the ZIF-8 mechanism wherein the zinc ions are thought to aggregate around the protein.61 In 
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either case, the presence of zinc and protein were vital to its formation. It was postulated that 
the concentration of zinc ions used was too high, causing the initial precipitation event; however, 
testing biocomposite preparation conditions with reduced zinc concentrations could not prevent 
the formation of this initial precipitate. 
For all further testing, only crystalline bioMOF-2-2 was used unless otherwise stated.  
Select proteins containing a highly conjugated heme group, such as catalase, HRP and myoglobin, 
absorb in the visible range, making them appear coloured. Preliminary observation of the colour 
of bioMOF-2-2 formed in the presence of these heme-containing proteins was conducted. This 
was also performed for bioMOF-2-2 formed in the presence of non-heme containing proteins. 
The colours of these materials were compared to bioMOF-2-2 (Table 12). 
Table 12:  Colours of bioMOF-2-2 biocomposites formed with various proteins. a coloured 
enzyme, b pI refers to the pH at which the protein carries no charge, c range of pIs resulting from 
mixture of isozymes. 
Protein (2 mg) pIb MW (kDA) Colour of solid 
No protein - - White 
HRPa 3-9c 44 White 
BSA 5.3 66 White 
Catalasea 5.4 250 Pale Brown 
Myoglobina 7.6 17 Pale Green 
Trypsin 10.7 23.3 White 
Lysozyme 11, 11.3 14.4 White 
 
Samples of bioMOF-2-2 formed with or without the addition of non-heme containing proteins 
were both white, whereas bioMOF-2-2 formed with catalase and myoglobin possessed colouring 
similar to that of the enzymes, indicating the presence of these enzymes in the biocomposites. 
However, this was not observed for HRP, either because the concentration was below the eye’s 
detection limit, or because HRP was not present in the bioMOF-2-2 sample.  
Solid-state UV-Vis spectroscopy was used to further confirm the presence of heme-containing 
enzymes in the bioMOF-2-2 samples (Figure 34). The presence of a Soret band at 400 nm 
indicates the presence of a heme group. BioMOF-2-2 showed no absorbance around 400 nm, 
and therefore any recorded absorbance in this region was attributed to the protein present. 
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Figure 34: Solid-state UV-Vis data for bare bioMOF-2-2 (black) compared to catalase@bioMOF-
2 (red), myoglobin@bioMOF-2-2 (blue) and HRP@bioMOF-2 (green). 
Only the UV-Vis data for myoglobin@bioMOF-2-2 contained a Soret peak at 400 nm, while no 
such peak was observed for catalase@bioMOF-2-2 and HRP@bioMOF-2-2. This indicated that 
neither catalase nor HRP were located in the composites at detectable concentrations, which 
contrasted with the visual inspection suggesting the former was likely to be present. The absence 
of catalase and HRP was most likely due to the initial protein-rich amorphous precipitate 
removing a significant proportion of the enzyme. This initial precipitate did not form in the 
presence of myoglobin, and so would explain why this was the only protein present in the 
bioMOF-2-2 samples.  
2.2.2.3 Analysis of protein encapsulation/protection within bioMOF-2-1 and bioMOF-2-2 
To conduct preliminary tests to determine whether enzyme encapsulation within bioMOF-2 
crystals was likely, confocal scanning laser microscopy (CLSM) was utilised. As noted previously, 
this assumes identical behaviour between the native and fluorescently tagged enzymes. 
Initially FITC-tagged catalase (FCAT) and FITC-tagged myoglobin (FMb) were used in the synthesis 
of bioMOF-2 to allow comparison of results for enzymes which did (catalase) or did not 
(myoglobin) form the initial amorphous material. While UV-Vis spectroscopy could not detect 
catalase within the bioMOF-2 samples, CLSM allowed for secondary confirmation. 
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In the presence of FCAT, bioMOF-2 did not precipitate out of solution within a 24-hour period, 
while bioMOF-2 formed overnight in the presence of FMb. These precipitation times, or lack-
there-of are significantly different than those observed for the native enzymes. To ensure that 
contamination of previously prepared FCAT and FMb solutions was not the cause, both stock 
solutions were re-purified by passing through an Illustra NAP-25 column. However, no change in 
precipitation was observed using these re-purified tagged enzymes. The significant 
inconsistencies between precipitation times for bioMOF-2 in the presence of FCAT and FMb 
compared to the native enzymes suggested that the fluorescent tag changed key properties of 
the enzymes. As such, it appeared that FITC-tagged catalase and myoglobin interacted with the 
MOF differently to the native enzymes. As such, CLSM was not performed for bioMOF-2 with 
FCAT or FMb as the confocal images were likely to not be indicative of the behaviour of native 
enzymes.  
To determine if the use of a different fluorescence tag could impact the enzymatic behaviour to 
a lesser extent, RbITC-tagged catalase (RbCAT) and myoglobin (RbMb) were used in the synthesis 
of bioMOF-2. The precipitation of bioMOF-2 in the presence of RbMb began after 3 hours, 
making it comparable to free enzyme, but subsequent precipitation occurred at an extremely 
slow rate. Further, bioMOF-2 formed after 5-6 hours in the presence of RbCAT, with no initial 
amorphous precipitate produced. Despite the RbITC tag appearing to have a reduced impact 
compared to FITC, there were still discrepancies in the way the MOF formed. Thus, CLSM was not 
performed for bioMOF-2 formed with RbMb and RbCAT as a result. 
Due to these significant discrepancies between the tagged and free enzymes, FITC-tagged HRP 
(FHRP) and BSA (FBSA) were used instead. The addition of FHRP or FBSA to the synthesis of 
bioMOF-2 both caused the immediate precipitation of an amorphous material, followed by a 
delayed overnight precipitation of crystalline zinc carnosine. Thus, suggesting that tagged and 
native HRP and BSA were interacting with the MOF in comparable ways. 
The difference in biocomposite formation for tagged catalase and myoglobin compared to tagged 
BSA and HRP may be due to changes in pI upon addition of the FITC (or RbITC) tag. As bioMOF-2 
was formed in a neutral (pH 7) solution, any change in pI could have had a significant impact on 
the interaction with the MOF precursors. 
Due to the apparent similarity between FITC tagged HRP and BSA and the native proteins, CLSM 
imaging was conducted on both the enzyme@bioMOF-2-1 and enzyme@bioMOF-2-2 
composites (Figure 35, Figure 36 and Figure 37).  
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Figure 35: CLSM images (fluorescence, bright field and overlay) of the initial amorphous 
precipitate FHRP@bioMOF-2-1. Tagged enzyme is shown in green. 
 
Figure 36: CLSM images (fluorescence, bright field and overlay) of second precipitate 
FHRP@bioMOF-2-2. Tagged enzyme is shown in green. 
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Figure 37: CLSM images (fluorescence, bright field and overlay) of the second precipitate 
FBSA@bioMOF-2-2. Tagged enzyme is shown in green. 
The confocal images for the first precipitate (Figure 35) show that FHRP is present throughout 
the whole sample, as indicated by the homogenous distribution of intense fluorescence 
observed. No high-quality images of the first precipitate with FBSA were able to be produced due 
to small particle size. This CLSM data supported previous observations which indicated that the 
initial precipitate contained very high concentrations of protein. Further, the images for the 
second precipitate formed in the presence of either FHRP or FBSA (Figure 36 and Figure 37 
respectively) both showed an inhomogeneous distribution of the fluorescence label across the 
crystals. While this data could confirm that the MOF and enzymes were co-located, it was difficult 
to determine whether the enzyme was encapsulated. 
To more definitively determine whether encapsulation was occurring, aqueous assays were used 
to give measures of the activity of either catalase or peroxidase. These assays were initially 
performed on the overall enzyme@bioMOF-2 composite prior to determining that the 
precipitation occurred in two steps. Following this realisation, the assays were also conducted on 
separate samples of bioMOF-2-1 and bioMOF-2-2, as CLSM had confirmed the presence of 
enzyme in both. These methods produce quantitative data with fewer potential sources of error 
compared to the methods used for bioMOF-1. The reason for conducting more extensive 
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research into the encapsulation and protective ability of bioMOF-2 compared to bioMOF-1 was 
primarily due to the greater similarities between the zinc carnosine and ZIF materials.   
To determine the enzymatic activity of catalase, a ferrous oxidation of xylenol orange (FOX) assay 
was conducted. This assay utilises the ability of catalase to promote the reduction of hydrogen 
peroxide by the following equation;104 
𝐻2𝑂2 →  𝐻2𝑂 + 𝑂2 
Hydrogen peroxide is able to oxidise ferrous iron (+2) to ferric iron (+3), which can subsequently 
bind to the xylenol orange dye, while ferrous iron cannot.105 Fe3+ bound to xylenol orange absorbs 
strongly at 560nm, while the unbound dye has minimal to no absorbance at this wavelength. This 
allows the use of UV-Vis spectroscopy to determine the amount of bound dye, and by extension 
the amount of hydrogen peroxide. A higher absorbance at 560 nm (purple colouration) is 
indicative of more bound Fe3+ xylenol orange, therefore a higher hydrogen peroxide 
concentration and so a lower catalase activity. A yellow colouration indicates the reverse. 
Experimentally, FOX assays are performed by placing the sample in a solution of hydrogen 
peroxide (0.25 mM) and after specific time intervals (1, 5, 10 minutes for this work) a volume of 
this hydrogen peroxide mixture (50 µL) is reacted with FOX reagent (950 µL) for 30 minutes prior 
to analysis. These time intervals have been shown to be sufficient lengths of time for 
catalase@ZIF biocomposites.106 Sampling over these time intervals also gave an indication of the 
rate at which any catalase present is able to decompose the hydrogen peroxide. 
To measure the activity of peroxidases, such as HRP, pyrogallol assays were conducted wherein 
the peroxidase catalyses the conversion of pyrogallol to purpurogallin (Scheme 3). The initial 
pyrogallol solution is virtually colourless, while purpurogallin has a very strong yellow colour. UV-
Vis spectroscopy can record the change in absorbance at 420 nm to determine the rate of 
purpurogallin production. A more rapid increase in absorbance at 420 nm indicates a higher 
purpurogallin production and, by extension, greater peroxidase activity. 
 
Scheme 3: Conversion of pyrogallol to purpurogallin in the presence of peroxide and H2O2. 
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The activity of CAT@bioMOF-2 was first analysed qualitatively using the FOX assays. This study 
was conducted for free catalase, bare bioMOF-2 and CAT@bioMOF-2 (Figure 38) to ensure that 
the catalase used was active and the bare MOF did not produce any false positives in the activity 
readings. These assays were performed on the combined precipitates as they were conducted 
prior to determining that precipitation occurred in two steps. 
 
Figure 38: Qualitative FOX assay results for free catalase, pure bioMOF-2 and CAT@bioMOF-2 
compared to 0 mM and 0.25 mM H2O2. Assays were performed with [H2O2] of 0.25 mM, times 
refer to the length of time the test substances were left in H2O2 solution before adding to FOX 
reagent. 
The qualitative results for free catalase showed assay solutions possessing coloration that 
matched that of the standards with 0 mM hydrogen peroxide. This indicated that all peroxide 
present in the solution was decomposed in under one minute, confirming that the catalase was 
highly active. The results also confirmed that pure bioMOF-2 sample was unable to decompose 
an observable quantity of peroxide. Finally, the CAT@bioMOF-2 sample showed slight enzymatic 
activity, with a much more gradual decomposition of hydrogen peroxide compared to the free 
enzyme. However, these assays were not performed with equivalent catalase concentrations and 
so the absolute activities of the free enzyme and CAT@bioMOF-2 samples could not be 
compared. 
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These qualitative assays were then repeated for free catalase and CAT@bioMOF-2 after 
exposure to a range of harsh external conditions including base, acid, elevated temperatures, 
organic solvents and protease. If the enzymatic activity of catalase within the MOF samples 
decreased to a lesser extent than the free enzyme, this suggested that the MOF was offering 
protection to the biomolecule, potentially due to successful encapsulation. However, if the 
enzymatic activity decreased to the same or greater extent than the free enzyme, then 
encapsulation and protection of the biomolecule by bioMOF-2 was deemed unsuccessful. The 
respective catalase activities for CAT@bioMOF-2 following exposure to these conditions are 
shown qualitatively in Figure 39. 
Controls confirmed that the presence of DMF, water, acid, base and protease had no effect on 
the assay (Figure 84 in the appendix). The free enzyme experienced no observable loss in 
enzymatic activity upon exposure to acidic and basic solvents, and only slight activity losses upon 
exposure to DMF and protease. Only after exposure to elevated temperatures (120°C) did the 
free enzyme appear to lose most or all enzymatic activity, which agreed with literature data as 
120°C falls far outside of the thermal stability region of catalase.16 The significant reduction in 
activity upon exposure of the free enzyme to organic solvent and protease also agrees with 
previous results from literature.65 The high stability of the free enzyme in basic conditions agrees 
with the literature data for pH stability as it is very close to the optimal pH of catalase, however, 
a pH of 3 is well below the accepted pH range in which catalase is stable, making this result 
unexpected.16 It is possible that the concentration of enzyme was too high, such that high enough 
concentration of catalase were present to fully decompose the H2O2 present even after some 
decomposition had occurred. 
The qualitative data indicated that, while the original CAT@bioMOF-2 possessed observable 
enzymatic activity, this activity was removed upon exposure to protease, heating, DMF, acid and 
base. Therefore, the enzyme in the CAT@bioMOF-2 biocomposites appeared to be less stable 
than the free enzyme, indicating that the MOF was unable to offer any protective capacity to the 
enzyme. This may have been because the enzyme was solely surface-bound, or it may be 
encapsulated but the MOF was unable to protect it from harsh external conditions. The former 
was supported by CLSM data in which the enzyme appeared to be predominantly located on the 
surface of the crystals. 
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Figure 39: Qualitative FOX assay results for free CAT (left) and CAT@bioMOF-2 (right) after 
treatment with protease (2mg/mL in 0.05 M Tris-HCl pH 8 buffer, 2 hrs), heating (120°C in water, 
1 hr), DMF (1 hr), acid (pH 3, dilute HCl, 1 hr) and base (pH 9.2 bicarbonate-carbonate buffer, 1 
hr). Assays were performed with [H2O2] of 0.25 mM, times refer to the length of time samples 
were left in H2O2 solution before adding to FOX reagent. 
  52 
One alternate possibility is that the diffusion of assay reagents through the MOF to the enzymatic 
active site may have been significantly hindered, meaning the activity of encapsulated enzymes 
may not have been detected. BioMOF-2 initially appeared very promising due to the 5 Å pore 
apertures, which are considerably larger than the 3.4 Å pore openings present in ZIF-8. However, 
the pore apertures in ZIF-8 open up into much larger pores 11.6 Å in diameter due to the sodalite 
topology, while in zinc carnosine the 5 Å openings continue as channels of the same width. Thus, 
while substrate diffusion through the initial pore apertures in ZIF-8 may be hindered, diffusion 
through the longer channels in bioMOF-2 may be more restricted overall.  
To test this theory, a method of decomposing the MOF without destroying any enzyme present 
was devised. This would allow the MOF to be dissolved, in turn releasing any encapsulated 
enzyme, making them freely accessible for subsequent assays. Thus, the activity of all enzyme 
present before and after exposure to harsh conditions could be compared without the potential 
issue of hindered substrate diffusion. Solutions of EDTA in pH 8 Tris-HCl buffer (0.05 M) were 
tested as EDTA has previously been shown to successfully decompose ZIF-8. However, EDTA 
interfered with the assays such that no conclusions could be made (Table 18 in the appendix).107 
No alternate method of decomposing catalase@bioMOF-2 could be identified. 
To further investigate bioMOF-2, enzymatic activities for catalase@bioMOF-2-1 (amorphous) 
and catalase@bioMOF-2-2 (crystalline) composites was determined (Figure 40). 
 
Figure 40: Relative catalase activity for free catalase, CAT@bioMOF-2-1 (initial amorphous 
precipitate) and CAT@bioMOF-2-2 (second crystalline precipitate). Assays were performed with 
[H2O2] of 0.25 mM and a 10-minute exposure time to H2O2 solution before adding to FOX reagent. 
Assays were performed with equal masses of samples. 
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The FOX assay data revealed that CAT@bioMOF-2-1 possessed a significantly higher enzymatic 
activity compared to CAT@bioMOF-2-2, supporting previous theories that the initial precipitate 
was protein-rich. In turn, this reduced the amount of enzyme present in solution and available 
for the second precipitate, causing CAT@bioMOF-2-2 to have a much lower catalase 
concentration and, thus, lower enzymatic activity. This low, and highly inhomogeneous, enzyme 
concentration is likely to be the key source of the large errors present in the CAT@bioMOF-2-2 
assay data. 
To investigate the difference in ability of the first and second precipitates to protect catalase 
present in the biocomposites, activity testing was conducted before and after treatment with 
protease (Figure 85 in the appendix). However, the uncertainties present in the assay results 
were too large to produce statistically significant conclusions. These high errors are likely a result 
of the inhomogeneous enzyme loading between samples, in addition to the low enzyme 
concentration in the CAT@bioMOF-2-2- biocomposites. 
To determine whether the lack of protective ability of bioMOF-2 for catalase was comparable to 
other enzymes, assays were then repeated for HRP@bioMOF-2-2 using the aforementioned 
peroxidase assay. To ensure that pure bioMOF-2-2 showed no detectable activity, preliminary 
tests were performed. Pure bioMOF-2-2 showed minimal activity, and therefore this was 
excluded from subsequent results. Controls with acid (pH 3, dilute HCl), base (pH 9.2, 
bicarbonate-carbonate buffer), DMF and protease were all performed, causing minor conversion 
of pyrogallol (Figure 86 in the appendix), which was subtracted from the calculated activity of 
the samples. 
The relative change in peroxidase activity was then determined for free HRP and HRP@bioMOF-
2-2 upon exposure to DMF, acid (pH 3), base (pH 9.2) and protease solutions (Figure 41). For free 
HRP, noticeable reductions in enzymatic activity were observed following treatment in all harsh 
conditions tested, with the greatest loss of 30% occurring after exposure to protease. After 
exposure to acidic (pH 3) and basic (pH 9.2) solutions, the former caused a greater reduction in 
enzymatic activity of the free HRP. This agreed with literature data that indicated that HRP was 
stable between pHs of 5.0 and 9.0 for 16 hours.108, 109 Yet, this may indicate that the activity loss 
following exposure to pH 3 should have been greater than 25%. However, the large errors, likely 
resulting from significant activity/stability variance for different HRP samples, indicates 
uncertainty in these measurements.  Further, literature data states that HRP loses all enzymatic 
activity in pure DMF after 4 hours, indicating that the recorded activity loss was much lower than 
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expected.110 Yet, the relatively small error in this data suggests high levels of certainty. The 30% 
loss of enzymatic activity upon proteolytic treatment for 2 hours seems reasonable when 
compared to a reported 50% reduction in activity of free HRP upon treatment with proteolytic 
enzymes for 24 hours.111 
 
Figure 41: Relative HRP activity for free HRP and HRP@bioMOF-2-2 before (purple) and after 
exposure to pH 3 (dilute HCl, 1 hr) (dark blue), pH 9.2 (bicarbonate-carbonate buffer, 1 hr) (light 
blue), DMF (1 hr) (aqua) and protease (2 mg/mL in 0.05 M Tris-HCl pH 8 buffer, 2 hr) (green). 
Concentration of the sample used per assay was 1 mg/5 mL H2O. 
Assay data for HRP@bioMOF-2-2 revealed that treatment with DMF led to a significant increase 
in enzymatic activity, which was not consistent with the expected results. Since the activity of 
catalase did not increase upon DMF exposure, the DMF was potentially interacting with HRP or 
the peroxidase assay, which may also explain why the observed activity of free HRP in DMF was 
higher than expected. No experimental or literature data was able to support this hypothesis. 
Conversely, following exposure to pH 3, pH 9.2 and protease the enzymatic activity of 
HRP@bioMOF-2-2 was completely removed. These results suggested a number of potential 
causes. Firstly, all HRP may have been present on the surface of the MOF, which would offer no 
protection. Secondly, enzyme may have been encapsulated within the MOF crystals, but this 
offered no protection against acidic, basic and proteolytic conditions. Thirdly, enzyme may have 
been encapsulated and protected but due to the large size of assay reagents and thus, an inability 
to diffuse through the framework, the activity of encapsulated enzyme may not have been 
detected. Regardless of the exact cause of these observations, the fact that the recorded 
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reduction in activity of HRP@bioMOF-2-2 in pH 3, pH 9.2 and protease was greater than that of 
the free enzyme suggests that the encapsulation or surface-binding process led to a reduction in 
the stability of the enzyme. 
To examine which theory is likely to be the case for HRP@bioMOF-2-2, the material before and 
after exposure to harsh conditions was subject to treatment with a 1% aqueous EDTA solution 
(Figure 87 in the appendix). This decomposed the MOF, while not resulting in activity loss of the 
enzyme. As such, diffusion of substrate would no longer be hindered by the framework. However, 
due to the low and inhomogeneous enzyme concentration present in the HRP@bioMOF-2-2 
composites, the data was inconsistent and so no conclusions could be made with statistical 
confidence.  
The exact reason for the inability of bioMOF-2 to effectively protect HRP in these specific 
conditions was difficult to confirm. It was postulated that it could have been because the MOF 
was decomposing slightly in these harsher conditions, which may have allowed the external 
solvent to reach the enzyme within the MOF. Alternatively, if the MOF was decomposing this 
may have caused enzyme to leach into solution where it would be fully exposed to the external 
conditions. While stability testing of bioMOF-2 was performed previously (Table 8 and Table 9), 
the sole use of PXRD data to make these conclusions was potentially unable to detect slight 
framework decomposition. 
2.3 Conclusions 
After an extensive literature review, two zinc bioMOFs containing L-Glutamic acid or L-Carnosine 
(β-Ala-L-His) linkers were chosen to explore biomimetic mineralisation of proteins.  
No changes to the synthesis of zinc glutamate (bioMOF-1) were required to ensure that it was 
compatible with biomolecule encapsulation. The rate of precipitation of bioMOF-1 could be 
controlled by altering the concentration of base added during the synthesis, with high 
concentrations causing a faster precipitation. The addition of a suite of proteins did not result in 
changes to the crystalline structure of bioMOF-1, as confirmed by PXRD data. UV-Vis 
spectroscopic data for protein@bioMOF-1 biocomposites indicated that proteins which were 
strongly attracted to the MOF caused delayed precipitation times, potentially due to protein 
complexing with the MOF components. Thus, the formation of protein@bioMOF-1 was unlikely 
to be undergoing biomimetic mineralisation, wherein added enzyme accelerates MOF growth. 
Instead, it was likely that the precipitation of bioMOF-1 was occurring either independently of 
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the enzyme, or as a co-precipitation event. UV-Vis, fluorescence and CLSM data for FITC-
protein@bioMOF-1 before and after treatment to remove all surface-bound enzyme, showed a 
significant reduction in the total quantity of protein present. Thus, it was concluded that the 
enzyme was predominantly surface bound in the enzyme@bioMOF-1 biocomposites, and no 
further testing was performed. 
For zinc carnosine (bioMOF-2), a new biomolecule-compatible synthetic procedure was devised 
using predominantly aqueous conditions at room temperature, wherein the rate of precipitation 
was controlled by the ethanol concentration. No changes in the crystalline structure of bioMOF-
2 were observed upon addition of protein, however, SEM images revealed that the presence of 
protein caused a change in the morphology of the MOF crystals. Further, the presence of proteins 
with pIs below approximately 6 caused the precipitation of an initial, amorphous solid prior to 
the formation of the MOF. This precipitate was deemed to be a protein-rich zinc salt. No such 
amorphous solid was produced when higher pI proteins were used, yet, due to lack of assays 
available for these proteins, no further analysis was performed. Future studies on these proteins 
in the enzyme@bioMOF-2 composites could be of benefit, in addition to modifying the chemical 
functionalisation of catalase or HRP to increase the pI. Use of other chemical modulators such as 
polyvinylpyrrolidone (PVP) has also been attempted, with preliminary results showing that it 
prevents the formation of the amorphous material. Yet the PVP concentrations used prevented 
MOF formation, as such this needs to be tuned. Further analysis was performed solely on the 
crystalline precipitate of enzyme@bioMOF-2. Aqueous assays revealed that for catalase and 
HRP, only small quantities of enzyme were likely to be encapsulated within the MOF. However, 
the low and inhomogeneous enzyme loadings (CLSM data) prevented reliable quantitative data 
from being measured for the composites. 
Thus, neither bioMOF-1 nor bioMOF-2 were shown to be able to encapsulate and protect 
enzyme by the approaches outlined. However, for bioMOF-2, this research indicates that further 
consideration of the synthetic approach (e.g. use of reagents such as PVP to stabilise the protein 
against initial precipitation), or chemical modification of the protein to achieve higher pIs could 
be used to develop stable protein@bioMOF-2 composites. Further, this research shows that the 
presence of imidazole functionality within a MOF does not necessarily ensure that biomolecule 
encapsulation will occur via biomimetic mineralisation. Instead, it is likely that the nitrogen donor 
groups within the imidazole group must be the only binding site in the linker, as is seen in many 
of the frameworks that have been successfully used for this application such as ZIF-8, ZIF-90 and 
MAF-7.  
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2.4 Experimental 
2.4.1: General Methods 
All chemicals and solvents were purchased from commercial suppliers and used as received with 
no further purification. 
Buffer Preparation: 
0.05 M Tris-HCl: Trisaminomethane (Tris) (0.30 g, 2.5 mmol) was dissolved in water (40 mL), the 
pH adjusted with 32% hydrochloric acid and the solution was made up to a final volume of 50 mL 
with water. 
Carbonate-bicarbonate (pH 9.2): Sodium carbonate (0.088 g, 0.83 mmol) was dissolved in water 
(4 mL). Sodium bicarbonate (0.74 g, 8.8 mmol) was dissolved in water (46 mL) and added to the 
sodium carbonate solution, followed by addition of water (150 mL). 
Phosphate buffered saline (PBS): Sodium chloride (0.80 g, 13.7 mmol), potassium chloride (0.02 
g, 0.27 mmol), Na2HPO4·2H2O (0.144 g, 0.81 mmol) and KH2PO4 (0.024 g, 0.18 mmol) were 
dissolved in water (80 mL). The pH was adjusted using 32% hydrochloric acid and the solution 
was made up to a final volume of 100 mL with water. 
Enzyme Modifications: 
Amination: A 2 mL solution of EDTA (0.268 g, 4.01 mmol) dissolved in MQ water was prepared 
and the pH adjusted to 4.5 using 6 M hydrochloric acid. The protein (20 mg) was dissolved in the 
EDTA solution, followed by EDC.HCl (7.2 mg, 0.038 mmol). The solution was stirred on ice for 2 h 
before being washed by ultra-filtration once with phosphate buffer (100 mM, pH 7.4) and twice 
with MQ water to remove excess salts (Vivacell 100, Sartorius Stedim, 10 kDA at 4000 rpm/1699 
g). 
FITC-tagged protein: Catalase (CAT; Sigma-Aldrich, catalase from bovine liver, 2000-5000 
units.mg-1 of protein, 20 mg) and fluorescein isothiocyanate (FITC) (1 mg, 0.0026 mmol) were 
dissolved in bicarbonate-carbonate aqueous buffer solution (0.1 M, pH 9.2, 2 mL) and stirred in 
darkness at room temperature for 2 h. The FITC-tagged protein was recovered by passing the 
reaction solution through an Illustra NAP-25 column (GE Healthcare Life Sciences, NSW, 
Australia). The obtained FCAT solution was stored in darkness at 4°C. 
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A similar method was used to prepare fluorescein-tagged peroxidase from horseradish (HRP; 
Sigma-Aldrich, Type VI-A, lyophilized powder, 950-2000 units.mg-1 of solid (using 2,2’-azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid)), ≥250 units.mg-1 (using pyrogallol)), fluorescein-tagged 
bovine serum albumin (BSA; Sigma-Aldrich, lyophilized powder, BioReagent, Suitable for cell 
culture, >96%) and fluorescein-tagged myoglobin (Mb; Sigma-Aldrich, myoglobin from equine 
skeletal muscle 95-10%, essentially salt-free, lyophilized powder). 
RbITC-tagged protein: Catalase (CAT; Sigma-Aldrich, catalase from bovine liver, 2000-5000 
units.mg-1 of protein, 20 mg) and Rhodamine b isothiocyanate (RbITC) (0.3 mg, 0.00056 mmol) 
were dissolved in bicarbonate-carbonate buffer solution (pH 9.2, 2.5 mL) and stirred at room 
temperature for 2 h. The RbITC-tagged protein was recovered by passing the reaction solution 
through an Illustra NAP-25 column (GE Healthcare Life Sciences, NSW, Australia). The obtained 
FCAT solution was stored in darkness at 4°C. 
A similar method was used to prepare rhodamine b-tagged myoglobin (Mb; Sigma-Aldrich, 
myoglobin from equine skeletal muscle 95-10%, essentially salt-free, lyophilized powder). 
2.4.2: Syntheses 
L-Glutamic acid derived materials:  
Zn Glutamate (bioMOF-1) (general method – see Table 15 in appendix  for specific conditions): L-
Glutamic acid and base were dissolved in water (5 mL). The zinc salt was dissolved in water (5 
mL) and the resultant solution was added dropwise to the glutamic acid solution with stirring to 
cause the precipitation of a white solid. The solid was isolated by filtration under reduced 
pressure, washed with water (x 3) and air dried to give a white solid. PXRD data is shown in Figure 
17 (literature synthesis), Figure 18 (varying base concentration with ZnSO4·7H2O) and Figure 19 
(varying base concentration with ZnOAc·2H2O). 
Enzyme@bioMOF-1: L-Glutamic acid (0.074 g 0.5 mmol), sodium bicarbonate (0.042 g, 0.625 
mmol) and protein (2 mg) were dissolved in water (5 mL). ZnSO4·7H2O (0.14 g, 0.5 mmol) was 
dissolved in water (5 mL) and the resultant solution was added dropwise to the glutamic acid 
solution with stirring to cause the precipitation of a white solid. The solid was isolated by filtration 
under reduced pressure, washed with water (x 3) and air dried to give a white solid. PXRD data is 
shown in Figure 20, UV-Vis data is shown in Figure 23 and CLSM images are shown in Figure 24. 
Precipitation times of the materials formed in the presence of a variety of enzymes are outlined 
in Table 2. 
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L-Carnosine derived materials: 
ZnC (bioMOF-2) – no alcohol (general method – see Table 6 for specific conditions): L-Carnosine 
and base were dissolved in water (5 mL). Zn salt was dissolved in H2O (5 mL) and the resulting 
solution was added dropwise to the glutamate solution with stirring to cause precipitation. The 
precipitate was isolated via centrifugation (6000 rpm, 2656 x g, 2 min), washed with water (x 3) 
and dried to give a white solid. 
ZnC (bioMOF-2) – with alcohol (general method – see Table 7 for specific conditions): L-Carnosine 
and base were dissolved in ethanol and half of the total volume of water. Zn(NO3)2·6H2O was 
dissolved in the remaining volume of water and the resulting solution was added dropwise to the 
carnosine solution, causing precipitation. The solid was isolated via centrifugation (6000 rpm, 
2656 x g, 2 min), washed with water (x 3) ethanol (x 1) and dried to give a white solid. PXRD data 
is shown in Figure 27 and SEM images are shown in Figure 29. 
Enzyme@bioMOF-2: L-Carnosine (0.05 g, 0.22 mmol) and protein (0.002 g) were dissolved in 
water (4.5 mL) and ethanol (1 mL). Zn(NO3)2·6H2O (0.13 g, 0.44 mmol) was dissolved in water (4.5 
mL) and the resultant solution was added dropwise to the carnosine solution to cause 
precipitation. The solid was isolated by centrifugation (6000 rpm, 2656 x g, 2 min), washed with 
ethanol and dried to give the protein-bioMOF composite. PXRD data is shown in Figure 30, SEM 
images are shown in Figure 31, UV-Vis data is shown in Figure 34 and CLSM images are shown in 
Figure 36 and Figure 37. Precipitation times of enzyme@bioMOF-2 for a variety of enzymes are 
outlined in Table 10. 
2.4.3: Characterisation 
Confocal scanning laser microscopy (CLSM):  
Images were taken on an Olympus FV3000 confocal laser scanning microscope, Olympus. The 
fluorescein-tagged proteins were excited at 488 nm and the fluorescence signal was collected 
between 495 and 545 nm. 
UV-Vis Spectroscopy:  
Solution absorption spectra was obtained using a Varian Cary 5000 UV-Vis spectrometer, using a 
1 cm quartz cell. Turbidity measurements were conducted using the ‘kinetics’ program. Solid 
state UV-Vis data was collected using the same equipment with a Harrick Praying Mantis DRP 
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accessory. Samples were crushed and packed flat. 100% transmittance was set by zeroing against 
a flat sample of spectroscopic grade KBr. 
Powder X-ray diffraction (PXRD):  
PXRD patterns were collected on a Bruker D4 ENDEAVOR using a Co anode to produce Kα 
radiation (λ = 1.788965 Å). Flat plate diffraction data was collected across a range of 2θ = 5° to 
40°. The PXRD data was converted to xy data using PowDLL converter (version 2.42.5186.29064). 
Simulated PXRD patterns were prepared in Mercury (version 3.9) and expressed as the cobalt-
source irradiated patterns. 
Scanning electron microscopy (SEM):  
Samples were imaged on a Philips XL30 field-emission scanning electron microscope (FESEM). 
Prior to analysis, samples were dry loaded onto adhesive carbon tabs on 12 mm aluminium stubs 
and coated in carbon. 
Fourier Transform Infrared (FTIR) Spectroscopy: 
FTIR spectra were obtained on a PerkinElmer Spectrum 100 FTIR spectrometer using a small 
portion of dried, ground sample. Sixteen scans were recorded over the range of 40,000 to 650 
cm-1. 
Fluorescence Spectrophotometry: 
Fluorescence data was collected on a Varian Cary Eclipse fluorescence spectrophotometer using 
a 1 cm disposable cuvette. 
NMR Spectroscopy:  
All 1H Nuclear Magnetic Resonance (NMR) spectra (499.818 MHz) were obtained using an Agilent 
DD2 NMR spectrophotometer at 26°C unless otherwise indicated. Spectra of samples were 
recorded in solutions in CDCl3, using TMS as an internal standard, D2O or d6-DMSO. 
FOX Assay: 
FOX Reagent: Sorbitol (3.6 g, 19.8 mmol), xylenol orange (0.0143 g, 0.02 mmol), water (50 mL) 
and concentrated sulfuric acid (281 µL) were combined, followed by the addition of 
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(NH4)2FeSO4.6H2O (0.0196 g, 0.02 mmol). The resulting solution was made up to a final volume 
of 200 mL with water. 
Calibration: Standard solutions of H2O2 (0.25, 0.125, 0.0625, 0.03125, 0.015625 mM) were 
prepared. 50 µL of sample was added to 950 µL of FOX reagent, followed by incubation at room 
temperature for 30 minutes, after which point the absorbance at 560 nm was recorded. From 
this data a calibration curve was produced. 
Assay procedure: 2 mg of the sample to be analysed was added to 0.25 mM H2O2 (200 µL), and 
after 1, 5 and 10 minutes 50 µL of this solution was added to 950 µL FOX reagent and incubated 
at room temperature for 30 minutes after which time the absorbance at 560 nm was recorded.  
Peroxidase Assay: 
Blank: H2O (2.1 mL), 0.05M Tris-HCl pH 6 buffer (0.32 mL), 0.5% H2O2 (0.16 mL) and 5% pyrogallol 
aq. solution (0.32 mL) were combined and left at rt for 10 minutes. H2O (0.1 mL) was added and 
the change in absorbance at 420 nm was immediately recorded over 3 minutes. 
Sample: H2O (2.1 mL), 0.05M Tris-HCl pH 6 buffer (0.32 mL), 0.5% H2O2 (0.16 mL) and 5% 
pyrogallol aq. solution (0.32 mL) were combined and left at rt for 10 minutes. Sample solution (2 
mg/10 mL H2O, 0.1 mL) was added and the absorbance at 420 nm was immediately recorded 
over 3 minutes. 
Calculations: 












 = maximum rate of change of abs at 420 over 20 seconds 
3 = volume (mL) of assay 
df = dilution factor 
12 = extinction coefficient of 1 mg/mL purpurogallin at 420 nm 
0.1 = volume (mL) of enzyme used 
units per mg solid =  
units per mL enzyme
mg solid per mL enzyme
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CHAPTER 3: Zn MOFs with N-donor group-based linkers for biomolecule 
encapsulation 
3.1: Introduction and scope of the chapter 
As discussed in chapter 1, the process of biomimetic mineralisation using metal-organic 
frameworks (MOFs) is a relatively new field of research and, as such, there are still many aspects 
that require further investigation. One example of this is the lack of understanding around what 
chemical (metal node and linker donor groups, pore surface chemistry) and structural (pore size 
and shape) features of MOFs are needed to ensure the biomolecule is successfully encapsulated 
and protected within the MOF without significant loss of activity. Given that MOFs are prepared 
from a building block approach that confers significant control over the MOF structure, pore 
surface chemistry and pore network, these aspects can be readily explored. 
The extensive use of zeolitic imidazolate frameworks (ZIFs) for biomimetic mineralisation has 
been mentioned previously. Within this family of materials, ZIF-86, 47, 57, 61 and, to a slightly lesser 
extent, ZIF-9065 are arguably the most used and studied for biomolecule protection. This is likely 
a result of the high porosity, excellent chemical and thermal stability, and low cytotoxicity.47 
Metal-azolate frameworks (MAFs), such as MAF-7, have also been shown to be able to effectively 
protect encapsulated enzyme.65 The ligands used in the synthesis of each of these MOFs are 
shown in Figure 42. These materials all have sodalite topology in their targeted form, noting that 
diamond112 and layered113 forms are also possible; the sodalite topology confers a relatively small 
limiting pore aperture size between 3.2 and 3.5 Å and thereby prohibits diffusion of molecules 
greater than ca. 5 Å. These limitations for the sodalite topology ZIF biocomposites could be 
addressed by identifying new MOFs with better structure metrics for reactant and product 
diffusion. 
 
Figure 42: Ligands used for the synthesis of a) ZIF-8, b) ZIF-90 and c) MAF-7. 
Each of these ligands contains basic N-donor binding sites (azine and azolate), and an absence of 
carboxylic acid groups that were present in the MOF linkers studied in Chapter 2. It is postulated 
that these MOFs are able to undergo biomimetic mineralisation due to a unique mechanism of 
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MOF growth initiated by Zn2+ ions aggregating around the biomolecule. Specifically, the 
mechanism for ZIF-8, and potentially other similar materials, involves the coordination of a metal 
node to the azine nitrogen, followed by deprotonation of the second nitrogen (azolate) which 
subsequently coordinates to a second metal centre (Scheme 4). This process repeats to form the 
ZIF-8 framework. This is the key reason why ZIF materials are believed to facilitate encapsulation 
via biomimetic mineralisation as growth is initiated by the high Zn2+ concentration at the 
biomolecule surface and propagated from the growing ZIF structure due to the facile 
deprotonation of coordinated imidazole.  
 
Scheme 4: The proposed mechanism of ZIF-8 formation. 
In general, according to the HSAB principle wherein groups are defined as hard or soft Lewis acids 
or bases, azoles are typically classed as soft bases despite being deprotonated in order to 
coordinate to metal cations; this is the key reason for the less rapid metal-ligand coordination 
for azolate-based ligands.114 It also must be noted that carboxylate MOF biocomposites are able 
to form, yet they are typically co-precipitated and so do not follow the biomimetic mineralisation 
mechanism seen for ZIF-8. One example of this is the immobilisation of soybean epoxide 
hydrolase with UiO-66-NH2 via co-precipitation.115 Nevertheless, studies have shown that 
biomolecules encapsulated within MOFs via biomimetic mineralisation are protected to a greater 
extent compared to those immobilised by co-precipitation.6  
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Thus, research presented in this chapter will utilise the observations obtained with ZIF materials 
to identify new MOFs with similar linkers that can undergo biomimetic mineralisation procedures 
rather than co-precipitation. 
A large number of MOFs have been formed using a wide range of different N-donor binding sites. 
These typically require the use of sp2 hybridised nitrogen atoms which bind to the metal nodes 
and can include groups such as azolates116-120 (pyrazolate, imidazolate, triazolate, tetrazolate 
etc.) and pyridines,121, 122 which refer to N-containing 5- and 6- membered rings respectively. 
3.1.1: Review of metal azolate MOFs for biomolecule encapsulation 
From the wide range of MOFs containing solely N-donor binding sites, a number were considered 
for their potential application to biomolecule encapsulation. To determine their suitability, the 
following criteria had to be met; 
• A 2-D or 3-D connected structure with > 3.4 Å pore openings; 
• Binary (or two component) MOFs; 
• Chemically and thermally stable materials demonstrating permanent porosity; 
• Commercially available or synthetically accessible linkers; 
• Use of a zinc metal ion; 
• Aqueous, room temperature MOF synthesis must be possible; and 
• Solely N-donor binding sites 
The majority of these criteria were also used in chapter 2 and are retained here for the same 
reasons. To add an element of consistency between all MOFs tested, only those with a zinc metal 
node will be studied. Further, while aqueous synthetic conditions at room temperature are 
desirable, it was noted in chapter 2 that MOF syntheses can be altered to meet this criterion.  
One family of MOFs identified utilises a 3,3′,5,5′-tetramethyl-4,4′-bipyrazole (H2Me4bpz) linker 
(Figure 43), and has been formed with zinc, but also cobalt, cadmium, copper and silver salts.123, 
124 As noted, to keep an element of consistency between these N-donor MOFs and the ZIF 
materials, only the zinc-based material will be considered. The zinc-based MOF has a cubic 
framework, with hourglass-shaped pores with a neck diameter of 3.3 Å and 10 Å pores.123 Thus, 
the structure is comparable to the pore aperture and cavities of ZIF-8 (3.4 and 11.6 Å). Further, 
a key advantage of this MOF is the isoreticular analogues using 4,4’-bipyrazole (H2bpz) and 1,4-
(4-bispyrazolyl)benzene ligand (H2bpb) linkers (Figure 44).125, 126 Thus, further studies could be 
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extended to the isoreticular MOFs. This would allow for an excellent comparison of the 
biomineralisation ability of each of these frameworks, and an investigation of whether different 
functional groups present impact this ability. However, one issues with Zn(Me4bpz) is that the 
reported synthesis requires extensive heating and the use of organic solvents, making it 
incompatible with biomolecule encapsulation. Thus, syntheses using aqueous conditions at room 
temperature would have to be designed to ensure compatibility with biomolecule encapsulation. 
 
Figure 43: a) H2Me4bpz ligand and b) Crystal structure of Zn(Me4bpz) viewed along the c axis.123 
 
Figure 44: Isoreticular analogues of Zn(Me4bpz): a) H2bpz ligand, b) Zn(bpz) MOF structure, c) 
H2bpb ligand and d) Zn(bpb) MOF structure.125, 126  
A number of other zinc-based MOFs have also been reported that contain ditopic N-donor 
ligands. MFU-4, MFU-4l and CFA-1 are three MOFs within this family (Figure 45).127-129 In DMF at 
140°C, MFU-4 forms as an open, cubic framework with pore apertures and sizes of 2.52 Å and 
3.87/11.94 Å respectively when van der Waals radii are considered.127 However, when the 
synthetic conditions are changed to include DMA at 120°C, an extremely dense coordination 
polymer forms. MFU-4l utilises an extended version of the linker used in MFU-4, such that two 
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distinct pores sizes form (11.97 Å and 18.56 Å), which were both larger than the pores present in 
MFU-4.128 CFA-1 is a chiral MOF, containing pore diameters in the range 9-12 Å.129 However, the 
syntheses for these ligands involves multiple steps, meaning scalability may be challenging. 
 
 
Figure 45: a) Ligand used to form  MFU-4, b) crystal structure of MFU-4 viewed along the a axis, 
yellow balls represent the size of imaginary spheres able to fit inside the framework pores,127 c) 
ligand used to form MFU-4l, d) crystal structure of MFU-4l viewed along the a axis, grey balls 
represent in the size of imaginary spheres able to fit inside the framework pores,128 e) ligand used 
to form CFA-1, f) crystal structure of CFA-1.129 
A further example of a zinc-based MOF comprised of N-donor containing ligands is Zn(TDT) 
(H3TDT = 4,5-di(1H-tetrazol-5-yl)-2H-1,2,3-triazole) (Figure 46). Zn(TDT) formed in 
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dimethylacetamide (DMA) at 95°C has sodalite topology with pore apertures of 6.4 Å opening up 
into pores with a diameter of 12 Å.40 Thus, the overall topology and pore size is comparable to 
that of ZIF-8, which has pores with a diameter of 11.6 Å.62 However, the larger pore apertures in 
Zn(TDT) would likely allow better substrate diffusion. Further, this MOF has also been reported 
as a potential drug-delivery agent for the anticancer drug 5-Fluorouracil, suggesting that it is able 
to successfully encapsulate other moderately sized guests.40  
 
Figure 46: a) H3TDT ligand, b) sodalite topology of Zn(TDT) formed in DMA at 95°C and c) primitive 
cubic topology of Zn(TDT) formed in DMF at 120°C.130 
Yet upon increasing the temperature and changing the solvent (DMF), Zn(TDT) forms with 
primitive cubic (pcu) topology.130 These observations show the MOF structure is heavily 
dependent on the synthesis conditions and thus, it is possible that different materials may form 
when attempting biomimetic mineralisation in predominantly aqueous solvents at room 
temperature. While forming a different MOF structure in the biocomposite may still provide 
protection, the sodalite topology form of Zn(TDT) could provide an ideal comparison to ZIF-8, ZIF-
90 and MAF-7 biocomposites. 
Zinc-based MOFs using a similar ligand (4, 5-bis(tetrazol-5-yl)imidazole (H3IDT)) have also been 
studied (Figure 47).131-135 Two examples have been reported, namely the formation of a 3-D MOF 
from an aqueous solution of zinc, linker and adenine at 160°C for 3 days, while a 2-D material 
was formed in identical conditions with the adenine replaced with 4,4’-bipyridine. Curiously, the 
syntheses required the use of adenine or 4,4’-bipyridine which, even though not part of the final 
structure, still add complexity to the synthesis. As such, these do not seem like prime candidates 
to asses for biomimetic mineralisation. 
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Figure 47: a) H3IDT ligand, b) crystal structure of Zn(IDT) formed in water in the presence of 
adenine at 160°C for 3 days and c) crystal structure of Zn(IDT) formed in water in the presence of 
4,4’-bipyridine at 160°C for 3 days .135 
Several tritopic MOFs reported by the Long group contain solely N-donor binding sites.136, 137 Two 
of these ligands are 1,3,5-tris(1H-pyrazol-4-yl)benzene (H3BTP) and 1,3,5-benzenetristetrazolate 
(H3BTP), which have been used to form 3-D MOFs with Ni/Cu/Zn/Co and Mn respectively (Figure 
48). As only zinc-based MOFs are to be investigated, only this material will be discussed. The zinc-
based MOF of BTP possesses relatively small 4 Å channels but was reported to have exceptional 
chemical and thermal stability, yet, both of these ligands required multistep syntheses (five 
synthetic steps) and so they were not considered for preliminary investigations.  
 
Figure 48: Synthesis of Zn/Co or Ni/Cu MOFs with H3BTP ligand (top) and synthesis of Mn MOF 
using H3BTT ligand (bottom).136, 137 
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Given the points raised above in relation to the criteria, Zn(Me4bpz) and Zn(TDT) appear to be 
the most suitable due to the synthetic accessibility of the linkers. Zn(Me4bpz) also has the key 
advantage of having a number of isoreticular analogues that could also be investigated. Further, 
the investigation of Zn(Me4bpz) and Zn(TDT) allows the comparison of MOFs synthesised using 
ditopic and tritopic linkers, while retaining the same metal ion.  
3.2: Results and Discussion 
3.2.1: Zn(Me4bpz) 
3.2.1.1: Biocompatible synthesis and characterisation of Zn(Me4bpz) 
The literature synthesis of Zn(Me4bpz) was performed by dissolving H2Me4bpz (50 mM) in DMF, 
followed by addition of Zn(CF3SO3)2 (50 mM).123 This solution was then stirred in a high-pressure 
glass tube at 130°C for 24 h. Due to the specific zinc salt and high-pressure equipment not being 
readily available, this literature synthesis was not attempted. Instead, attempts to form this zinc-
based MOF in aqueous conditions at room temperature were undertaken directly. This involved 
using a 1:1 molar ratio of metal to Me4bpz ligand as this is the ratio in the target structure, as 
well as the stoichiometry used in the literature synthesis. The MOF synthesised in aqueous 
conditions is hereafter referred to as Zn(Me4bpz)-aq. The ligand was insoluble in water, and so a 
minimum volume of methanol was used to solubilise it. By increasing the methanol to water 
ratio, it was found that a 1:10 ratio resulted in the addition of the minimum quantity of methanol 
needed to fully solubilise the ligand. MOF synthesis was then attempted by dissolving the ligand 
in water and methanol with or without added base, followed by the dropwise addition of an 
aqueous solution of zinc nitrate. In the absence of base, no precipitate formed, and in the 
presence of ammonia an amorphous material was produced. Finally, it was established that the 
use of sodium bicarbonate as the base was required to induce precipitation of crystalline material 
(Figure 49). However, analysis of the PXRD data revealed that the X-ray diffraction data for the 
crystalline material does not entirely match the simulated powder patterns of other zinc-
containing MOFs formed with the same or similar ligands.123, 138, 139 However, the lowest angle 
peaks in both the experimental and synthesised PXRD patterns overlapped, suggesting that the 
overall structure is similar. Therefore, it is possible that the synthesised Zn(Me4bpz)-aq material 
forms with a cubic arrangement, as is seen in the reported zinc MOFs containing an identical or 
similar ligand. 
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Figure 49: Experimental PXRD patterns of synthesis attempts for Zn(Me4bpz)-aq using NH3 (red) 
and NaHCO3 (blue) compared to patterns for Zn(Me4bpz),123 Zn(Me2bpz)138 and Zn(bpz-NO2)139 
simulated from single crystal data. 
The key difference in the PXRD pattern of the experimentally synthesised Zn(Me4bpz)-aq and the 
three reported N-donor containing Zn-MOFs are the peaks between 2θ = 16° and 18°. The single 
peak present within this range in the PXRD pattern of the synthesised MOF is approximately 
midway between the two peaks present in the simulated pattern, possibly suggesting some 
change in symmetry. 
It was postulated that slight differences in the PXRD pattern may be due to the different solvents 
with which each sample is solvated. To examine this, samples of Zn(Me4bpz)-aq were soaked in 
a variety of solvents for 1 hour, collected by centrifugation and analysed by 1H NMR spectroscopy 
(solvate composition) and PXRD. The solvents of interest were dichloromethane (DCM), acetone 
and dimethylformamide (DMF) as these were the solvents used to wash the MOFs reported in 
the literature. Stepwise soaking of acetone followed by DCM, each for 1 hour, was also trialled 
to reduce the polarity change compared to if the water-solvated sample was solely treated with 
DCM. The 1H NMR spectra for Zn(Me4bpz)-aq samples soaked in acetone, DMF or DCM each 
showed peaks corresponding to these solvents, in addition to water. Thus, as water was still 
present in the sample, soaking the samples for 1 hour was unable to fully exchange the MOF 
solvates. Nevertheless, PXRD data was collected to determine if changes to the solvation may 
have caused changes in the MOF structure. However, PXRD data revealed no observable changes 
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in peak positioning after soaking the as-synthesised material in each of these solvents (Figure 
50). This lack of change indicated that solvation was not the main cause of the differences in the 
PXRD patterns. 
 
Figure 50: PXRD of Zn(Me4bpz)-aq exposed to DCM, DMF and acetone, as well as a dried sample 
compared to Zn(Me4bpz)-aq synthesised and Zn(Me2bpz),138 Zn(Me4bpz)123 and Zn(bpz.NO2)139 
simulated from single crystal data. 
Further, to confirm the presence of zinc in the original Zn(Me4bpz)-aq material synthesised using 
the 1:1 metal to ligand ratio, scanning electron microscopy (SEM) and energy dispersive X-ray 
spectroscopy (EDX) was performed (raw data shown in Table 21 and Figure 94 in appendix). EDX 
data confirmed the presence of zinc, with an average Zn:N ratio of 1:3.5 across the sample, 
corresponding to a metal to ligand ratio of 1:0.9.  
Thus, the EDX data supports the composition of Zn(Me4bpz)-aq being very similar to the 
composition of material synthesised via the literature solvothermal methods, which has a 1:1 
metal to ligand ratio, despite small discrepancies in the PXRD data. However, there have also 
been a number of other reported Zn MOFs containing the Me4bpz ligand with a 1:1 metal to 
ligand ratio. One example is Zn(Me4bpz)(SO4); a 2-D MOF with Zn(Me4bpz) sheets held together 
via SO4 molecules.140 This highlights that a 1:1 Zn to Me4bpz ratio (N:Zn = 4:1) is not necessarily 
indicative only of the cubic structure of Zn(Me4bpz) MOF.123 
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Figure 51: SEM image of Zn(Me4bpz)-aq, the outlined region is spectrum 15 which had a 6 At% 
zinc concentration as determined by EDX, with the top-left corner of the outlined region 
containing material that appears distinct from the bulk material.  
As the exact structure of the synthesised Zn(Me4bpz)-aq was not known, gas adsorption was 
used to determine whether the material had similar porosity to the reported Zn(Me4bpz) MOF. 
To ensure that the gas adsorption data for the synthesised MOF could be compared to the 
reported MOF, identical conditions were used for the activation and gas adsorption 
experiment.123 Activation was performed at 110°C overnight, after which the uptake of N2 at 77K 
was recorded (Figure 52). PXRD analysis confirmed that no decomposition of the MOF had 
occurred under the activation conditions used (Figure 89 in appendix).  
 
Figure 52: Gas adsorption isotherm for Zn(Me4bpz)-aq under N2 at 77K. 
3
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77 K N2 adsorption data shows an initial uptake of N2 at low pressures, indicating the presence 
of micropores, while an additional uptake at higher pressures suggests that mesopores are also 
present. These observations were also made for the literature MOF with the same Me4bpz ligand. 
Slight hysteresis is observed, further supporting the presence of mesopores. 
Using this data, a calculated BET surface area of 203 m²/g was obtained, which is notably lower 
than the BET surface area of 396 m2/g reported in the literature for Zn(Me4bpz).123 The resulting 
pore size distribution data derived from the gas adsorption data (Figure 53) indicated a pore 
width of approximately 16 Å, which is significantly different to the ca. 10 Å pore width reported 
for the literature MOF.123 Other peaks in the pore size distribution data were likely due to large 
mesopores present with pore widths of 25 Å and 40-60 Å, which vary slightly from the 25-50 Å 
mesopores reported for the literature Zn(Me4bpz) material. For the literature material, these 
‘mesopores’ were deemed to be interparticle voids, which may also be the case for the 
Zn(Me4bpz)-aq material given the crystal morphology seen via SEM. 
 
Figure 53: Pore size distribution of Zn(Me4bpz)-aq determined by applying the NLDFT to the N2 
isotherms. 
The notable deviations in both the pore size distribution and surface area calculations, coupled 
with differences in the PXRD patterns, for the synthesised Zn(Me4bpz)-aq material compared to 
the reported MOF strongly suggested that the structure of the two materials are different. This 
may be due to missing linker defects or slight deviations in the structure. 
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To better understand the structure of Zn(Me4bpz)-aq, attempts were made to grow single 
crystals of the material (Table 22 in the appendix). A number of conditions were trialled, some 
of which were reflective of the original aqueous conditions outlined above but with variations 
such as the use of a different base, slow mixing or evaporation to try and reduce the rate of 
precipitation. Numerous attempts were also trialled with excess ligand added as it has been 
shown for other MOFs such as ZIF-8 that altering the metal to ligand ratio can alter the particle 
size produced, with excess ligand promoting the formation of larger crystals.141 The use of 
solvothermal methods, with DMF as the solvent, was also attempted as this was reflective of the 
original synthesis conditions reported in the literature for Zn(Me4bpz).123 
The results show that slow evaporation was the only method that was able to grow single 
crystals, yet, this was also only the case when an excess molar concentration of ligand was used. 
Metal to ligand ratios of 1:2, 1:4 and 1:16 were used, with and without base. For the attempts 
with added base, the initial precipitate that formed was isolated by centrifugation, and the 
supernatant was collected and allowed to undergo slow evaporation. This was performed with 
and without added enzyme (BSA) to determine whether the presence of enzyme could promote 
crystal formation. Attempts with no added base were also conducted to prevent the initial 
precipitation event, and, therefore, ensuring that sufficient concentrations of ligand and metal 
remained in solution to allow crystal growth.  
All attempts with no added base successfully formed single crystals. The 1:16 metal to ligand 
ratio produced large, needle-like crystals overnight, while the 1:4 and 1:2 ratios formed smaller, 
cubic or tetragonal crystals after two and ten days respectively (Figure 54a-c). For the attempts 
with added base, only the supernatant from the synthesis using the 1:4 metal to ligand ratio in 
the presence of BSA was successful, forming large crystals after seven days (Figure 54d). 
 
Figure 54: Microscope images of single crystals formed for a) 1:16, b) 1:4 and c) 1:2 metal to 
ligand ratio with no base and no BSA and d) 1:4 metal to ligand ratio with base and BSA. 
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To determine whether the structure of each of the single crystals synthesised matched that of 
the original Zn(Me4bpz)-aq material synthesised, PXRD data was collected for crushed samples 
of each single crystal (Figure 55). In particular, this was performed to ensure that changing the 
metal to ligand ratio did not impact the structure of the material formed. 
 
Figure 55: PXRD data for crushed single crystals of Zn(Me4bpz)-aq produced using 1:16 (red), 1:4 
(orange), 1:2 (blue) metal to ligand ratio (no base, no BSA) and 1:4 metal to ligand ratio (with 
base and BSA, green) compared to the Zn(Me4bpz)-aq precipitate (1:1 metal to ligand ratio, 
purple).  
The PXRD data for the single crystals were significantly different to that of Zn(Me4bpz)-aq 
synthesised with a 1:1 metal to ligand ratio. While there appeared to be slight overlap of peaks 
around 2θ = 11.5°, the remainder of the powder pattern indicated that the two materials were 
distinct. Yet, PXRD results revealed that all four single crystal samples had matching powder 
patterns, with the only significant discrepancies being changes in relative peak intensities, likely 
due to different preferred orientations during crystal growth as a result of the varying 
crystallisation times.  
To investigate the new structure, a portion of one of the crystals formed in the 1:16 metal to 
ligand ratio sample was used to obtain a single crystal structure. No zinc could be identified in 
the structure, and so the material was deemed to be a hydrogen-bonded organic framework, 
hereafter referred to as Me4bpz-HOF. The material crystallised with a tetragonal crystal system 
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and in the I41/acd space group with the structure shown in Figure 56, (unit cell parameters a = 
24.7504(4) Å, b  = 24.7504(4) Å and c = 14.8658(4) Å). The asymmetric group contains a single 
ligand and a singly deprotonated water molecule (Figure 57).The methyl groups present in the 
Me4bpz linker point into the otherwise square-shaped channels along the c axis. Water molecules 
are shown to occupy the x-shaped pores when viewed along the c axis.  
 
Figure 56: a-c) Unit cell for Zn(Me4bpz)-aq formed with a 1:16 metal to ligand ratio viewed along 
the a, b and c axes and d) space-filling data for Zn(Me4bpz)-aq viewed along the c axis. H atoms 
omitted for clarity (C = grey, N = purple, O = red). 
The lack of zinc, in addition to the extensive hydrogen-bonding occurring throughout the 
structure revealed that the material formed from solutions containing excess ligand was a 
densely packed hydrogen-bonded organic framework. Thus, it is likely that by increasing the ratio 
of ligand to metal, there was no longer sufficient concentration of zinc present in solution to form 
the desired MOF. The presence of the methyl groups and structurally important water molecules 
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block any channels  and render the material non-porous. Thus, this material is still referred to the 
Me4bpz-HOF for simplicity sake despite HOFs typically possessing porosity. This close-packed, 
non-porous structure is not desirable for enzyme encapsulation as it would significant hinder 
substrate diffusion through the framework to reach the enzymatic site within. 
 
Figure 57: Asymmetric unit of Me4bpz-HOF. (C = grey, N = purple, O = red, H = light grey). The 
hydrogen atom of the pyrazole ring that hydrogen bonds with a symmetry generated pyrazole is 
disordered over both nitrogen atoms, whereas pyrazole NH hydrogen bonded to the water 
molecule was localised. These hydrogen positions could be located in the electron density 
difference map. 
As mentioned above, extensive hydrogen-bonding was observed within the crystal structure, 
including hydrogen bonding between the bis-pyrazole compound and water molecules present 
in the pores in a tetrahedral arrangement (Figure 58).  
 
Figure 58: Single crystal data for the Me4bpz-HOF showing the tetrahedral hydrogen bonding 
formed between the water molecules and ligand. (C = grey, N = purple, O = red, H = white, dashed 
lines = H-bonding contacts). 
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Given that the synthetic conditions used to obtain Me4bpz-HOF contained Zn2+ ions, the synthesis 
was further investigated. Curiously, no precipitation immediately occurred upon dissolving only 
the ligand and base; instead the HOF formed immediately upon addition of zinc. Yet, when a 
solution of ligand and base was allowed to undergo slow evaporation, clear and colourless 
needle-like crystals of Me4bpz-HOF formed overnight. This suggested that the zinc acted as a 
catalyst to promote the instantaneous formation of the hydrogen-bonded framework. 
To confirm that the single crystal data was representative of the bulk samples obtained under all 
slow evaporation conditions, a PXRD pattern was simulated from the single crystal data and 
compared to the experimental pattern of the synthesised Me4bpz-HOF crystals (Figure 59). The 
identical peak positions in both PXRD patterns indicated that the crystal structure was 
representative of the bulk with no additional crystalline phases present.  
 
Figure 59: PXRD data for experimentally synthesised Me4bpz-HOF (black) compared to the PXRD 
pattern simulated from single crystal data. 
Analysis by SEM-EDX was used to further confirm the absence of zinc in the Me4bpz-HOF 
samples. EDX data calculated zinc percentages between 0.0 and 0.2%, strongly supporting the 
conclusions that this material was a hydrogen-bonded organic material. Any trace quantities of 
zinc present in the sample are likely to be left-over from the synthetic procedure. 
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3.2.1.2: Synthesis of protein@Zn(Me4bpz)-aq and protein@Me4bpz-HOF biocomposites 
While permanently porous materials are desirable for biocatalysis applications, both 
Zn(Me4bpz)-aq and the Me4bpz-HOF were used for enzyme encapsulation attempts, despite the 
close-packed nature of the latter. Such hydrogen-bonded organic frameworks lacking in 
permanent porosity may still be applicable to biomolecule therapeutic delivery and thus 
biocomposites of this dense phase were investigated. To form the Me4bpz-HOF, a 1:16 metal to 
ligand ratio was used as this was the only ratio that was able to form as a microcrystalline 
precipitate upon combining the metal and ligand/base solutions. While it was found that the 
presence of zinc was not required to form crystals of the Me4bpz-HOF, the addition of zinc 
allowed for precipitation of the microcrystalline powder which is easier to characterise. 
To examine whether protein would alter the structure of the frameworks formed, syntheses 
were conducted with a sample of enzymes. For the Zn(Me4bpz)-aq MOF and Me4bpz-HOF, FITC-
tagged catalase (FCAT) was used, predominantly due to the FOX assay allowing for rapid 
determination of enzymatic activity. Catalase was tagged with FITC to remove any inconsistencies 
between results from CLSM and other techniques that would have otherwise been performed 
with native enzymes. For both materials, the protein encapsulation procedure involved the 
addition of enzyme to the ligand solution followed by subsequent addition of the zinc solution. 
PXRD analysis confirmed that the addition of FCAT did not change the structure of the 
Zn(Me4bpz)-aq or Me4bpz-HOF materials that formed (Figure 60).  
 
Figure 60: PXRD for Zn(Me4bpz)-aq and Me4bpz-HOF synthesised with and without added FCAT. 
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To determine whether the addition of enzyme influenced the rate of growth for either of the 
frameworks, turbidity data was collected (Figure 61). By extension, this was used to provide 
insight into whether enzyme encapsulation might occur via biomimetic mineralisation, through 
biomolecules accelerating framework growth. 
As outlined in chapter 2, turbidity analysis is performed by measuring the change in absorbance 
of a wavelength not absorbed by the material forming. Thus, increases in absorbance are due to 
the formation of a solid that scatters incident light. More rapid increases in absorbance are 
indicative of more rapid precipitation.  
 
Figure 61: Turbidity graphs for a) the  Zn(Me4bpz)-aq MOF (inserted image is the sample 
immediately after turbidity testing) and b) Me4bpz-HOF with (black) and without (red) the FCAT 
added initially. 
Turbidity data reveals that the Zn(Me4bpz)-aq MOF forms very rapidly, both with and without 
added enzyme, upon addition of zinc to the ligand solution, as seen by the immediate sharp 
increase in absorbance, agreeing with experimental observations. After this initial precipitation 
  81 
event, the absorbance reaches a maximum, followed by a subsequent reduction in absorbance, 
likely due to aggregation of the precipitate on the surface of the solution (Figure 61a insert). 
While rapid stirring was used throughout the entire duration of turbidity analysis, this was not 
sufficient to ensure thorough mixing of the entire contents of the cuvette. Nevertheless, 
comparison of the initial precipitation rates of Zn(Me4bpz)-aq with and without added enzyme 
reveals that the presence of enzyme resulted in a small but observable increase in the 
precipitation rate, suggesting that biomimetic mineralisation may be occurring. 
The turbidity results for the Me4bpz-HOF material showed a similar trend to that of Zn(Me4bpz)-
aq, wherein an initial rapid precipitation was seen within the first minute, both with and without 
added enzyme, agreeing with experimental observations. However, no decrease in absorbance 
was seen over the course of the analysis, likely because the material was denser and did not float. 
Comparison of turbidity data for the HOF material with and without added FCAT showed no 
significant difference in the rate or precipitation, making biomimetic mineralisation unlikely. 
To confirm the presence of FCAT in all samples formed, solid state UV-Vis analysis was conducted. 
Free FCAT absorbs strongly at 500 nm due to the fluorescein isothiocyanate tag (Figure 62).  
 
Figure 62: Solution-state UV-Vis absorbance for free FCAT. 
Solid-state UV-Vis data for both pure Zn(Me4bpz)-aq and pure Me4bpz-HOF showed that neither 
of these materials absorbs strongly around 500 nm, and so any absorbance at this wavelength 
for the FITC-enzyme@Zn(Me4bpz)-aq and FITC-enzyme@Me4bpz-HOF samples was assumed to 
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be due to the presence of FITC-tagged enzyme. Solid-state UV-Vis analysis of FCAT@Zn(Me4bpz)-
aq and FCAT@Me4bpz-HOF strongly indicated the presence of FCAT within these samples (Figure 
63); however, the technique does not provide spatial information demonstrating whether the 
enzyme is present within the crystals or purely surface bound. 
 
Figure 63: Solid-state UV-Vis absorbance for Zn(Me4bpz) and Me4bpz-HOF formed with and 
without added FCAT. 
To ensure future testing of enzymatic activity within the FCAT@Zn(Me4bpz)-aq and 
FCAT@Me4bpz-HOF materials could be performed with equal enzyme concentrations, the 
percentage FCAT loading within each of the frameworks was calculated. A limitation of the assay 
data presented in chapter 2 for the zinc carnosine MOF was that the enzyme concentrations in 
each sample were not consistent, meaning that only the relative changes in activity could be 
compared. Thus, by calculating the enzyme loading within each sample, all future tests can be 
performed with consistent enzyme concentrations to allow for comparison of absolute activities. 
To determine the FCAT loading in the Me4bpz-HOF, a known mass of the FCAT@HOF sample was 
dissolved in citrate buffer (pH 5, 0.1 M), and the fluorescence of the resultant solution was 
measured. Calibration data was then used to convert this fluorescence reading into a 
concentration of FCAT and, by extension, a %w/w loading of FCAT within the HOF. This method 
was not compatible with the FCAT@Zn(Me4bpz)-aq sample as the MOF was unable to be 
dissolved in any solvents that would not impact the fluorescent tag. Instead, inductively coupled 
plasma mass spectrometry (ICP-MS) was used to determine the sulfur concentration of free FCAT 
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and FCAT@Zn(Me4bpz)-aq after digestion in a mixture of concentrated nitric and hydrochloric 
acids. The calculated FCAT loadings are outlined in Table 13, with raw data and calculations 
shown in appendix (Table 19 (ICP-MS) and Figure 90 & Figure 91 & Table 20 (fluorescence)). This 
data is consistent with loadings achieved for other enzyme@ZIF materials.142 
Table 13: Calculated %w/w FCAT loading within Me4bpz HOF and Zn(Me4bpz) MOF samples. 
 %w/w FCAT Loading 
Zn(Me4bpz)-aq (ICP-MS) 1.7 ± 0.8% 
Me4bpz-HOF (Fluorescence) 1.6 ± 0.5% 
 
3.2.1.3: Analysis of protein encapsulation/protection within Zn(Me4bpz)-aq and Me4bpz-HOF 
To provide preliminary insight into the spatial distribution of the FITC-tagged enzyme relative to 
the MOF and HOF crystals, CLSM was used (Figure 64). As noted, this tool provides overlayed 
optical and fluorescence microscopy images which can indicate whether the enzyme is co-located 
with the crystals. If the particles are sufficiently large, these images can also suggest whether the 
enzyme is likely to be predominantly surface-bound or encapsulated. 
 
Figure 64: Confocal images (fluorescence, bright field and overlay) for a) 1:1 FCAT@Zn(Me4bpz)-
aq MOF and b) FCAT@Me4bpz-HOF. Tagged enzyme is shown in green. 
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CLSM data revealed that the crystals for both the Zn(Me4bpz)-aq MOF and the Me4bpz-HOF were 
extremely small, and beyond the resolution of the microscope. As such, it was impossible to 
determine whether the enzyme was predominantly located on the surface of the crystals or 
encapsulated within. While there were a small number of slightly larger crystals in the 
Zn(Me4bpz)-aq sample which appeared to potentially have encapsulated enzyme, it was 
unknown whether these were representative of the bulk sample. 
To expand on the preliminary CLSM data, quantitative assays were used to determine whether 
the enzyme was encapsulated within and protected by the MOF and HOF crystals. Specifically, 
ferrous oxidation of xylenol orange (FOX) assays, which have been explained in chapter 2, will be 
used to determine the presence and stability of the FCAT present.  
General MOF stability testing 
To determine the test conditions to which the FCAT@Zn(Me4bpz)-aq and FCAT@Me4bpz-HOF 
samples would be exposed, the chemical and thermal stability of the frameworks needed to be 
ascertained. This ensured that no framework decomposition would occur during the FOX assays. 
Specifically, both frameworks were exposed to elevated temperatures, organic solvents and pHs 
from 5 to 10f for three minutes, followed by PXRD analysis (Figure 65). Both Me4bpz-HOF and 
FCAT@Me4bpz-HOF dissolved in DMF and so no PXRD data was obtained. 
The PXRD data for Zn(Me4bpz)-aq revealed that the MOF was stable in all conditions tested, with 
the exception of the pH 5 buffer for which a slight reduction in crystallinity was observed, as 
indicated by the lower signal-to-noise ratio. However, the PXRD data for all conditions tested also 
contained a low intensity peak at 2θ = 7°, which was not present in the pattern for the original 
material. This suggested that a new phase may be beginning to form, or the framework is 
beginning to slowly decompose. Nevertheless, the retention of all key peaks following exposure 
to each of the conditions tested suggested that the frameworks would remain intact. 
Conversely, the PXRD data for Me4bpz-HOF revealed that it had much lower stability compared 
to Zn(Me4bpz)-aq, likely as a result of the weaker hydrogen bonding interactions. In all conditions 
tested, with the exception of pH 10, the HOF material either completely or partially decomposed 
during the three-minute exposure time. Curiously, when identical stability testing was performed 
for FCAT@Me4bpz-HOF samples, the PXRD results indicated that the enzyme had a stabilising 
effect on the framework, as no observable decomposition occurred following exposure to pH 5 
and 80°C. However, the presence of FCAT was unable to stabilise the HOF in organic solvents. 
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Figure 65: PXRD patterns for a) Zn(Me4bpz)-aq (1:1) and b) Me4bpz-HOF before and after 
exposure to DMF, THF, pH 5 (0.1M citric-trisodium citrate buffer), pH 10 (0.1 M glycine buffer) 
and 80°C for 3 minutes. 
The exact cause of this stabilising effect had by the enzyme is not known, however, there were 
two possibilities considered. The first was that the formation of an enzyme surface-coating 
around the MOF which limited exposure to the harsh external conditions. Another explanation 
was that encapsulated enzyme within the HOF prevented it from collapsing and/or dissolving. 
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The inability of the enzyme to stabilise the framework in THF and DMF was noted too. The PXRD 
of the Me4bpz-HOF after exposure to these solvents, without added enzyme, showed it was 
amorphous. Hydrogen-bonded organic frameworks rarely show stability in polar organic 
solvents,143 due to the ability of such solvents to disrupt the hydrogen-bonding within the 
material, which could have caused the rapid loss of crystallinity.  
Therefore, the Zn(Me4bpz)-aq MOF was deemed to be sufficiently stable for activity testing 
under all of the conditions tested, while the Me4bpz-HOF was only considered to be stable for 
activity testing at elevated temperatures and pH 5 to 10. 
To ascertain that Zn(Me4bpz)-aq and Me4bpz-HOF do not decompose hydrogen peroxide and, 
by extension, create false positive enzymatic activity readings in the FOX assays, assays were 
carried out for these materials (Figure 66). This was performed by exposing either material to 
0.25 mM hydrogen peroxide, with aliquots of the hydrogen peroxide/sample suspension taken 
at specific time intervals which were then reacted with FOX reagent. This assay data revealed 
minimal hydrogen peroxide decomposition compared to the initial concentration of 0.25 mM, 
indicating that both materials were inactive.  
 
Figure 66: Hydrogen peroxide decomposition by Zn(Me4bpz)-aq and Me4bpz-HOF determined via 
FOX assay. Initial [H2O2] was 0.25 mM. Time refers to the period of time the samples were exposed 
to the 0.25 mM H2O2 solution before reacting with the FOX reagent. Error bars show the standard 
error of three independent measurements. 
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Protective capacity toward elevated temperatures 
To determine the protective capacity of both Zn(Me4bpz)-aq and Me4bpz-HOF for encapsulated 
FCAT at elevated temperatures, the reduction in enzymatic activity for the FCAT@MOF/HOF 
samples upon heating was determined and compared to that of the free enzyme. The heating 
procedure involved exposure of aqueous stock solutions of FCAT@Zn(Me4bpz)-aq, 
FCAT@Me4bpz-HOF and free FCAT to elevated temperatures. To depict the rate of change of 
enzymatic activity, aliquots of the sample stock solutions were taken at specific time intervals up 
until 3 minutes and immediately cooled on ice to prevent further decomposition due to residual 
heat. Each aliquot was then reacted with 0.25 mM hydrogen peroxide for 10 minutes before 
transferring 50 µL of the hydrogen peroxide solution into 950 µL of FOX reagent. After 30 
minutes, the absorbance at 560 nm of the FOX reagent was measured and converted to a 
hydrogen peroxide concentration using a calibration curve. 
Raw data showing the change in enzymatic activity of each sample, including free FCAT, after 
exposure to elevated temperatures for 3 minutes are shown in Figure 67. High hydrogen 
peroxide concentrations, close to 0.25 mM, indicate minimal hydrogen peroxide decomposition 
and, thus, low catalase activity, while low hydrogen peroxide concentrations indicate the reverse.  
The information provided by the raw data was two-fold; first it indicates the relative activities of 
each sample and secondly, it shows the rates of activity loss upon heating. The raw data revealed 
that the free FCAT had a much higher overall enzymatic activity up to 70°C compared to the FCAT 
within either of the frameworks. Several scenarios can explain this reduction in activity. If no 
encapsulation occurred (i.e. surface bound or a conglomerate), then the presence of the 
framework may decrease the enzymatic activity of the catalase (surface adsorption can inactivate 
enzymes65). Alternatively, if encapsulation was successful (the CLSM analysis was equivocal to 
this point), it caused a reduction in the activity of the enzyme, possibly  due to reduced 
accessibility of the active sites. For the assay, reagents must reach the FCAT encapsulated within 
either of the frameworks; to do so they must diffuse through the pores, a process that is more 
hindered than when the enzyme is free in solution. As such, more hindered diffusion would lead 
to less enzymatic activity being utilised in a given period of time, causing a reduction in the 
recorded activity. This is commonly observed that encapsulated enzymes are not as active as the 
free enzyme under optimal conditions.65, 98 This latter hypothesis was supported by the 
observation that the enzymatic activity for FCAT in Me4bpz-HOF was negligible due to the lack of 
pores present in this material. Any activity present for this sample would have been due to 
surface-bound enzyme of crystal defects that allow for substrate diffusion. 
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Figure 67: Catalytic activity of FCAT in a) free FCAT, b) FCAT@Zn(Me4bpz)-aq and c) 
FCAT@Me4bpz-HOF after exposure to 25, 50, 60, 70 and 80°C for 3 minutes. The assay was 
performed with [FCAT] = 30 nM and initial [H2O2] = 0.25 mM with a H2O2 exposure time of 10 
minutes. Exposure time refers to the time over which the sample was exposed to elevated 
temperatures. Error bars show the standard error for three independent measurements. 
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The raw data was then used to determine the overall relative activity losses after exposure to the 
elevated temperatures for both the free enzyme and the FCAT@framework samples (Figure 68).  
 
Figure 68: Relative FCAT activity (relative to 25°C for each sample) in free FCAT, 
FCAT@Zn(Me4bpz)-aq and FCAT@Me4bpz-HOF after exposure to 25, 50, 60, 70 and 80°C for 3 
minutes. The assay was performed with an FCAT concentration of 30 nM and initial H2O2 mM. 
Error bars show the standard error for three independent measurements. 
This assay data depicted the expected trend for the free enzyme wherein the activity gradually 
decreased as the temperature in increased, with an 84% reduction in enzymatic activity upon 
heating to 80°C. Catalase is reported to be stable up to temperatures of 60°C, and so the 
significant loss of enzymatic activity observed after 80°C treatment agrees with literature data.16 
For both the FCAT@Zn(Me4bpz)-aq and FCAT@Me4bpz-HOF samples the enzymatic activity 
appeared to increase initially as the exposure temperature was increased to 70°C and 50°C, 
respectively, before the activity decreased. However, an increase in activity was not expected; it 
is likely that this was due to enzyme leaching from the composites. If this occurred, the enzyme 
would be more freely accessible, and not limited by substrate diffusion through the pores or 
defect pathways of the HOF and MOF coatings, likely leading to an increase in the observed 
activity. Further, it is noted that the subsequent decreases in enzymatic activity occur at 
temperatures at which the MOF and HOF respectively were unable to offer protection to any 
enzyme that may have been encapsulated.  As catalase is significantly larger than the pore 
apertures in either of the frameworks (the HOF is non-porous), this indicates that some 
decomposition must be occurring upon heating the MOF to these elevated temperatures to allow 
enzymes to be released into solution. The enzyme must be protected by the material but 
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displaced during the heating/icing step before the assay. As such, the observation that the 
temperature at which the enzymatic activity reduces for the FCAT@Me4bpz-HOF biocomposite 
is lower than that of the FCAT@Zn(Me4bpz)-aq agrees with previous data showing that the HOF 
material was less stable than the MOF. Thus, decomposition of the framework to the point at 
which it is unable to protect encapsulated enzyme would be likely to occur at lower temperatures 
for the less stable HOF material. Further, if the MOF was decomposing, it is likely that zinc was 
leached into solution as well, which may also affect the assay. This is due to the ability of zinc to 
bind to the xylenol orange dye, such that the zinc-bound dye absorbs strongly at 570 nm. Thus, 
significant absorption at 560 nm is also observed, leading to a false enzymatic activity reading.144 
To determine the proportion of enzyme activity due to leaching, FOX assays were performed 
separately on the supernatant and isolated solid materials after exposure to elevated 
temperatures. Any enzymatic activity in the supernatant was assumed to be due to leached 
enzyme or zinc (the latter for MOF only). ICP-MS was used to determine the concentration of zinc 
in the supernatant after exposing the MOF to elevated temperatures. This concentration was 
then converted to an effective enzymatic activity using a calibration curve shown in appendix 
(Figure 92). The total observed activity of the samples was broken down into proportions 
reflecting the activity due to encapsulated enzyme, leached zinc and leached enzyme (Figure 69). 
 
Figure 69: Relative activity for free FCAT, FCAT@Zn(Me4bpz)-aq and FCAT@Me4bpz-HOF caused 
by encapsulated enzyme (purple), leached zinc (light blue) and leached enzyme (dark blue). 
Activities relative to the activity for each sample at 25°C. The assay was performed with an FCAT 
concentration of 30 nM and initial H2O2 concentration of 0.25 mM. 
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The assay data revealed that for Zn(Me4bpz)-aq a significant proportion of the activity observed 
was due to the supernatant. ICP-MS data showed that high zinc concentrations were present in 
all of the FCAT@Zn(Me4bpz)-aq supernatants after heating samples to elevated temperatures, 
indicating that MOF decomposition was occurring. While stability testing had been done 
previously, PXRD analysis may not have been sufficient to detect this decomposition.  
After removing the activity in the supernatant due to zinc, the remaining activity was assumed 
to be due to leached enzyme. Importantly, there was also high proportions of activity due to 
leached zinc and enzyme for the FCAT@Zn(Me6bpz)-aq biocomposite in water at room 
temperature (25°C). This indicated that significant proportions of the enzyme present in the 
biocomposite were loosely bound to the MOF or co-precipitated such that any treatment 
dislodges it. This observation was further confirmed by washing the FCAT@Zn(Me4bpz)-aq 
biocomposite with water several times before performing fluorescence analysis of these washes 
(Figure 93b). All four water washes performed had observable fluorescence readings, 
corresponding to FCAT concentrations between 7 and 9 nM indicating a high proportion of FCAT 
present in the biocomposite was loosely bound. Further, the leached zinc in water at room 
temperature also indicates that the stability of Zn(Me4bpz)-aq is very low, such that some 
decomposition occurs at room temperature. 
The assay data for FCAT@Zn(Me4bpz)-aq also revealed that at 80°C, the leached zinc and enzyme 
accounted for 100% of all activity observed. This supported the previous hypotheses that at this 
temperature the MOF decomposed to the point at which it is no longer able to offer protection 
and so there is no remaining active encapsulated enzyme. The significant increase in the activity 
due to leached enzyme upon increasing the temperature from 70°C to 80°C also supports 
significant MOF decomposition. The residual enzyme@MOF activity, solely due to the solid MOF 
sample after the activity due to leached enzyme and zinc had been subtracted, still showed an 
increase upon heating to 60°C and 70°C relative to the activity at room temperature. This may be 
due to defects (e.g. cracks) forming in the MOF composite that allowed for less hindered diffusion 
of assay reagents to the enzymatic site which would in turn make the enzyme appear more active 
as it could be more readily detected. 
For the Me4bpz-HOF it was assumed that any zinc present from the synthesis would have been 
removed during the washing procedures and, thus, no ICP-MS analysis was performed on the 
supernatant. Assay results from the separated solid sample and the supernatant after exposure 
to the elevated temperatures showed that, at all temperatures, 100% of the activity observed 
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was due to leached enzyme. One possible explanation for this was the reduced stability of the 
HOF compared to Zn(Me4bpz)-aq, which either allowed the complete destruction or leaching of 
encapsulated enzyme (likely only at the higher temperature treatments) or encapsulated enzyme 
was unable to be detected by the assay. Given the very high-density and lack of porosity in the 
hydrogen-bonded framework, the latter is reasonable; the assay reagents and products may not 
have been able to diffuse through to the enzymatic site. Thus, while active enzyme may have 
been present within the composite, its activity was unable to be observed. As a result, this data 
provided no insight into the encapsulation ability nor the protective capacity of the HOF. 
Protective capacity of frameworks across pH 5 - 10 
To determine the protective capacity of both Zn(Me4bpz)-aq and the Me4bpz-HOF for 
encapsulated FCAT across a range of pHs, the reduction in enzymatic activity for the 
FCAT@MOF/HOF samples upon exposure to various buffers of known pH was determined and 
compared to that of the free enzyme. The procedure involved exposure of FCAT@Zn(Me4bpz)-
aq, FCAT@Me4bpz-HOF and free FCAT to buffers with pH 5 to 10 for 3 minutes. Each sample was 
then worked up via the method reported for the thermal stability testing. 
Raw data showing the change in enzymatic activity of free FCAT, FCAT@Zn(Me4bpz)-aq and 
FCAT@Me4bpz-HOF across the pHs 5 to 10 are shown in Figure 70. Hydrogen peroxide 
concentrations close to 0.25 mM indicate a low catalase activity as minimal hydrogen peroxide 
decomposition has occurred, while low hydrogen peroxide concentrations indicate the reverse. 
The raw data reveals a similar trend in the relative activities of each sample as was seen for the 
thermal stability testing wherein the free enzyme generally has the greatest enzymatic activity, 
followed by FCAT@Zn(Me4bpz)-aq and then FCAT@Me4bpz-HOF. The activity data for 
FCAT@Me4bpz-HOF indicates that it is essentially inactive which, as has been discussed 
previously, is likely due to the extremely dense packing of this material, leading to hindered or 
impossible diffusion of assay reagents through to the enzymatic site. 
Overall the free FCAT appears to be active over the pH range of 5 to 10, agreeing with literature 
data.16 The free FCAT showed the highest activity in the pH 9.2 buffer, which is in agreement with 
literature studies showing that pH 9 is the optimal pH for catalase.16 Further, the free FCAT 
appeared to be least stable in the pH 5 buffer, which seems plausible as this is the lowest pH at 
which catalase is deemed to be active.16 A reduction in activity upon exposure to pH 7 and pH 8 
compared to pH 6 and pH 9.2 was also observed, despite expecting this trend to only have one 
  93 
local point of minimum activity. Yet, due to the relatively large uncertainties present in this data 
set, there is no statistical basis to this observation. The exact cause of the relatively large errors 
present in the free FCAT data is difficult to understand, however, it is noted that two of the three 
measurements were performed at a separate instance to the initial run. While new calibration 
data was produced for each run, removing potential errors due to variations in absolute hydrogen 
peroxide concentration or the FOX reagent, there may have been slight variations in the activity 
of the FCAT stock solution used. 
 
Figure 70: Catalytic activity of free FCAT (purple), FCAT@Zn(Me4bpz)-aq (blue) and 
FCAT@Me4bpz-HOF (green) after exposure to pH 5-10 for 3 minutes. pH 5 buffer – 0.1 M Citric-
tri-sodium citrate buffer solution, pH 6-8 buffers – 0.1 M phosphate buffered solution and pH 9.2-
10 buffers – 0.1 M glycine buffer. The assay was performed with an FCAT concentration of 30 nM 
and initial H2O2 concentration of 0.25 mM, with an exposure time of 10 minutes. . Exposure time 
refers to the time over which the sample was exposed to elevated temperatures. Error bars show 
the standard error for three independent measurements. 
The pH stability testing data was then extrapolated to give the overall percentage of activity 
change in all samples after three minutes in buffers ranging from pH 5 to 10 compared to the 
samples in pure water. However, the resultant data had extremely high errors, and so was not 
able to provide meaningful conclusions. This was most likely a result of inhomogeneous 
  94 
distribution of the solid samples throughout the stock solutions, leading to inconsistencies in the 
masses of solid present in each aliquot used for assay analysis. 
Nevertheless, studies were conducted to determine whether MOF decomposition and enzyme 
leaching had occurred using the same methods outlined above for thermal testing. Similar to the 
thermal data, these results showed that significant proportions of the total calculated enzymatic 
activity were due to leached enzyme and zinc. For FCAT@Zn(Me4bpz)-aq, no activity was 
observed in the solid biocomposite sample at pHs of 7 and below, indicating a significant 
decomposition of the MOF in these neutral to acidic conditions, likely as a result of protonation 
of the N-donor sites in the ligand. Yet, for pHs of 8 and above, the solid biocomposite retained 
activity, suggesting that the MOF was less susceptible to decomposition in basic conditions. A 
reverse trend was observed for FCAT@Me4bpz-HOF wherein no enzymatic activity was observed 
in the solid biocomposite following exposure to pHs of 9 and 10, while activity was retained by 
the biocomposite for pHs 5 to 8, suggesting that this material was more susceptible to 
decomposition due to deprotonation in basic environments. This is expected as deprotonation 
would destroy the hydrogen-bonding interactions holding the material together. 
Thus, due to the uncertainty in some of the original measurements, no conclusions can be made 
confidently in regard to the overall protective capacity of Zn(Me4bpz)-aq and Me4bpz-HOF across 
this pH range. Yet, the results still suggest that a large proportion of the enzyme was loosely 
bound to the surface of the material and readily leached into solution. 
Protective capacity of frameworks in organic solvents 
To determine the protective capacity of Zn(Me4bpz)-aq for encapsulated FCAT in organic 
solvents, the reduction in enzymatic activity for the FCAT@MOF samples upon exposure to THF 
and DMF for 3 minutes was determined and compared to that of the free enzyme. Each sample 
was then worked up via the same method reported for the thermal and pH stability testing. No 
organic stability testing was conducted for FCAT@Me4bpz-HOF due to instability of the material 
in these solvents. Raw data showing the change in enzymatic activity of free FCAT and 
FCAT@Zn(Me4bpz)-aq  in THF and DMF are shown in Figure 71. Hydrogen peroxide 
concentrations close to 0.25 mM indicate a low catalase activity as minimal hydrogen peroxide 
decomposition has occurred, while low hydrogen peroxide concentrations indicate the reverse. 
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The raw data shows trends that agree with the pH and thermal stability testing, wherein the free 
enzyme is consistently more active than FCAT in the Zn(Me4bpz)-aq sample, once again 
attributed to hindered substrate diffusion. 
 
Figure 71: Catalytic activity of FCAT in free FCAT and FCAT@Zn(Me4bpz)-aq after exposure to a) 
DMF and b) THF for 3 minutes. The assay was performed with [FCAT] = 30 nM and initial [H2O2] = 
0.25 mM, with a H2O2 exposure time of 10 minutes. Exposure time refers to the time over which 
the sample was exposed to elevated temperatures. Error bars show the standard error for three 
independent measurements. 
This data was then extrapolated to give the overall percentage of activity loss in all samples after 
three minutes in organic solvents (Figure 72). 
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Figure 72: Relative FCAT activity in FCAT and FCAT@Zn(Me4bpz)-aq after exposure to a) DMF and 
b) THF for 3 minutes. The assay was performed with an FCAT concentration of 30 nM and initial 
H2O2 concentration of 0.25 mM, with an exposure time of 10 minutes. Error bars show the 
standard error for three independent measurements. 
This data revealed that the free enzyme was more stable in DMF, with an activity loss of only 5%, 
compared to 67% after exposure to THF. Literature data reported an 85% reduction in activity of 
free FCAT after exposure to THF for 2 hours, and so a 67% activity loss after 1 hour seems 
reasonable.65 However, quantitative data could not be found in the literature for the expected 
activity loss upon exposure to DMF. Nevertheless, the very small errors observed after 
performing the assays in triplicate suggests that data is reliable. 
For FCAT@Zn(Me4bpz)-aq, the assay data showed no change in activity, within error, upon 
exposure to DMF and THF. As the data for free FCAT showed that minimal activity loss occurred 
upon DMF exposure it is difficult to ascertain whether the MOF is offering protection against this 
solvent. However, free FCAT experienced significant activity loss upon exposure to THF, 
suggesting that Zn(Me4bpz)-aq may be able to protect encapsulated FCAT in this organic solvent. 
To remain consistent with the thermal and pH activity testing, the activity due to zinc and enzyme 
leaching was determined. The concentration of zinc in the organic solvent supernatant was not 
able to be determined via ICP-MS as the organic solvents were not compatible with this method. 
The total observed enzymatic activity was then broken down into proportions corresponding to 
the activities due to encapsulated enzyme and leached zinc and enzyme (Figure 73). 
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Figure 73: Relative activity for free FCAT and FCAT@Zn(Me4bpz)-aq caused by encapsulated 
enzyme (purple) and leached zinc/enzyme (blue). Activities relative to the activity for each sample 
in water. Assays were performed with an [FCAT] = 30 nM and initial [H2O2] = 0.25 mM. 
The activity data for FCAT@Zn(Me4bpz)-aq revealed that 100% of the activity observed after 
exposure to DMF was due to leached zinc and enzyme. Conversely, the activity data for 
FCAT@Zn(Me4bpz)-aq following exposure to THF showed that less than 50% of the recorded 
activity was due to leaching. Upon removing the activity due to leaching, the FCAT@Zn(Me4bpz)-
aq sample appeared to have slightly increased enzymatic activity following THF exposure. This 
was again attributed to defect formation in the MOF composite, causing any encapsulated 
enzyme to appear more active. 
Thus, the assay data for all test conditions indicated that a significant proportion of the enzyme 
present in both the FCAT@Zn(Me4bpz)-aq and FCAT@Me4bpz-HOF biocomposites was loosely 
bound to the surface of the material or located in the subsurface region of the crystals. This 
allowed it to be easily removed upon washing with or suspending in water, buffers or organic 
solvents. Further, the results from ICP-MS analysis showed that significant concentrations of zinc 
were being leached into solution, indicating that suspending the MOF in water, buffers or organic 
solvents led to partial MOF decomposition.  
Due to the enzyme and zinc leaching, in combination with the MOF decomposition occurring, the 
data was unable to conclusively determine whether enzyme was able to be encapsulated and 
protected by either Zn(Me4bpz)-aq or Me4bpz-HOF. Yet, the results do highlight that the low 
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stability of both materials make them unsuitable for biomolecule encapsulation and protection 
in comparison to other materials such as the aforementioned ZIFs and MAFs which exhibit much 
higher thermal and chemical stability.1, 3, 145 
3.2.2: Zn(TDT) 
3.2.2.1: Biocompatible synthesis and characterisation of Zn(TDT) 
Due to the inability of Zn(Me4bpz)-aq to encapsulate and protect enzymes, likely as a result of 
low stability and significant surface-binding or co-precipitation occurring, another N-donor MOF, 
Zn(TDT), was investigated in hopes more ZIF-like performance would be encountered. This MOF 
was primarily chosen because of its sodalite topology and large pore apertures (6.4 Å), which 
would allow for excellent comparison between this and other sodalite materials such as ZIF-8, 
with less hindered substrate diffusion. 
To initially ensure the repeatability of the Zn(TDT) synthesis, the literature MOF synthesis was 
performed (Figure 74).40 PXRD data confirmed that Zn(TDT) with sodalite topology was prepared. 
 
Figure 74: PXRD data for Zn(TDT) synthesised via the solvothermal literature conditions (red) 
compared to the simulated data for sodalite Zn(TDT) constructed from single crystal data 
(black).40 
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To ensure that synthesis of Zn(TDT) was compatible with biomolecule encapsulation, organic 
solvents and elevated temperatures needed to be replaced with predominantly aqueous 
conditions at room temperature. However, solubility issues were encountered as the ligand was 
unable to be dissolved in water, methanol, ethanol and various buffers. 
In an attempt to overcome solubility issues, the water-soluble sodium salt of the H3TDT ligand 
was synthesised by mixing a 1:2 molar ratio of H3TDT and sodium hydroxide in water, before 
isolating the solid by filtration and drying. 1H NMR data for the sodium salt showed a complete 
removal of peaks corresponding to NH groups, indicating that all had been deprotonated to form 
a trisodium salt, while IR showed key stretches associated with the ligand. Numerous methods 
for the synthesis of Zn(TDT) were attempted in aqueous conditions at room temperature (Figure 
75 and Table 23). Alcohols were used as these had been shown to promote the formation of 
crystalline Zn Carnosine and ZIF-8.100 The Zn(TDT) material synthesised using the sodium salt of 
the H3TDT ligand is hereafter referred to as Zn(TDT)-Na. 
 
Figure 75: Baseline corrected PXRD patterns for Zn(TDT) synthesised using the sodium salt of the 
H3TDT ligand at room temperature compared to the simulated pattern for the sodalite Zn(TDT) 
MOF constructed from single crystal data. 
PXRD data revealed that the materials synthesised in aqueous, or predominantly aqueous, 
conditions with added base were crystalline, however it did not match Zn(TDT) synthesised 
solvothermally. Washing solvothermally synthesised Zn(TDT) with methanol and ethanol 
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confirmed that solvent effects were not the cause of the variations in PXRD data (Figure 95 in the 
appendix). 
To further investigate the nature of the crystalline material formed via the biomimetic conditions, 
PXRD data for the experimentally synthesised material was collected on wet (solvated) samples 
(Figure 76). Given the anticipated high chemical stability of Zn(TDT), all previous PXRD data for 
this material had been collected from dried samples. PXRD data revealed that the wet sample 
possessed greater crystallininity than the dried sample, indicating that crystallinity had been lost 
upon drying. Thus, this suggested that the stability of the material synthesised in water was much 
lower than the Zn(TDT) MOF synthesised via solvothermal conditions, as the latter showed no 
loss of crystallinity upon drying.  
 
Figure 76: PXRD of wet loaded and dry loaded Zn(TDT) formed using the sodium H3TDT ligand in 
water with added NaHCO3 compared to the simulated pattern of sodalite Zn(TDT) constructed  
from single crystal data. Figure on right shows enlarged PXRD pattern for the wet Zn(TDT) sample. 
This low stability suggested Zn(TDT)-aq may be an organic salt or hydrogen-bonded material. To 
test this theory, SEM-EDX was used to determine zinc concentration. SEM images showed that 
Zn(TDT)-Na formed as a very irregular material containing a large variation in particle size and 
morphology. 
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Figure 77: SEM image of Zn(TDT)-Na. Outlined rectangles show the sites selected for EDX analysis. 
The EDX results (Table 24 and Figure 102 in appendix) revealed an average Zn:N ratio of 2:12, 
which is close to the expected 2:11 ratio based on the 2:1 zinc to ligand ratio present in 
solvothermally prepared Zn(TDT). There were also consistently high proportions of sodium 
present throughout the sample, up to 23%, yet it is not known whether the sodium is present in 
the structure or left over from the MOF synthesis.  
While attempts were made to synthesise single crystals of the Zn(TDT)-Na material, no success 
was had. Thus, the focus was shifted to synthesising a more stable phase of Zn(TDT)-Na, such 
that it could be further investigated for use in biomolecule encapsulation. A number of synthetic 
factors were investigated including the base concentration, ethanol concentration, zinc source 
and reduced temperature (Figure 96, 97 and 98 respectively in the appendix), however none of 
these resulted in a more stable material. The addition of 3% w/v 2-methylimidazole was trialled 
to investigate whether this could form ZIF-8 crystals to seed the growth of sodalite Zn(TDT). 
However, PXRD data (Figure 99 in the appendix) and 1H NMR data showed that only ZIF-8 was 
formed under these conditions. To prevent this preferential ZIF-8 formation, ZIF-8 seed crystals 
were synthesised separately and added during the Zn(TDT)-Na synthesis, however, this resulted 
in the formation of a precipitate that did not match any known material and so no further analysis 
was performed (Figure 100 in the appendix). 
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In further attempts to form stable Zn(TDT), the tetrabutylammonium salt of the TDT linker was 
synthesised by combining a solution of potassium carbonate and H3TDT in acetone with a 
solution of tetrabutylammonium (TBA) bromide in DCM (1:1 molar ratio of TBA and H3TDT). NMR 
analysis confirmed the presence of both TBA and TDT and showed that a bis(TBA) salt had 
formed. Attempts to synthesise Zn(TDT) using this TBA salt, were performed in pure water and a 
10:1 water to ethanol mixture with added base. This formed a crystalline material, referred to as 
Zn(TDT)-TBA, which showed no loss of crystallinity upon drying (Figure 78). However, the lack of 
low angle peaks in the PXRD patterns suggested it was a crystalline salt with a relatively small 
unit cell.  
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Figure 78: PXRD data for attempted syntheses of Zn(TDT) using the sodium salt (blue and green) 
and tetrabutylammonium salt (orange and red) of the H3TDT ligand in a) pure water and b) a 10:1 
mixture of water and ethanol and a 1:1:4.75 molar ratio of metal to ligand to base compared to 
the patterns of Zn(TDT) (black) constructed from single crystal data. 
N2 gas adsorption was performed on an activated sample of Zn(TDT)-TBA to investigate the 
porosity of the material. The absence of low angle peaks below 2θ = 15° in the PXRD pattern 
suggested that this material might be close-packed. This was supported by N2 gas adsorption data 
(Figure 79), which showed minimal evidence of porosity and a low BET surface area of 49.8 m²/g. 
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Figure 79: N2 gas adsorption isotherm for Zn(TDT)-TBA at 77 K. The sample was activated by 
washing with DCM and then drying under high vacuum overnight. 
SEM-EDX was also performed on Zn(TDT)-TBA for further characterisation of the material (raw 
data in Table 25 and Figure 103 in appendix). Zn(TDT)-TBA formed as regular cubic particles 
approximately 4 µm in size (Figure 80), with a consistent Zn:N ratio of 2:1. Yet, this Zn:N ratio is 
significantly different to the expected 2:1 metal to ligand ratio (2:11 Zn:N), suggesting that the 
synthesised Zn(TDT)-TBA material had a very high zinc concentration, whether this be from a 
higher quantity of zinc present in the framework, or zinc remaining in the sample from the MOF 
synthesis. 
 
Figure 80: a) SEM image of Zn(TDT)-TBA, with high magnification images of b) cubic crystals and 
c) spherical crystals. Outlined rectangles show the sites selected for EDX analysis. 
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Thus, no method was found to synthesise sod- or pcu-Zn(TDT) in aqueous conditions at room 
temperature. Further, the stability of Zn(TDT)-Na was unable to be improved, nor could the TBA 
salt of the H3TDT linker promote MOF formation in aqueous conditions at room temperature. 
3.2.2.2: Synthesis of protein@Zn(TDT) biocomposites 
Despite the inability to successfully form sodalite Zn(TDT) in aqueous conditions, the ability of 
Zn(TDT)-Na to encapsulate enzymes was still investigated. The main reason for conducting these 
experiments was to determine whether the presence of enzyme could stabilise the material. As 
the experiments above provided no evidence to suggest that the use of ethanol in the solvent 
system was advantageous in regard to the stability or crystallinity of Zn(TDT)-Na, only pure water 
was used in the enzyme encapsulation experiments to increase the biocompatibility. FITC-tagged 
catalase (FCAT), bovine serum albumin (FBSA) and myoglobin (FMb) were added during 
syntheses of Zn(TDT)-Na to represent enzymes with a range of pIs and molecular weights. The 
biomolecule encapsulation procedure involved the dropwise addition of an aqueous zinc solution 
to an aqueous solution of the sodium salt of the H3TDT linker, sodium bicarbonate and enzyme. 
In the presence of each of the three enzymes, precipitation occurred immediately upon addition 
of the zinc solution. PXRD data revealed that the presence of FBSA and FMb resulted in the 
precipitation of amorphous material, regardless of whether it was wet or dry, while the presence 
of FCAT formed a crystalline material which lost significant crystallinity upon drying (Figure 81).  
 
Figure 81: PXRDs for Zn(TDT) formed in the presence of a) FCAT, b) FBSA and c) FMb analysed wet 
or dry, before and after suspending in ethanol. 
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Thus, the addition of enzyme was unable to stabilise Zn(TDT)-Na, and select enzymes also 
prevented the formation of crystalline material. As such, the stability of the material was 
considered to be too low and so further investigation of this MOF was deemed impractical. 
3.3: Conclusions 
Given that MOFs which reliably encapsulate biomolecules (ZIF-8, ZIF-90, MAF-7) are comprised 
of azolate ligands (e.g. imidazoles and triazoles), it was hypothesised that chemically similar, 
albeit structurally distinct materials could be used for biomimetic mineralisation. Thus, a 
literature review was conducted to identify azolate-based (N-donors) MOFs with differing 
structure metrics to the sodalite materials (ZIF-8, ZIF-90, MAF-7) routinely used for biomolecule 
protection. From the suite of N-donor containing MOFs surveyed, two materials were identified; 
Zn(Me4bpz) and Zn(TDT). The two ligands needed to prepare these MOFs were synthesised with 
the intention of using these to synthesise the target zinc-based MOFs under aqueous conditions 
at room temperature. However, the materials formed via biocompatible syntheses did not match 
the expected structures of the target MOFs synthesised solvothermally. 
Me4bpz was used to form a MOF, Zn(Me4bpz)-aq and a hydrogen-bonded organic framework, 
Me4bpz-HOF, both in aqueous conditions at room temperature.  Zn(Me4bpz)-aq gave a PXRD 
pattern similar to that of the Zn(Me4bpz) MOF synthesised under solvothermal conditions. EDX 
data confirmed that the Zn(Me4bpz)-aq MOF possessed the same 1:1 metal to ligand ratio as the 
literature material. Gas adsorption data revealed that Zn(Me4bpz)-aq was permanently porous, 
with pores of 16 Å compared to 10 Å pores seen in the solvothermally synthesised MOF.  Thus, 
the characterisation data suggested that the Zn(Me4bpz) MOF synthesised in aqueous and 
solvothermal conditions were similar. However, due to the synthetic approach, single crystals of 
Zn(Me4bpz)-aq could not be obtained and so the definitive structure of this MOF remained 
unknown. Gas adsorption data showed that Me4bpz-HOF was close-packed and significantly less 
stable than the MOF. 
The addition of enzyme caused no structural changes that were observable by PXRD in either of 
the materials, and the enzyme loading for FCAT was determined to be 1.7 ± 0.8% and 1.6 ± 0.5% 
for the MOF and HOF respectively. Turbidity data showed that the presence of enzyme increased 
the rate at which the Zn(Me4bpz)-aq MOF formed, while not appearing to impact the rate of 
Me4bpz-HOF formation, suggesting that biomimetic mineralisation could be the formation 
mechanism of the former. However, CLSM data for both biocomposites were inconclusive as the 
bulk of the material was too small and beyond the resolution of the microscope. 
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The stability tests conducted for Zn(Me4bpz)-aq and Me4bpz-HOF in DMF, THF, pH range 5 to 10 
and elevated temperatures up to 80°C showed that the former was stable in all test conditions, 
while the latter showed evidence of decomposition in all conditions except pH 10. Interestingly, 
the presence of enzyme had a stabilising effect as FCAT@Me4bpz-HOF biocomposites showed 
no such reduction in crystallinity following exposure to pH 5 and elevated temperatures. Enzyme 
was unable to stabilise the HOF in organic solvents. 
Assays were then conducted to quantify the activity of enzyme in the FCAT@Zn(Me4bpz)-aq and 
FCAT@Me4bpz-HOF biocomposites. The assays were performed before and after each sample 
was exposed to test conditions to ascertain the protective ability of both materials towards the 
encapsulated enzyme. For FCAT@Zn(Me4bpz)-aq, a significant portion of the observed 
enzymatic activities was due to leached zinc and enzyme. Enzyme leaching occurred even at room 
temperature in water, indicating a high proportion of loosely-bound enzyme. Further, the 
leached zinc indicated that MOF decomposition was occurring in the conditions tested, which 
could form defects in the protective shell to facilitate enzyme leaching. Similar observations were 
made for the FCAT@Me4bpz-HOF biocomposite in that significant enzymatic activity was due to 
enzyme in solution, suggesting that the enzyme was loosely bound to the HOF and/or the HOF 
was unstable. The closely packed nature of this material would also significantly hinder substrate 
diffusion. These observations deemed Zn(Me4bpz)-aq and Me4bpz-HOF unsuitable for enzyme 
encapsulation and protection.  
While further characterisation with different biomolecules could be of interest, the low stability 
of both the Zn(Me4bpz)-aq and Me4bpz-HOF materials would be consistent, regardless of the 
enzyme used and so no further investigation was deemed necessary. Despite neither of the 
Me4bpz derived materials being able to successfully encapsulate or protect biomolecules, these 
results still provide useful information. Notably, the sole presence of azole N-donor groups in the 
MOF does not guarantee the ability to form a biocomposite able to encapsulate and protect 
protein. Further, the stability of frameworks must be more rigorously tested to ensure that no 
decomposition occurs in the conditions where it is being used to protect the encapsulated 
biomolecules. This particularly applies to cases where the MOF has been induced to form rapidly, 
under aqueous conditions, and will likely not form the desired defect-free materials that 
produced via solvothermal conditions. Understanding the thermal and chemical stability of the 
rapidly precipitated form of the framework would provide confidence that the observed activity 
for the biocomposites is unlikely to be due to enzyme leaching. 
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Zn(TDT) was synthesised from the ligand, H3TDT (4,5-di(1H-tetrazol-5-yl)-2H-1,2,3-triazole. A 
significant challenge with this material was the insolubility of the ligand, which required the 
formation of the sodium or organic salts to ensure its solubility in aqueous, or predominantly 
aqueous, conditions. Attempts to synthesise Zn(TDT) using the sodium ligand salt (designated 
Zn(TDT)-Na) resulted in the formation of a crystalline material that was distinct from Zn(TDT) 
synthesised solvothermally. SEM-EDX analysis confirmed it had a 2:1 metal to ligand ratio, in 
agreement with that of the solvothermally synthesised Zn(TDT). However, the stability of 
Zn(TDT)-Na was significantly less stable than the solvothermally synthesised MOF. No conditions 
trialled, including the addition of enzyme, were able to increase the stability. Further, the use of 
the bis(tetrabutylammonium) ligand salt resulted in the formation of a crystalline material 
(Zn(TDT)-TBA) with low porosity, low surface area (49.8 m²/g) and a high zinc concentration. 
3.4: Experimental 
3.4.1: General Methods 
All chemicals and solvents were purchased from commercial suppliers and used as received with 
no further purification. 
Buffer syntheses and enzyme-tagging methods are outlined in the experimental section of 
chapter 2. 
3.4.2: Syntheses 
Me4bpz derived materials: 
Ligand Synthesis: 
Sodium Acetylacetone: Using a procedure modified from that of 
Charles,146 sodium hydroxide (10.0 g, 0.25 mol) was dissolved in water 
(12.5 mL), followed by the addition of methanol (50 mL). The solution was 
added to acetylacetone (25.5 mL, 0.25 mol) slowly, with stirring. The solution was cooled on ice 
for 2 hours, filtered, washed with cold methanol (x 2) and dried to give sodium acetylacetone as 
a pale orange crystalline solid (22.86 g, 74%). 1H NMR (DMSO-d6, 500 MHz): 1.93 (3H, s, CH3-
C=O), 1.98 (3H, s, CH3-C=CH), 5.41 (1H, s, CH) ppm. This matches the literature 1H NMR data 
exactly. 
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3,4 Diacetyl-hexane-2,5-dione: Using a procedure modified from that of 
Charles,146 sodium acetylacetone (14.45 g, 0.10 mol) was ground to a fine 
powder, followed by the addition of diethyl ether (150 mL). Iodine (12.70 g, 
0.05 mol) was dissolved in diethyl ether (150 mL) and added to the sodium 
acetylacetone solution dropwise via dropping funnel over approximately 3 hours. The suspension 
was left to evaporate overnight. Water (250 mL) was added and the suspension was stood at 
room temperature for 2 hours. The solid was collected by filtration, washed with water, dried 
and recrystallised (methanol) to give 3,4-diacetyl-hexane-2,5-dione as an off-white solid (9.91 g, 
14%), 1H NMR (DMSO-d6, 500 MHz): 1.98 (12H, s, CH3), 13C NMR(DMSO-d6, 500 MHz): 195.9, 
110.83, 26.5 ppm. This is mostly in agreement with literature data, with some slight deviations 
in chemical shift. 
3,3′,5,5′-Tetramethyl-4,4′-bipyrazole (H2Me4bpz): Using a procedure 
modified from that of Boldog et al.,147 3,4 diacetyl-hexane-2,5-dione (1.34 
g, 6.75 mmol) was dissolved in water (1.4 mL). The solution was added 
portion wise to hydrazine hydrate (1.6 mL, 33.8 mmol) and cooled on ice. 
The suspension was stirred at room temperature for 2 hours, filtered, washed with ice water and 
recrystallised (water) to give H2Me4bpz as an off-white crystalline solid (0.81 g, 63 %). 1H NMR 
(DMSO-d6, 500 MHz): 1.95 (12H, s, CH3), 12.14 (2H, s, br, NH) ppm, 13C NMR (DMSO-d6, 500 
MHz): 111.43 ppm. This in agreement with literature data. 
Zn(Me4bpz): Me4bpz (9.5 mg, 0.05 mmol) and sodium bicarbonate (52.5 mg, 0.625 mmol) were 
dissolved in methanol (1 mL) and water (5 mL). Zn(NO3)2·6H2O (14.9 mg, 0.05 mmol) was 
dissolved in  water (5 mL) and added dropwise to the Me4bpz solution with stirring which resulted 
in precipitation of a white solid. The suspension was stirred for 30 minutes at room temperature 
and the solid was collected by centrifugation (7000 rpm, 3615 x g, 2 min). PXRD data shown in 
Figure 50, N2 gas adsorption data shown in Figure 52 and pore size distribution data shown in 
Figure 53. 
Enzyme@Zn(Me4bpz): Me4bpz (9.5 mg, 0.05 mmol) and sodium bicarbonate (52.5 mg, 0.625 
mmol) were dissolved in methanol (1 mL) and water (4 mL). Enzyme (2 mg) was dissolved in water 
(1 ml) and added to Me4bpz solution. Zn(NO3)2·6H2O (14.9 mg, 0.05 mmol) was dissolved in  water 
(5 mL) and added dropwise to the Me4bpz solution with stirring resulting in precipitation of a 
white solid. The suspension was stirred for 30 minutes at room temperature and the solid was 
collected by centrifugation (7000 rpm, 3615 x g, 2 min). PXRD data shown in Figure 60, solid-state 
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UV-Vis data shown in Figure 63, CLSM images shown in Figure 64 and enzyme (catalase) loadings 
listed in Table 13. 
Me4bpz HOF microcrystalline powder (added zinc): Me4bpz (152 mg, 0.8 mmol) and sodium 
bicarbonate (52.5 mg, 0.625 mmol) were dissolved in methanol (3 mL) and water (4 mL). 
Zn(NO3)2·6H2O (14.9 mg, 0.05 mmol) was dissolved in  water (5 mL) and added dropwise to the 
Me4bpz solution with stirring resulting in precipitation of a white solid. The suspension was 
stirred for 30 minutes at room temperature, and the solid was collected by centrifugation (7000 
rpm, 3615 x g, 2 min). 
Enzyme@Me4bpz HOF: Me4bpz (152 mg, 0.8 mmol) and sodium bicarbonate (52.5 mg, 0.625 
mmol) were dissolved in methanol (3 mL) and water (3 mL). Enzyme (2 mg) was dissolved in water 
(1 mL) and added to Me4bpz solution with stirring. Zn(NO3)2·6H2O (14.9 mg, 0.05 mmol) was 
dissolved in  water (5 mL) and added dropwise to the Me4bpz solution with stirring resulting in 
precipitation of a white solid. The suspension was stirred for 30 minutes at room temperature, 
and the solid was collected by centrifugation (7000 rpm, 3615 x g, 2 min). PXRD data shown in 
Figure 60, solid-state UV-Vis data shown in Figure 63, CLSM images shown in Figure 64 and 
enzyme (catalase) loadings listed in Table 13. 
Preparation of single crystals: 
1:4 (with zinc, base and BSA): The Zn(Me4bpz) synthesis were performed as outlined above, the 
precipitate was isolated by centrifugation (7000 rpm, 3615 x g, 2 min), and the supernatant was 
left to sit at room temperature, exposed to air to allow slow evaporation. Clear, slightly cubic 
crystals formed after 1 week. 
1:2, 1:4 and 1:16 (with zinc, no base): The Zn(Me4bpz) synthesis was performed as outlined 
above, omitting the base, such that no immediate precipitation occurred. The solution was left 
to sit open at room temperature for slow evaporation. 1:16 formed clear, needle-like crystals 
overnight, 1:4 and 1:2 formed clear, irregular crystals after 2 and 10 days respectively. 
Me4bpz single crystals (no zinc): Me4bpz (76 mg, 0.4 mmol) and sodium bicarbonate (26.3 mg, 
0.3125 mmol) were dissolved in methanol (1.5 mL) and water (1.5 mL). The solution was left 
exposed to air and allowed to evaporate. Clear and colourless crystals of the Me4bpz HOF formed 
overnight. 
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PXRD data for single crystals is shown in Figure 55 and single crystal data is shown in Figure 56 
(unit cell), Figure 57 (asymmetric unit) and Figure 58 (hydrogen-bonding). 
H3TDT derived materials: 
Ligand Synthesis: 
 4,5 Dicyano-1H-(1,2,3)-triazole: Using a modified procedure from that of 
Crawford,148 a slurry of diaminomaleonitrile (2.70 g, 25 mmol) in water (31 mL) 
was acidified with hydrochloric acid (1 M, 25 mL). The solution was cooled to 
0°C and sodium nitrite (1.72 g, 25 mmol) was added portion wise. The 
suspension was then warmed to room temperature and stirred for 1 hr. The solution was 
extracted with diethyl ether (5 x 20 mL) and the combined ether extracts were evaporated to 
dryness under reduced pressure to yield 4,5-dicyano-1H-(1,2,3)-triazole as an orange solid (2.81 
g, 94%). 1H NMR (DMSO-d6, 500 MHz): 9.39 (1H, s, br, NH) ppm. IR (cm-1): 3256.1 (NH, m, br), 
2262.8 (C=N, m), 1478.5 (CH, w), 1381.6 (CH, m). This data is in agreement with literature results. 
4,5 Bis(1H-tetrazol-5-yl)-2H-1,2,3-triazole (H3TDT): Using a modified 
procedure from that of Dinca,136 a mixture of 4,5-dicyano-1H-(1,2,3)-
triazole (0.47 g, 4.0 mmol), sodium azide (1.56 g, 24 mmol) and 
triethylamine hydrochloride (3.30 g, 24 mmol) were suspended in a 
mixture of toluene (30 mL) and methanol (6 mL), and the suspension  was 
heated at reflux for 3 days. The suspension was cooled to room temperature and aq. sodium 
hydroxide (1 M, 20 mL) was added. The solution was stirred at room temperature for 30 minutes. 
The aqueous layer was treated with aq. hydrochloric acid (1 M, 20 mL) and the precipitate was 
collected via filtration, dried, and dissolved in aq. sodium hydroxide (1 M, 30 mL). Aq. 
hydrochloric acid (1 M, 25 mL) was added until a pH of 4-5 was obtained. The precipitate was 
collected by filtration, washed with water (x 3), methanol (x 2) and acetone (x 1) to yield 4,5-
di(1H-tetrazol-5-yl)-2H-1,2,3-triazole as a pale orange solid (0.77 g, 94%). 1H NMR (DMSO-d6, 500 
MHz): 6.84 (3H, s, br, NH) ppm. 13C NMR (DMSO-d6, 500 MHz): 134.27, 151.68 ppm. IR (cm-1): 
3497.3 (NH, m, br), 3372.7 (NH, m, br), 3238.2 (NH, m, br), 3024.3 (NH, w), 2470.3 (OH, br, m), 
1848.7 (CH, m), 1687.0 (C=N, w), 1654.6 (C=C, m), 1586.3 (C=C, s). This is in moderate agreement 
with the literature data. 
CAUTION: Metal azides are water sensitive and potentially explosive and should be handled with 
care. Although no incidents were encountered while handling H3TDT or Zn(TDT) MOFs under the 
  112 
conditions of these experiments, previous reports have suggested that handling H3TDT at 
temperatures exceeding 160°C is potentially hazardous and the melting with decomposition 
(explosion) may occur at 280°C.149 
4,5 Bis(1H-tetrazol-5-yl)-2H-1,2,3-triazole trisodium salt: Using a modified procedure from that 
of Tanaka,150 a 48% aqueous sodium hydroxide solution (0.275 mL, 5 mmol) was added to a 
suspension of 4,5-di(1H-tetrazol-5-yl)-2H-1,2,3-triazole (0.52 g, 2.5 mmol) in water (25 mL). The 
solution was stirred at room temperature for 1 hour, followed by filtration. The filtrate was 
evaporated to dryness under reduced pressure to give the sodium salt of 4,5-di(1H-tetrazol-5-
yl)-2H-1,2,3-triazole as a pale orange solid (0.60 g, 96%). 1H NMR (D2O): no peaks, IR (cm-1): 
3600.0 (NH, w), 3207.5 (NH, br, s), 1644.2 (NH, br, m), 1537.0 (C=C, m), 1409.1 (CH, s). 
 4,5 Bis(1H-tetrazol-5-yl)-2H-1,2,3-triazole bis(tetrabutylammonium) salt: Using a modified 
procedure from that reported by Katritzky,151 a suspension of anhydrous potassium carbonate 
(0.70 g, 5 mmol) and 4,5-di(1H-tetrazol-5-yl)-2H-1,2,3-triazole (0.62 g, 3 mmol) in acetone (30 
mL) was stirred at room temperature for 10 minutes. A solution of tetrabutylammonium bromide 
(0.97 g, 3 mmol) in dichloromethane (30 mL) was added to the reaction suspension and stirred 
at room temperature for 3 hours. The reaction suspension was filtered, and the filtrate was 
concentrated under reduced pressure. The residue was extracted with acetone, the extract was 
filtered, and the solvent was removed under reduced pressure to give the tetrabutylammonium 
salt as a pale yellow solid (0.91 g, 57%). 1H NMR (DMSO-d6, 500 MHz): 0.93 (3H, t, J = 3 MHz, CH3-
CH2),  1.30 (2H, sx, J = 7 MHz, CH3-CH2-CH2), 1.56 (2H, p, J = 7.5 Hz, CH2-CH2-CH2), 3.16 (2H, t, J = 
10 MHz, CH2-CH2-N), 3.49 (1H, s, br, NH) ppm. IR (cm-1): 2958.9 (NH, s), 2873.8 (NH, m), 2734.1 
(CH, w), 1698.3 (C=N, w), 1606.1 (C=C, w), 1473.7 (CH, s).  
Zn(TDT)-Na (general procedure – see conditions and results in Table 23): HTDT·2Na (31.1 mg, 
0.125 mmol), base and any additional chemicals excluding zinc were dissolved in water (half of 
the total volume used) and any additional solvents used. Zinc source (0.125 mmol) was 
dissolved in the remaining water and then added dropwise to the ligand solution with stirring. 
The reaction solution was stirred at room temperature for 30 minutes after which the solid was 
isolated by centrifugation (7000 rpm, 3615 x g, 2 minutes). Samples to be dried were washed 
with ethanol (x 1) and then dried in a vacuum desiccator. PXRD data is shown in Figure 75, 
Figure 76 (wet vs dried samples), Figure 99 (3% HmIM added), Figure 96 (varying base 
concentration), Figure 97 (varying ethanol concentration) and Figure 98 (zinc acetate metal 
source). 
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ZIF-8/Zn(TDT)-Na: ZIF-8 crystals were synthesised via the reported synthesis in Liang, W et al.,65 
zinc acetate dihydrate (22.0 mg, 0.12 mmol) was dissolved in water (1.5 mL) and added to a 
solution of 2-methylimiazole (HmIM) in water (1.5 mL). The solution was left static at room 
temperature for 24 h. The precipitate was isolated by centrifugation (10,000 rpm, 7378 x g, 5 
min) to give a white solid. The ZIF-8 material was then re-suspended in a solution of H3TDT.2Na 
(31.1 mg, 0.125 mmol) and sodium bicarbonate (50.0 mg, 0.595 mmol) in water (1.25 mL). 
Zn(NO3)2.6H2O (37.5 mg, 0.125 mmol) was dissolved in water (1.25 mL) and this solution was 
added to the ZIF-8 suspension. The suspension was left static at room temperature for 1 h. The 
precipitate was isolated by centrifugation (10,000 rpm, 7378 x g, 5 min) to give a white solid. 
PXRD data is shown in Figure 100. 
Zn(TDT)-TBA (water only): HTDT·bis(TBA) (26.3 mg, 0.0625 mmol) and NaHCO3 (25 mg, 0.30 
mmol) were dissolved in water (0.625 mL). Zn(NO3)2·6H2O (18.8 mg, 0.0625 mmol) was dissolved 
in water (0.625 mL) and then added dropwise to the ligand solution with stirring. The reaction 
solution was stirred at room temperature for 30 minutes after which the solid was isolated by 
centrifugation (7000 rpm, 3615 x g, 2 minutes). Samples to be dried were washed with ethanol 
(x 1) and then dried in a vacuum desiccator. PXRD data is shown in Figure 78. 
Zn(TDT)-TBA (10:1 water and ethanol): HTDT·bis(TBA) (26.3 mg, 0.0625 mmol) and NaHCO3 (25 
mg, 0.30 mmol) were dissolved in water (0.625 mL) and ethanol (0.125 mL). Zn(NO3)2·6H2O (18.8 
mg, 0.0625 mmol) was dissolved in water (0.625 mL) and then added dropwise to the ligand 
solution with stirring. The reaction solution was stirred at room temperature for 30 minutes after 
which the solid was isolated by centrifugation (7000 rpm, 3615 x g, 2 minutes). Samples to be 
dried were washed with ethanol (x 1) and then dried in a vacuum desiccator. PXRD data is shown 
in Figure 78. 
Protein@Zn(TDT)-Na: H3TDT·2Na (31.1 mg, 0.125 mmol), NaHCO3 (50.0 mg, 0.595 mmol) and 
protein (2 mg) were dissolved in water (1.25 mL). Zn(NO3)2·6H2O (37.5 mg, 0.125 mmol) was 
dissolved in water (1.25 mL) and then added dropwise to the ligand solution with stirring. The 
reaction solution was stirred at room temperature for 30 minutes after which the solid was 
isolated by centrifugation (7000 rpm, 3615 x g, 2 minutes). Samples to be dried were washed 
with ethanol (x 1) and then dried in a vacuum desiccator. PXRD data is shown in Figure 81. 
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3.4.3 Characterisation 
For methods used for CLSM, PXRD, NMR, FTIR and fluorescence spectroscopy see experimental 
section in chapter 2. 
Scanning electron microscopy (SEM):  
Samples were imaged on a Philips XL30 field-emission scanning electron microscope (FESEM). 
Prior to analysis, samples were dry loaded onto adhesive carbon tabs on 12 mm aluminium stubs 
and coated in platinum. 
Gas Adsorption 
Zn(Me4bpz): Gas adsorption isotherm measurements were collected on a Micromeritics 3-Flex 
Analyser. Pure samples of Zn(Me4bpz) were activated by washing methanol (x 1) and dried under 
high vacuum at 110°C overnight prior to gas sorption measurements. Gas adsorption 
measurements were performed in N2 at 77K. The BET surface areas were determined using 
proprietary software. 
Zn(TDT)-TBA: Gas adsorption isotherm measurements were collected on a Micromeritics 3-Flex 
Analyser. Pure samples of Zn(TDT)-TBA were activated by washing methanol (x 1) and 
dichloromethane (x 1) and dried under high vacuum at room temperature overnight prior to gas 
sorption measurements. Gas adsorption measurements were performed in N2 at 77K. The BET 
surface areas were determined using proprietary software. 
Single Crystal X-ray Data: 
A single crystal of Zn(Me4bpz) was mounted in paratone-N oil on a nylon loop and X-ray 
diffraction data were collected at 150(2) K on an Oxford X-calibur single crystal diffractometer 
using Mo Kα radiation. The data set was corrected for absorption using a multi-scan method, and 
the structures solved by direct methods using SHELXS-2008 and refined by full-matrix least 
squares on F2 by SHELXL-2014,152-154 interfaced through the programs X-Seed155 and Olex152 
(Tables).156 Unless otherwise stated, non-hydrogen atoms were refined anisotropically and 
hydrogen atoms were included as invariants at geometrically estimated positions. The hydrogen 
atoms involved in hydrogen bonding (pyrazole-NH and water-OH) were located in the difference 
map and refined with U(iso) parameters of 1.2 and 1.5 times the pyrazole-N and water-O atoms, 
respectively. DFIX restraints (-0.95) were used to ensure the pyrazole-NH and water-OH bond 
lengths were chemically sensible but allowed to refine. The pyrazole-NH involved in hydrogen 
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bonding the pyrazole nitrogen is disordered over two positions and was refined over both 
positions with 50% occupancy of each site. The table below provides the crystal data and 
structure refinement details for Zn(Me4bpz). 
Table 14: Crystal data and structure refinement for Me4bpz-HOF (TP-ZnP1-16). 
Identification code TP-ZnP1-16 
Empirical formula C20H30N8O 
Formula weight 398.52 
Temperature/K 150(2) 
Crystal system Tetragonal 












Crystal size/mm3 0.45 x 0.33 x 0.2 
Radiation MoKα (λ = 0.71073) 
2θ range for data collection/° 7.32 to 57.376 
Index ranges -19 ≤ h ≤ 31, -28 ≤ k ≤ 30, -18 ≤ l ≤ 20 
Reflections collected 18995 
Independent reflections 2631 [Rint = 0.0371, Rsigma = 0.0250] 
Data/restraints/parameters 2631/4/148 
Goodness-of-fit on F2 1.032 
Final R indexes [I>2σ (I)] R1 = 0.0467, wR2 = 0.1237 
Final R indexes [all data] R1 = 0.0628, wR2 = 0.1351 
Largest diff. peak/hole / e Å-3 0.30/-0.23 
 
FOX Assays: 
FOX Reagent: Sorbitol (3.6 g, 19.8 mmol), xylenol orange (0.0143 g, 0.02 mmol), water (50 mL) 
and concentrated sulfuric acid (281 µL) were combined, followed by the addition of 
(NH4)2FeSO4.6H2O (0.0196 g, 0.02 mmol). The resulting solution was made up to a final volume 
of 200 mL with water. 
Calibration: Standard solutions of H2O2 (0.25, 0.125, 0.0625, 0.03125, 0.015625 mM) were 
prepared. 50 µL of standard was added to 950 µL of FOX reagent, followed by incubation at room 
temperature for 30 minutes, after which point the absorbance at 560 nm was recorded. From 
this data a calibration curve was produced. 
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Assay procedure (thermal testing): For free FCAT, 20 µL of FCAT stock solution (3.77 mg/mL) was 
added to 180 µL of water. This solution was heated to the desired temperature. After 10, 30, 60, 
120 and 180 second, 30 µL aliquots were removed and placed on ice immediately. To these 
aliquots, H2O2 (0.25 mM, 1500 µL) was added. After 10 minutes, 50 µL of this aliquot/H2O2 
solution was added to 950 µL of FOX reagent. After 30 minutes the absorbance at 560 nm was 
recorded and converted to a [H2O2] using the aforementioned calibration curve. 
For FCAT@Zn(Me4bpz) and FCAT@Me4bpz HOF, stock solutions to be tested were made up of 
4.2 mg (FCAT loading = 1.7%) and 4.7 mg (FCAT loading  = 1.6%) respectively in 200 µL water. All 
remaining analysis was performed as above for the free FCAT. 
Assay procedure (organic solvent testing): For free FCAT, 20 µL of FCAT stock solution (3.77 m/mL) 
was added to 180 µL of the desired organic solvent. The remainder of the assay was performed 
as outlined above for the free FCAT thermal analysis. 
For FCAT@Zn(Me4bpz) and FCAT@Me4bpz HOF, stock solutions to be tested were made up of 
4.2 mg (FCAT loading = 1.7%) and 4.7 mg (FCAT loading  = 1.6%) respectively in 200 µL organic 
solvent. All remaining analysis was performed as above for the free FCAT. 
Assay procedure (pH testing): For free FCAT, 3 µL of FCAT stock solution (3.77 m/mL) was added 
to 27 µL of the buffer of desired pH. After 3 minutes, H2O2 (0.25 mM, 1500 µL) was added. The 
remainder of the assay was performed as outlined above for the free FCAT thermal analysis. 
For FCAT@Zn(Me4bpz) and FCAT@Me4bpz HOF, stock solutions to be tested were made up of 
4.2 mg (FCAT loading = 1.7%) and 4.7 mg (FCAT loading  = 1.6%) respectively in 30 µL buffer. All 
remaining analysis was performed as above for the free FCAT. 
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
ICP-MS was performed on a Solution 7500cs ICP-MS spectrophotometer. All ICP-MS experiments 
were completed in triplicate. 
Calibration: Stock solutions of element to be measured were made in 3% ICP-MS grade HNO3 
(concentrations used were 1000, 500, 200, 100, 50, 20, 10 and 0 ppb). 
Process blank: 150 µL conc. HCl and 250 µL conc. ICP-MS grade HNO3 were combined at left at 
room temperature overnight. The solution was vented and centrifuged to remove any solid 
impurities. 0.3429 mL of supernatant was made up to 5 mL using MQ water. 
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Sample preparation: A precisely measured quantity of sample (free enzyme ≈ 1 mg, 
enzyme@Zn(Me4bpz) ≈ 1 mg and enzyme@Me4bpz HOF ≈ 0.5 mg) was dissolved in conc. HCl 
(150 µL) and conc. ICP-MS grade HNO3 (250 µL) and left at room temperature overnight. The 
solution was vented and centrifuged to remove any solid impurities. 0.3429 mL of supernatant 
was made up to 5 mL using MQ water.  
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Chapter 4: Conclusions and Future Directions 
In chapter 2 two bioMOFs were synthesized; zinc glutamate (bioMOF-1) and zinc carnosine 
(bioMOF-2) (L-carnosine = β-alanine-L-histidine). The use of both MOFs for biomolecule 
encapsulation and protection was attempted, targeting the formation of biocomposites via 
biomimetic mineralisation. PXRD data revealed that the structure of neither MOF changed upon 
the inclusion of protein. However, changes in the morphology of bioMOF-2 crystals were noticed, 
where pure bioMOF-2 and enzyme@bioMOF-2 formed as sheet-like and block-shaped crystals 
respectively. For bioMOF-2, addition of proteins with pI less than 6 led to the formation of an 
amorphous precipitate, likely a protein-rich zinc salt, prior to the precipitation of bioMOF-2, 
potentially due to pH effects. This led to a reduction in the concentration of protein available to 
be encapsulated within bioMOF-2. No amorphous precipitate was formed upon addition of 
proteins with higher pIs. 
UV-Vis spectroscopy data for the protein@bioMOF-1 composites revealed that those that 
contained protein experienced a longer precipitation time compared to pure bioMOF-1. This 
suggested that interactions between protein and the MOF components hindered MOF 
formation, potentially due to the formation of complexes between the protein and MOF 
component. Thus, the formation of protein@bioMOF-1 composites was different to biomimetic 
mineralisation wherein the presence of protein accelerates MOF growth. Further, 
CLSM/fluorescence data for FITC-tagged protein@bioMOF-1 samples, before and after removing 
surface-bound enzyme showed significant reduction in the total quantity of protein present. This 
data suggested that the protein was predominantly surface-bound and therefore minimal 
quantities of protein were encapsulated within the MOF crystals.  
For the protein@bioMOF-2 composites, aqueous assays were used to determine the change in 
enzymatic activity upon exposing the biocomposites to harsh conditions. These results confirmed 
that the initial amorphous precipitate had a higher enzymatic activity than the protein@bioMOF-
2 samples. Further, the assay data showed that for CAT@bioMOF-2 and HRP@bioMOF-2, the 
MOF was unable to offer protection to the catalase present upon exposure to elevated 
temperatures, organic solvents and acidic and basic conditions. Instead, it appeared that the 
MOF made the enzymes more susceptible to decomposition. 
Thus, despite the inability of either bioMOF to successfully encapsulate and protect enzymes, 
these results still produced useful information. Specifically, increasing the complementarity 
between the MOF and biomolecule does not necessarily lead to greater chances of successful 
  119 
biomolecule encapsulation. For the two bioMOFs investigated, this increased compatibility may 
have instead caused undesirable observations such as the formation of the amorphous 
precipitate during bioMOF-2 syntheses, or the delayed precipitation of bioMOF-1 when protein 
was attracted to the MOF components, potentially due to pH effects. Further, the imidazole side 
chain of carnosine does not ensure that the MOF will undergo successful biomimetic 
mineralisation. Instead, it is more likely that the N-donor groups must be the sole binding sites 
in the ligands such that no hard donor groups such as carboxylates can promote much more rapid 
MOF growth. 
Chapter 3 was concerned with the synthesis and investigation of frameworks containing purely 
azolate linkers. Two different N-donor ligands were synthesized and used for the formation of 
zinc-based MOFs; Me4bpz and H3TDT (4,5-di(1H-tetrazol-5-yl)-2H-1,2,3-triazole). The former was 
used to form Zn(Me4bpz)-aq and Me4bpz-HOF.  
The PXRD data of Zn(Me4bpz)-aq did not match that of the solvothermally synthesised material, 
and the inability to synthesise single crystals meant that the structure was unable to be 
determined. By comparing PXRD and gas adsorption data for Zn(Me4bpz)-aq and the 
solvothermally synthesised material, it was postulated that the two materials were only slightly 
different, potentially as a result of missing linker defects.  
Me4bpz-HOF was discovered during attempts to grow single crystals of Zn(Me4bpz)-aq. Single 
crystal data for Me4bpz-HOF revealed it to be a closely-packed material comprising only organic 
building blocks. The structure also contained hydrogen-bonded water molecules that were 
integral to the structure.  
As expected, Zn(Me4bpz)-aq was found to be significantly more stable than Me4bpz-HOF, 
however, the presence of protein was able to stabilize the latter in acidic solutions and at 
elevated temperatures. Turbidity testing revealed that Zn(Me4bpz)-aq experienced accelerated 
growth in the presence of protein, while the Me4bpz-HOF grew identically with and without 
added enzyme, suggesting that only the former was potentially undergoing biomimetic 
mineralisation. Aqueous assays were then conducted on both FCAT@Zn(Me4bpz) and 
FCAT@Me4bpz-HOF samples which revealed that significant proportions of the enzymatic 
activity observed was due to leached zinc or enzyme. This leaching was also observed in water at 
room temperature, indicating that a large proportion of the enzyme present was loosely-bound 
to the surface of the material. Upon accounting for this leaching, the remaining enzymatic activity 
present in the solid samples still increased following exposure to harsh environments including 
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THF and elevated temperatures. This suggested that defects were forming in the crystals which 
allowed for less hindered diffusion of assay reagents through the framework or further, more 
significant enzyme leaching. As a result of the low stability of both Zn(Me4bpz) and Me4bpz-HOF, 
in addition to the close-packed nature of the latter, and the high prevalence of loosely bound 
enzyme, these two materials were deemed to be unsuitable for enzyme encapsulation. 
The second N-donor containing ligand (H3TDT) was used to synthesise Zn(TDT). However, despite 
attempting this with both the sodium and tetrabutylammonium (TBA) ligand salts to ensure 
solubility in aqueous conditions, the reported sodalite Zn(TDT) MOF was unable to be 
synthesised. The material formed using the sodium salt (Zn(TDT)-Na) was extremely unstable, 
with no conditions, including the addition of enzyme, being able to increase the stability of the 
material. Further, PXRD data and N2 adsorption analysis for the material formed with the TBA 
salt (Zn(TDT)-TBA) revealed that it was a non-porous structure. 
Thus, despite the similar coordination chemistry of these linkers and those used in the ZIF-8 and 
related materials, the low stability of the materials and the observed decomposition that 
occurred following exposure to test conditions makes Zn(Me4bpz) and Zn(TDT) unsuitable for 
biomolecule encapsulation.  
Despite the inability to successfully encapsulate and protect biomolecules within either of the 
Me4bpz derived materials, key pieces of information were still ascertained. The sole presence of 
azolate groups does not guarantee that the MOF will be able to undergo biomimetic 
mineralisation to result in successful enzyme protection. Further, rigorous stability testing must 
be performed on materials used for biomolecule encapsulation to ensure that they do not 
decompose, whether partially or fully, upon exposure to the conditions in which they are being 
used to protect the biomolecule. This would ensure that significant enzymatic activity is not due 
to leached metal or enzyme. 
One of the areas of future research activity with regard to using MOFs to encapsulate and protect 
biomolecules includes investigation of a greater range of frameworks. This will provide a wider 
understanding of key features necessary to facilitate biomimetic mineralisation and form stable 
biocomposites. Additional bioMOFs could be investigated, for example those comprised of 
histidine- or proline-containing peptides to further investigate the effect of imidazole 
functionality or rigidity respectively. BioMOFs using alternate biological linkers such as 
cyclodextrins and porphyrins could also be investigated for their ability to encapsulate and 
  121 
protect biomolecules; the former gives access to the co-called ‘edible MOFs’ when combined 
with sodium or potassium ions. 
Further, a more targeted area of future work is to prevent the formation of the initial amorphous 
precipitate during the enzyme@bioMOF-2 syntheses with lower pI enzymes. This would ensure 
ample protein concentrations are available to precipitate with the crystalline material. Proteins 
with high pIs could be investigated if suitable assays are available. Alternatively, surface 
modification of low pI enzymes by processes such as amination could be performed to increase 
the pI, meaning that previously used assays were still viable. Modulators such as 
polyvinylpyrrolidone (PVP) could also be added as these have been shown to aid encapsulation 
via co-precipitation.  
The isoreticular structures of Zn(Me4bpz) could be studied to investigate the effect the changing 
the ligand (e.g. functionality, steric bulk) has on the ability to encapsulate and protect enzymes, 
without changing the structure of the MOF. Changing the ligand functionality could modify the 
solubility of the linker and allow stable biocomposite formation in aqueous conditions. Additional 
steric bulk would only be feasible if the linker length was increased to ensure no reduction in 
pore size. A wider variety of N-donor containing frameworks should also be investigated, such as 
the MFU-4, MFU-4l and CFA-1 MOFs mentioned in the introduction of chapter 3. The use of these 
three MOFs would investigate the effect of ligand length and MOF chirality on the ability of a 
framework to successfully undergo biomimetic mineralisation. 
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Appendix 1: Supplementary Information for Chapter 2 
Table 15: Conditions for synthesis of bioMOF-1. All tests were conducted in water (10 mL). Shaded 
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Table 16: Washing procedures used to remove surface bound FCAT and FMb from bioMOF-1 (% 






No Wash - 
  
10% SDS 4 
  
1% EDTA 3 
  










5 µm 5 µm 
5 µm 5 µm 
5 µm 5 µm 
5 µm 5 µm 
5 µm 5 µm 
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Figure 82: Solid-state UV-Vis data for CAT@bioMOF-1 before and after washing with a 1:1 
mixture of 10% SDS and 1% EDTA. 
 
Table 17: Acidic and basic stability tests for bioMOF-2. 
pH Acid or base used After 1 hour PXRD Conclusion 
0 Conc. HCl Dissolved (immediate) N/A Unstable 
3 Acetic acid Dissolved (30 min) N/A Unstable 
3 Diluted HCl No observable decomposition Correct Stable 
5 Diluted HCl No observable decomposition Correct Stable 
9 Bicarbonate-carbonate buffer No observable decomposition Correct Stable 
11 NaOH Slightly dissolved Amorphous Unstable 
14 NaOH Dissolved (immediate) N/A Unstable 
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Figure 83: PXRD data for bioMOF-2 samples following exposure to various pHs, DMF, water and 
elevated temperatures to determine the stability of the material. 
 
Figure 84: Qualitative controls for DMF, pH 3 (dilute HCl), pH 9.2 (bicarbonate-carbonate buffer) 
and water in the FOX Assay compared to 0 mM and 0.25 mM H2O2 standards. Each control was 
performed by reacting 50 µL of solvent with 1 mL of 0.25 mM H2O2 for 10 minutes before adding 
50 µL of this reaction solution to 950 µL of FOX reagent. Photo was taken after reacting FOX 
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Table 18: Analysis of success for solutions of EDTA in Tris-HCl buffer (pH 8, 0.05 M) of varying 
concentrations for the decomposition of bioMOF-2, plus qualitative FOX assays for free catalase 
after exposure to the EDTA solutions. All samples were exposed to the EDTA solutions for 10 
minutes. Percentage concentrations are m/V. 1-, 5- and 10-minute times refer to length of time 
samples were exposed to 0.25 mM H2O2 prior to addition to FOX reagent.  
 Did MOF dissolve PXRD after 10 min 
FOX assay EDTA controls 
1 min 5 min 10 min 
0% EDTA Did not dissolve ZnCarn 
 
0.1% EDTA Did not dissolve Amorphous 
 
1% EDTA Dissolved N/A 
 
10% EDTA Dissolved N/A 
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Figure 85: Relative (activity relative to the original activity of each sample prior to protease 
exposure (after 10 min exposure to 0.25 mM H2O2)) catalase activity for CAT@bioMOF-2-1 (initial 
amorphous precipitate) and CAT@bioMOF-2-2 (second crystalline precipitate) before and after 
exposure to protease (2 mg/mL in 0.05 M Tris-HCl pH 8 buffer, 2 hr). Assays were performed with 
[H2O2] of 0.25 mM, times refer to the length of time samples were left in H2O2 solution before 
adding to FOX reagent. Activity values are relative to the activity of each sample prior to protease 
treatment with 10 min H2O2 treatment time. 
  128 
 
Figure 86: Raw data from the solvent controls run for the peroxidase assay with DMF, protease 
(2mg/mL in Tris buffer (0.05 M, pH 8)), acid (pH 3, dilute HCl) and base (bicarbonate-carbonate 
buffer, pH 9.2). Change in absorbance at 420 nm indicates the rate of conversion of pyrogallol to 
purpurogallin. 
 
Figure 87: Relative HRP activity for HRP@bioMOF-2 before (purple) and after exposure to pH 3 
(dilute HCl, 1 hr) (dark blue), pH 9.2 (bicarbonate-carbonate buffer, 1 hr) (light blue), DMF (1 hr) 
(aqua) and protease (2 mg/mL in 0.05 M Tris-HCl pH 8 buffer, 2 hr) (green) with and without 
subsequent treatment with EDTA (1% w/v EDTA in 0.05 M Tris-HCl pH 8 buffer). 
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Figure 88: a) Raw fluorescence data for calibration of FCAT in 5% EDTA with excitation at 488 nm 
and b) calibration curve for FCAT concentration (in 0.1M pH 5 citric-trisodium citrate buffer) 
against fluorescence intensity at 518 nm. 
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Appendix 2: Supplementary Information for Chapter 3 
 
Figure 89: PXRD of Zn(Me4bpz) before (red) and after (black) N2 gas adsorption following 
activation at 110°C overnight. 
Table 19: ICP-MS data and FCAT loading calculations for FCAT@1:1 and 1:16 Zn(Me4bpz) – 
52.209 mg of FCAT per mg of S recorded (based off of free FCAT ICP-MS data). 





Average ± error 
(std. dev.) (%) 
FCAT@1:1 
Zn(Me4bpz) 
81.496 0.021274 1 2.127435 
1.685223 ± 
0.791023 
<23.658 < 0.006176 0.8 < 0.771981 
115.640 0.030188 1.4 2.156254 
FCAT@1:16 
Zn(Me4bpz) 
<23.658 < 0.006176 0.5 < 1.235169 1.509651 ± 
0.475417 
 
<23.658 < 0.006176 0.3 < 2.058615 
<23.658 < 0.006176 0.5 < 1.235169 
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Figure 90: a) Raw fluorescence data for calibration of FCAT in 0.1 M pH 5 citric-trisodium citrate 
buffer with excitation at 488 nm (sample 1 only). b) calibration curve for FCAT concentration (in 
0.1M pH 5 citric-trisodium citrate buffer) against fluorescence intensity at 518 nm. 
 
Figure 91: a) Raw fluorescence data for calibration of FCAT in 0.1 M pH 5 citric-trisodium citrate 
buffer with excitation at 488 nm (samples 2 and 3 only). b) calibration curve for FCAT 
concentration (in 0.1M pH 5 citric-trisodium citrate buffer) against fluorescence intensity at 518 
nm. 
Table 20: Fluorescence data and FCAT loading calculations for FCAT@1:16 Zn(Me4bpz) in 0.1 M 
























1 446.66 201.13 4.0 0.19 9.2 2.10 % 
1.6 ± 0.5 % 2 60.27 69.60 1.5 0.025 2.0 1.25 % 
3 52.88 58.84 1.5 0.021 1.6 1.32 % 
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Figure 92: Decomposition of H2O2 by aq. zinc solutions in the FOX assay. Results were obtained 
by adding 30 µL of Zn(NO3)2·6H2O stock solution in water to H2O2 (0.25 mM, 1500 µL) and leaving 
to react for 10 minutes before adding 50 µL of the stock/H2O2 solution to FOX reagent (950 µL). 
After standing at room temperature for 30 minutes, the absorbance at 560 nm was recorded. 
These absorbances were converted to [H2O2] concentrations using a calibration curve, and % H2O2 
decomposition is relative to the 0.25 mM starting concentration. Errors at the standard error of 
three independent measurements. 
 
Figure 93: a) Calibration data for FCAT fluorescence in water and b) raw data showing 
fluorescence intensity of supernatant from the FCAT@Zn(Me4bpz)-aq synthesis and water 
washes of the synthesised material to remove loosely bound FCAT. 
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 Table 21: Raw EDX data for atomic percentages in various sites within a sample of Zn(Me4bpz). 
 Atomic Percent (%) 
Site C O N Zn Na Pt S Si Zr Ti Mo 
1 73.1 14.2 8.7 2.0 1.6 0.3 0.2 - - - - 
2 76.0 15.1 4.7 2.1 1.6 0.2 0.2 - - - - 
3 72.5 13.2 7.8 3.9 2.1 0.4 - - - - - 
4 70.5 11.8 9.8 4.1 3.1 0.3 - 0.3 0.1 - - 
5 62.9 19.3 11.7 3.0 2.4 0.2 0.2 0.2 - - - 
6 72.5 13.2 7.8 3.9 2.1 0.4 - - - - - 
7 76.6 12.9 5.9 2.5 2.0 0.2 - - - - - 
8 83.1 11.8 - 2.9 1.8 0.3 0.2 - - - - 
9 83.9 11.0 - 2.5 2.0 0.4 - - - 0.1 - 
10 67.6 12.9 14.8 2.5 1.7 0.3 0.1 - - - - 
11 65.9 12.2 18.5 1.8 1.0 0.3 0.1 0.1 - - - 
12 87.8 9.6 - 2.1 - 0.3 - - - - 0.2 
13 59.4 13.0 19.6 3.7 3.7 0.2 - 0.3 - - - 
14 59.4 14.3 19.3 4.3 2.4 0.2 - - - - - 
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Figure 94: SEM images of Zn(Me4bpz) showing regions used to produce EDX spectra 1-15. 
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Table 22: Crystallisation attempts for Zn(Me4bpz)-aq 
Crystallisation Method Top Layer Bottom Layer Results 
Slow diffusion via 
layering 
Me4bpz in EtOH (1 mL, 
20 mM) 
Zn(NO3)2 in 28% aq. NH3 
(1 mL, 20 mM) 
No crystals 
Me4bpz in MeOH (1 mL, 
20 mM) 




Crystallisation Method Vial 1 Vial 2 Method Results 
Slow mixing 
Zn(NO3)2 in 





M) in MeOH (2 
mL) 
Place vial 1 in vial 2, 
the slowly add water 
to vial 2 until 
solutions in both 
vials combine 
White powder formed 
around rim of vial 1 (1-
2 days). 
 








Solvent system Conditions Results 
Solvothermal 
14.9 (0.05 mmol) 9.5 (0.05 mmol) 
DMF (5 mL) 
HNO3 (1 drop) 
85°C 
overnight 
No single crystals 
7.5 (0.025 mmol) 9.5 (0.05 mmol) DMF (5 mL) 
85°C 
overnight 
No single crystals 
14.9 (0.05 mmol) 9.5 (0.05 mmol) DMF (5 mL) 
120°C 
overnight 
























H2O (5 mL) 
MeOH (0.5 
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H2O (5 mL) 
MeOH (0.5 
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MeOH (1.5 
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Figure 95: PXRD patterns for Zn(TDT) synthesised via the literature method with subsequent 
MeOH (red) and EtOH (blue) washes. 
 
Table 23: Synthesis attempts for Zn(TDT) at room temperature using the sodium H3TDT ligand. 
All tests were performed with HTDT·2Na (31.1 mg, 0.125 mmol) and Zn(NO3)2·6H2O (37.5 mg, 






Precipitation Time PXRD 
A No H2O (2.5 mL) Immediate Amorphous 
B Yes H2O (2.5 mL) 10 s Crystalline 
C No 
H2O (2.5 mL) 
MeOH (0.25 mL) 
Immediate Amorphous 
D Yes 
H2O (2.5 mL) 
MeOH (0.25 mL) 
Immediate Crystalline 
E No 
H2O (2.5 mL) 
EtOH (0.25 mL) 
Immediate Amorphous 
F Yes 
H2O (2.5 mL) 
EtOH (0.25 mL) 
Immediate Crystalline 
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Figure 96: PXRD patterns for Zn(TDT) formed in a 10:1 water/ethanol mixture. Ratio in 
parentheses refers to the molar ratio of metal to ligand to base. 
 
 Figure 97: PXRD patterns for Zn(TDT) formed in various ratios of water to ethanol (ratio in 
parentheses), compared to the simulated pattern for sodalite Zn(TDT) constructed from single 
crystal data. 
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Figure 98: PXRD patterns for Zn(TDT) formed with zinc acetate in pure water (red (dry 
sample)/orange (wet sample)) or a 10:1 mixture of water and ethanol (green (dry sample)/blue 
(wet sample)) compared to the simulated pattern for Zn(TDT) constructed from single crystal 
data. 
 
Figure 99: Baseline corrected PXRD patterns for Zn(TDT) formed in the presence of 3% w/v 2-
methylimidazole (HmIM) compared to simulated patterns for ZIF-8 and Zn(TDT) constructed from 
single crystal date.  
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Figure 100: PXRD patterns for the attempted formation of Zn(TDT) around sod-ZIF-8 for wet 
(orange) and dry (red) samples compared to the data for synthesised Zn(TDT)-Na (green) and ZIF-
8 (aqua) as well as simulated patterns for sod-ZIF-8 (purple), sod-Zn(TDT) (dark blue) and pcu-
Zn(TDT) (light blue). 
 
 
Figure 101: 1H NMR spectrum for a sample of Zn(TDT)-Na formed in the presence of 3% 2-
methylimidazole in an attempt to seed growth of sod-Zn(TDT)-Na. Only peaks corresponding to 
H atoms present in the 2-methylimidazole ligand can be observed, as highlighted in green, blue 
and orange, with no peaks corresponding to NH group in the H3TDT linker. 
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Table 24: Raw EDX data for atomic percentages in various sites within a sample of Zn(TDT)-Na. 
 Atomic Percentage (%) 
SITE C O N Na Zn Pt Cl Zr 
41 33.9 29.8 20.2 12.6 3.2 0.3 - - 
42 23.9 22.5 32.8 14.1 6.3 0.3 - - 
43 47.6 15.2 20.0 9.7 6.0 0.3 0.3 - 
44 15.7 34.3 29.2 16.8 3.8 0.3 - - 
45 23.0 34.8 25.0 13.5 3.4 0.3 - - 
46 24.5 28.0 32.1 11.0 4.1 0.4 - - 
47 21.6 43.1 8.6 21.4 3.0 0.6 1.7 - 
48 10.8 50.5 11.5 23.2 2.3 0.3 1.1 0.3 
49 13.3 45.3 11.8 22.7 4.5 0.8 1.5 - 
50 15.8 35.7 29.4 14.7 4.1 0.3 - - 
51 17.9 29.1 31.6 14.8 6.2 0.5 - - 
52 16.4 34.1 30.2 13.9 4.9 0.4 - - 
53 37.4 31.1 19.2 9.1 3.0 0.3 - - 
54 - 39.7 31.1 22.0 6.7 0.6 - - 
55 35.8 25.1 26.1 9.0 3.6 0.2 - 0.1 
56 13.1 36.1 29.7 15.1 5.5 0.3 - - 
57 9.5 42.7 27.1 16.4 4.1 0.3 - - 
58 12.7 39.5 29.0 14.4 3.9 0.1 - 0.4 
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Table 25: Raw EDX data for atomic percentages in various sites within a sample of Zn(TDT)-TBA. 
 Atomic Percentage (%) 
SITE C O N Na Zn Pt Zr 
16 25.5 45.2 7.4 11.0 10.5 0.2 - 
17 26.2 44.0 7.3 10.4 11.9 0.2 - 
18 25.1 46.5 6.7 11.3 10.2 0.2 0.0 
19 26.8 45.7 5.1 10.6 11.5 0.3 0.1 
20 - 56.9 9.9 14.0 18.9 0.4 - 
21 24.1 45.2 6.9 10.8 12.7 0.3 - 
22 24.6 45.5 6.8 10.9 11.8 0.2 0.2 
23 26.2 46.2 7.7 9.4 10.4 0.2 - 
24 21.1 46.0 6.6 13.4 12.7 0.2 - 
25 23.2 47.2 6.9 11.4 11.1 0.2 - 
26 27.1 48.1 4.9 10.3 9.3 0.3 - 
27 23.9 48.2 6.4 10.9 10.4 0.2 - 
34 22.8 47.0 6.2 11.6 11.7 0.0 0.8 
35 25.9 44.6 3.3 9.4 16.4 0.4 - 
36 29.6 42.0 6.2 9.2 12.7 0.4 - 
37 25.5 43.6 5.5 12.1 13.1 0.2 - 
38 21.7 52.5 4.8 11.9 8.8 0.3 - 
39 23.6 43.8 9.2 8.4 14.9 0.2 - 
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Figure 103: SEM images of Zn(TDT)-TBA showing regions used to produce EDX spectra 16-27, 
34-39. 
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